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ABSTRACT 
 
The application of pharmacological small-molecule inhibitors of cyclin-dependent kinases 
is a quite new and promising therapeutical strategy in combating cancer. Two inhibitors 
belonging to the group of purine analogues, namely roscovitine (ROSC) and olomoucine II 
(OLO II) seem to be of great clinical importance.  
In this diploma thesis the action of both inhibitors on two different human cervix carci-
noma cell lines was analyzed in detail. Considering the fact that ROSC and OLO II are 
structurally closely related – they differ in only one hydroxyl group – it was of interest to 
assess and to compare their effects on human HeLa and HTB-31 cervical cancer cells dif-
fering in the p53 and G1/S checkpoint status. The question was raised whether and if yes, 
to what extent they would affect cellular proliferation, cell cycle progression and pro-
grammed cell death. In HeLa cells both tumor suppressor proteins, p53 and pRb, are not 
functional due to HPV infection, whereas in HTB-31 cells both tumor suppressor genes are 
mutated. In this context the issue appeared whether both inhibitors would be able to repress 
HPV-encoded proteins and in this way to reactivate p53 and restore the checkpoint in 
HeLa cells. 
Our results demonstrated the high anti-proliferative effects of ROSC and OLO II. Both 
inhibitors reduced the numbers of living cells in a time- and concentration dependent man-
ner. The reduction of cell numbers was attributable to induction of cell cycle arrest and/or 
apoptosis. However, the outcome strongly depends on drug concentration. ROSC at lower 
dosage (20 µM) induced a G2/M arrest that in HTB-31 cells appeared with some delay. 
Higher concentrations of the same drug induced caspase-dependent apoptosis primarily in 
HeLa cells, as evidenced by activation of caspase-3. The increase of caspase-3 coincided 
with changes in a balance between pro- and anti-apoptotic factors: the upregulation of the 
pro-apoptotic protein Bad and the concomitant inactivation of survivin. Unlike HeLa cells, 
HTB-31 cells were more resistant to ROSC action and apoptotic cells appeared after a 
longer treatment time (48h or longer). These observations are not surprising because p53 
and pRb tumor suppressor proteins are mutated and CDK inhibitors are not able to reacti-
vate them. 
Interestingly, OLO II was more efficient than ROSC in both cell lines, exerting exactly the 
same effects, however at lower doses. 
Moreover, the importance of the status of cancer cells prior to the onset of treatment for the 
outcome of therapy was examined. Asynchronously growing cells and synchronized cells 
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were exposed to drugs. Medication of asynchronously growing cells was started at differ-
ent time points after cell plating. Cells after a short recovery period (10h) were G1-arrested 
and entered the active cell cycle after a longer period of time (22h) after plating. Interest-
ingly, cells after a short recovery period were less sensitive to drugs than cells at 22h post-
plating. Additionally, synchronized cells released from the block were also exposed to 
CDK inhibitors. ROSC was able to prolong cell cycle arrest of synchronized HeLa cells 
only in early but not in late G1 phase. 
Analysis of cellular proteins in samples obtained from untreated controls and cells treated 
with both CDK inhibitors for increasing periods of time by immunoblots provided details 
about the mechanism of the action of ROSC and OLO II. 
Both inhibitors abrogated activation of CDK7 and in this way were able to repress the site-
specific phosphorylation of CTD of RNA Polymerase II resulting in the block of overall 
transcription in HeLa cells. Transcriptional breakdown led to downregulation of E6 and E7 
oncogenic proteins in HeLa cells. In untreated HeLa cells these virally encoded proteins 
bind and inactivate p53 and pRb, respectively, thereby contributing to malignant transfor-
mation. Hence, abrogation of E6 and E7 reconstituted the G1 restriction checkpoint, evi-
denced by the reactivation of pRb protein and the strong p53 upregulation after ROSC 
treatment. Restored p53 activity contributes to cell cycle arrest and apoptosis and repre-
sents a further mechanism of ROSC action. HTB-31 cells in contrast were not affected in 
p53 levels, indicating that CDK inhibition is not sufficient to counteract the mutated pro-
tein. Additionally, synchronization of HeLa cells with trichostatin A, a deacetylase inhibi-
tor, before the actual ROSC treatment revealed improved effects of the latter in comparison 
to a treatment of unsynchronized cells. 
Taken together, ROSC and OLO II display high therapeutic potential due to their increased 
selectivity towards transformed cells. Their ability to modulate the cell cycle and to induce 
a controlled cell death additionally is associated with relatively low, if any, cytotoxicity. 
The weak cytotoxicity of CDK inhibitors is a great advantage. Moreover, the pleiotropic 
effects exerted by ROSC and OLO II are of advantage too. 
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KURZZUSAMMENFASSUNG 
 
Die Anwendung von pharmakologischen Cyclin-abhängigen Kinase Inhibitoren ist eine 
ziemlich neue und vielversprechende therapeutische Strategie in der Bekämpfung von 
Krebs. Zwei Inhibitoren, die zur Gruppe der Purine Analoge zählen, nämlich Roscovitin 
(ROSC) und Olomoucin II (OLO II), scheinen von großer klinischer Bedeutung zu sein. 
In dieser Diplomarbeit wurden die Effekte beider Inhibitoren auf zwei verschiedene huma-
ne Zervix Karzinom Zelllinien im Detail untersucht. Zieht man die Tatsache in Betracht, 
dass ROSC und OLO II in ihrer Struktur sehr ähnlich sind – sie unterscheiden sich in nur 
einer Hydroxylgruppe voneinander – war es von Interesse ihre Wirkung auf humane HeLa 
und HTB-31 Zervix Krebszellen, die sich im p53 und G1/S Checkpoint Status unterschei-
den, zu bestimmen und untereinander zu vergleichen. Die Frage kam auf, ob und wenn ja, 
in welchem Ausmaß beide Inhibitoren die zelluläre Proliferation, die Zellzyklusprogressi-
on und den programmierten Zelltod beeinflussen würden. In HeLa Zellen sind beide Tu-
morsuppressor Proteine, p53 und pRb, auf Grund einer HPV Infektion nicht funktionell, 
wobei in HTB-31 Zellen beide Tumorsuppressor Gene mutiert sind. In diesem Zusammen-
hang tauchte die Frage auf, ob beide Inhibitoren im Stande sein würden die HPV-kodierten 
Proteine zu reprimieren und dadurch p53 zu reaktivieren und den Checkpoint in HeLa Zel-
len wiederherzustellen. 
Unsere Resultate zeigen die starken anti-proliferativen Effekte von ROSC und OLO II. 
Beide Inhibitoren reduzierten die Zahl der lebenden Zellen in einer Zeit- und Konzentrati-
ons-abhängigen Art und Weise. Die Abnahme der Zellzahl ist auf die Induktion eines Zell-
zyklusarrests und/oder Apoptose zurückzuführen. Das Ergebnis hängt jedoch stark von der 
Medikamentenkonzentration ab. ROSC in einer niedrigeren Dosierung (20 µM) induzierte 
einen G2/M Arrest, welcher in HTB-31 mit einiger Verzögerung auftrat. Höhere Konzent-
rationen desselben Medikaments verursachten eine Caspase-abhängige Apoptose primär in 
HeLa Zellen, die durch die Aktivierung der Caspase-3 nachgewiesen wurde. Die Zunahme 
von Caspase-3 stand in Einklang mit den Veränderungen in der Balance zwischen pro- und 
anti-apoptotischen Faktoren: die erhöhte Expression des pro-apoptotischen Proteins Bad 
und die zeitgleiche Inaktivierung von Survivin. Im Gegensatz zu HeLa Zellen waren HTB-
31 Zellen gegenüber der Wirkung von ROSC resistenter und apoptotische Zellen traten erst 
nach einer längeren Behandlungszeit auf (48h oder länger). Diese Beobachtungen sind 
nicht überraschend, da die p53 und pRb Tumorsuppressor Proteine mutiert sind und CDK 
Inhibitoren nicht fähig sind sie zu reaktivieren.  
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Interessanterweise war OLO II in beiden Zelllinien effizienter als ROSC, wobei es dieselbe 
Wirkung, allerdings bei niedrigeren Dosen, ausübte. 
Weiters wurde die Bedeutung des Zustandes von Krebszellen vor dem Beginn der Behand-
lung für den Ausgang der Therapie untersucht. Asynchron wachsende und synchronisierte 
Zellen wurden den Medikamenten ausgesetzt. Die Verabreichung der Medikamente wurde 
im Fall der asynchron wachsenden Zellen nach unterschiedlichen Zeitpunkten nach dem 
Ansetzen vorgenommen. Zellen, die eine kurze Erholungszeit (10h) hatten, wurden in der 
G1 Phase arretiert und betraten den aktiven Zellzyklus nach einer längeren Zeit (22h) nach 
dem Ansetzen. Interessanterweise waren Zellen nach einer kurzen Erholungszeit weniger 
empfindlich gegenüber den Medikamenten als Zellen nach 22h nach dem Ansetzen. Zu-
sätzlich wurden synchronisierte Zellen, die aus dem Arrest entlassen wurden, verschiede-
nen CDK Inhibitoren ausgesetzt. ROSC war im Stande den Zellzyklusarrest von synchro-
nisierten HeLa Zellen in der frühen, nicht aber in der späten, G1 Phase zu verlängern. 
Die Analyse der zellulären Proteine in Proben von unbehandelten und mit beiden CDK 
Inhibitoren behandelten Zellen über zunehmende Zeitspannen durch Immunoblots gaben 
Einsicht in die Mechanismen der ROSC und OLO II Wirkung. 
Beide Inhibitoren unterdrückten die Aktivierung von CDK7 und waren dadurch im Stande 
die ortsspezifische Phosphorylierung der CTD der RNA Polymerase II zu hemmen. Daraus 
resultierte ein Block der allgemeinen Transkription. Der Zusammenbruch der Transkripti-
on führte zur verminderten Expression der E6 und E7 onkogenen Proteine in HeLa Zellen. 
In unbehandelten HeLa Zellen binden und inaktivieren diese viral kodierten Proteine p53 
beziehungsweise pRb und tragen dadurch zur malignen Transformation bei. Demzufolge 
stellte die Außerkraftsetzung von E6 und E7 den G1 Restrikionscheckpoint wieder her. 
Dies wurde durch die Reaktivierung des pRb Proteins und der starken Hochregulation von 
p53 nach einer ROSC Behandlung nachgewiesen. Die wiederhergestellte p53 Aktivität 
trägt zum Zellzyklusarrest und zur Apoptose bei und repräsentiert dabei ein weiterer Me-
chanismus der ROSC Wirkung. 
Im Gegensatz dazu wurden die p53 Mengen in HTB-31 Zellen nicht beeinflusst. Das weist 
daraufhin, dass die Hemmung von CDKs nicht ausreichend ist um dem mutierten Protein 
entgegenzuwirken. Zusätzlich zeigte die Synchronisierung von HeLa Zellen mit Trichosta-
tin A, ein Deacetylase Inhibitor, vor der eigentlichen ROSC Behandlung die verbesserte 
Wirkung von ROSC im Vergleich zur Behandlung von nicht synchronisierten Zellen.  
Insgesamt weisen ROSC und OLO II ein hohes therapeutisches Potential auf Grund ihrer 
erhöhten Selektivität gegenüber transformierten Zellen auf. Ihre Fähigkeit den Zellzyklus 
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zu modulieren und zusätzlich einen kontrollierten Zelltod zu induzieren hängt mit ihrer 
relativ niedrigen, wenn überhaupt vorhandenen Zytotoxizität zusammen. Die geringe Zyto-
toxizität  von CDK Inhibitoren ist ein großer Vorteil ebendieser. Außerdem sind die plei-
otropen Effekte, die von ROSC und OLO II ausgeübt werden, ebenfalls ein großer Vorteil. 
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 1.  INTRODUCTION 
 
Cancer is one of the most common diseases mankind is confronted with. According to the 
American Cancer Society cancer is the second leading cause of death in the United States. 
Nearly everybody has or was indirectly confronted with this disease. [1] In Austria nearly 
25 % of carcinoma patients die finally. [2]  
Due to the fact that cancer is a process creeping over years until fully developed, it can 
remain long time undiscovered and displays then severe effects. It is quite scaring that  
everyone of us can develop cancer, but the most striking certainty is that 30 % of all cancer 
death can be prevented by simple lifestyle changes. [3] 
Cancer is a disease not easy to cure, especially when it is not detected in early stages. This 
is because of the sophisticated and subtle network cells display and cancer targets. Besides, 
tumorigenic cells have the ability to spread throughout the body forming metastasis in late 
stages of development and even if cancer is treated, reoccurrence is very likely. However, 
mortality seemed to decline in the last few years, a success attributed to treatment thera-
pies. Nevertheless, up to the present anti-cancer therapies like radiotherapy, chemotherapy 
with cytostatics or even surgery are not highly selective and may exert various side effects 
as cytotoxicity towards healthy cells. Hence, they are associated with severe undesired 
complications. Therefore the interest in appropriate treatments is great.  
Recently discovered pharmacological cyclin-dependent kinase inhibitors seem to be a 
promising novel therapy in combating cancer. This diploma thesis will deal with this new 
form of treatment analyzing their effects on a special type of cancer cells maintained in 
culture.  
But to start from the beginning, basic cellular proliferation and its regulation mechanisms 
have to be understood first in order to understand cancer. They will be depicted in detail in 
the next sections. 
 
 1.1. The eukaryotic cell cycle 
The eukaryotic cell cycle is an essential process in every cell’s life which ensures its 
proper proliferation including correct DNA replication and cell division. The ultimate re-
sult is the generation of two identical daughter cells. [4] 
The cell cycle is divided into a mitosis phase (M phase) and an interphase, each subdivided 
into more phases fulfilling different functions (Fig. 1). [5] 
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Fig. 1: Schematic view of cell cycle stages [6] 
 
 1.1.1.  Interphase 
The interphase is the phase between two sequential mitosis representing 95 % of the 
mammalian cell cycle. During interphase chromosomes are decondensed, cells start grow-
ing doubling their size and DNA replication proceeds. In other terms cells prepare for the 
next cell division round. [5] 
Three distinct phases can be distinguished in interphase: 
 
 1.1.1.1. G1 phase 
The gap phase 1 is the phase between mitosis and S phase. Cells in G1 phase are metaboli-
cally active; they synthesize RNA and proteins [7] and start to grow. Thus they prepare for 
the upcoming DNA synthesis. [5] At this stage cells are responsive for growth signals [4], 
nutrients or external/internal inhibitors influencing a cell’s decision to enter or to leave the 
cell cycle. [8] Once cells cross the G1 restriction checkpoint in late G1 phase the decision for 
cell cycling is irreversible. 
 
 1.1.1.2. S phase 
During the synthesis phase a cell replicates its DNA, while RNA and protein synthesis are 
maintained. [7] Specific regulation mechanisms assure that chromosomes are duplicated 
only once per cell cycle. Therefore cells are committed to proceed to M phase before be-
ginning a new replication round (though a few exceptions exist). [9] At the end of this phase 
a twofold chromosome set is present. 
 
 1.1.1.3. G2 phase 
The gap phase 2 is a postsynthetic phase, where cell growth reaches a maximum. RNA and 
proteins important for the sequential mitosis are synthesised. At this stage specific control 
17 
 
 
mechanisms proof fidelity of DNA replication, size of cells and energy supply necessary to 
proceed to M phase. [7] 
 
 1.1.2.  Mitosis 
The mitosis phase is the shortest phase but probably the most spectacular one. [5] Cells use 
their whole energy for the nuclear division with a subsequent cytokinesis. Hence, protein 
synthesis continues at a low rate and RNA synthesis takes only place in early prophase and 
late telophase. [7] 
During mitosis the DNA is condensed to chromosomes and changes in the rearrangement 
of mitotic spindles, cytoskeleton and nuclear envelope occur. Thus a faithful segregation of 
the chromosomes is facilitated. [8] Mitosis leads to a reduction of tetraploidy resulting in 
two diploid cells. [7]   
Mitosis includes four distinct phases: 
 
 1.1.2.1. Prophase 
During prophase the DNA is condensed to chromosomes in order to enable the following 
separation, whereas sister chromatids are only kept together at centromeres. The centro-
somes move to the opposite poles and the mitotic spindle starts to develop. Finally the nu-
clear envelope is disintegrated. [5] 
 
 1.1.2.2. Metaphase 
Microtubules attach to chromosome kinetochors and link centrosomes to the condensed 
DNA. Due to microtubule movement (by pulling or pushing) chromosomes are aligned at 
the metaphase plate and are ready for segregation. [5] 
 
 1.1.2.3. Anaphase 
The first event in anaphase is the separation of sister chromatids at the kinetochor. Then 
microtubule contraction pulls the chromatids to opposite poles of the mitotic spindle. [5] 
 
 1.1.2.4. Telophase 
In telophase nuclei start to reform around each mitotic spindle and chromosomes decon-
dense again. [5] 
To complete cell division, cytokinesis takes place. Cytokinesis is the division of the cyto-
plasm during late anaphase and telophase. It is accomplished by a contractile ring com-
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posed of myosin II and actin filaments. As a consequence constriction of the cell mem-
brane occurs. The position of ring formation is dependent on the position of the mitotic 
spindle. [5] 
 
However, not all eukaryotic cells participate in the cell cycle. Some cells do not proliferate 
or grow anymore. They exit the active cell cycle and remain in a quiescent stable state, the 
G0 phase. [10] Either they have reached their final developmental state and do not need to 
proliferate any more, e.g. neuronal or muscle cells, or different environmental factors in-
fluence them to leave the cell cycle. [11] Quiescence is lifelong or reversible after undefined 
periods of time. Mitogenic signals can reactivate cells, but re-entry into G1 phase of cell 
cycle needs continuous stimulation until the G1 restriction checkpoint is overwhelmed. [12] 
 
 1.1.3.  Cell cycle regulation 
Evidently the cell cycle is a temporal and sequential restricted process which has to be 
tightly regulated. Thus progression through different cell cycle stages is coordinated by 
different proteins. The main positive regulators are heterodimeric serine/threonine kinase 
complexes each composed of a catalytic cyclin-dependent kinase (CDK) and a regulatory 
cyclin (cyc) subunit. In contrast inhibitory proteins of the Cip/Kip or INK4 family influ-
ence indirectly the cell cycle. [13] 
 
 1.1.3.1.  Cyclin-dependent kinases 
Cyclin-dependent kinases (CDKs) have different functions in cellular proliferation and 
RNA transcription. The most CDKs supervise cell cycle stages (e.g. CDK1, 2, 4), whereas 
transcriptional CDKs (e.g. CDK7, 8, 9) phosphorylate the carboxy-terminal domain of 
RNA polymerase II. Thus transcriptional activation takes place. [14] Up to now 11 different 
CDKs and 9 CDK-like proteins have been discovered. [15] 
CDKs are expressed during the cell cycle at constant levels as inactive proteins and under-
lie a two-step activation process involving several other proteins. Their association with 
cyclins leads to a partial activity, whereas postsynthetic modification in the conserved T-
loop (e.g. phosphorylation, acetylation) triggers full activity. This is accomplished by the 
CDK-activating kinase (CAK), being a CDK-cyclin complex itself. [13] Additionally inhibi-
tory phosphorylation at threonine and tyrosine residues by Wee1/Myt1 kinases can occur. 
Cdc25 phosphatases reverse the process. If CDKs are phosphorylated at inhibitory and 
activating residues, the whole protein is inactive.  
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The interaction of CDKs with CDK inhibitors leads to their inactivation thus modulating 
the cell cycle. Finally CDK activity is regulated by protein folding and subcellular localiza-
tion. [15] 
Figure 2 summarizes the different regulation mechanisms acting on CDKs.  
 
 
Fig. 2: Regulation mechanisms of CDKs [15] 
 
 1.1.3.2.  Cyclins 
As regulatory subunits cyclins induce conformational changes in CDKs, thus activating 
them. [16] However, they exhibit a nuclear localization signal (NLS) as well, so that CDKs 
are directed to the nucleus to accomplish their role in cell cycle. [17] 
The expression of cyclins oscillates during the cell cycle (Fig. 3). At defined points of time 
distinct cyclin amounts slightly increase until they reach a certain threshold level. This 
triggers the activation process of CDKs and indicates the passage of a cell cycle stage. Af-
ter fulfilling their mission, cyclins decline abruptly. [18] Hence, cyclins are regulated due to 
a balance between de novo synthesis and targeted degradation. Consequently CDK activa-
tion occurs in a time-dependent manner, whereas the availability of different cyclins de-
termines the type of CDK activated and the type of substrate targeted. [19] Cyclin regulation 
may also be achieved by phosphorylation or subcellular localization. 
Proteolytic degradation of cyclins is a multi-step process which involves site-specific phos-
phorylation creating phosphodegron, polyubiquitin tagging of proteins mediated by spe-
cific E3 ubiquitin ligase, nuclear export and subsequent degradation in proteasome. [20] 
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Fig. 3: Cyclin expression during cell cycle [21] 
 
The purpose of activated CDK-cyclin complexes is the phosphorylation of target proteins 
at specific serine or threonine residues to coordinate progression through or entry into the 
next cell cycle phase. Such target proteins are among others the tumorsuppressor protein 
pRb, Wee1 kinase, cdc25 phosphatase, cytoskeletal proteins or microtubules. [10] 
 
 1.1.3.3.  CDK inhibitors 
As mentioned above CDK inhibitors counteract CDK-cyclin activity and are important 
regulation processes of healthy cells. Anti-proliferative signals (e.g. DNA damage, limiting 
nutrients etc.) or intracellular factors directly activate CDK inhibitors to stop cell cycle 
progression and to direct cells to a quiescent state. [21] 
CDK inhibitors can be subdivided into two classes: the Cip/Kip protein family (e.g. 
p21Cip1/Waf1, p27Kip1, p57Kip2) and the INK4 proteins (inhibitors of CDK4, e.g. p16INK4a, 
p15INK4b, p18INK4c, p19INK4d). [22] 
The Cip/Kip family members bind to active CDK-cyclin complexes to inhibit both of 
them. It was documented that Cip/Kip inhibitors bind exactly to the ATP binding site in 
CDKs. Thus insertion into the catalytic cleft blocks ATP binding and CDK’s catalytical 
activity. [13] Additionally, Cip/Kip proteins have also different functions in apoptosis, tran-
scriptional regulation, cell fate determination and cell migration. [23] 
INK4 proteins in contrast are specific for G1 phase CDKs, that means CDK4 and 6, and 
bind to their monomeric form. CDK activation by cyclins is not inhibited by blocking the 
cyclin binding site, but results from allosteric changes inside the very same position. Thus 
they prevent the activation by cyclins. Although it was also reported that INK4 inhibitors 
deform the ATP binding site. [13] 
 
21 
 
 
 1.1.3.4.  Cell cycle checkpoints 
Cell cycle checkpoints are quality control points between cell cycle phases. They provide 
opportunity for cells to interrupt the cell cycle and to carefully examine if physiological 
conditions permit a further progression. Physiological conditions refer to certain external 
factors (e.g. nutrients, growth factors, cell density, presence of DNA damaging agents) 
and/or internal factors (e.g. DNA content and integrity) which exert influence on cells. 
Once a checkpoint is traversed, return to the previous stage is irreversible. [24] 
Each checkpoint disposes of a sensor mechanism to recognize aberrant or incomplete cell 
cycle events and a signal transduction pathway to transfer the signal to effector proteins. 
As a consequence measures are taken to reconstitute the proper cell cycle. [4] Cell cycle 
checkpoints themselves are mainly controlled by CDK inhibitors and CDK-cyclin com-
plexes. 
The main checkpoints are outlined in Figure 4 and described in more detail underneath. 
 
 
 
Fig. 4: Cell cycle checkpoints restricted to defined spots [4] 
 
 1.1.3.4.1. G1 restriction checkpoint 
The G1 restriction checkpoint in the middle/late G1 phase permits cells to assure them-
selves if nutrients and proliferating signals are sufficient to be committed to DNA replica-
tion. Proliferative signals are required until the restriction checkpoint is passed. If this is 
not the case, cells return to a quiescent state leaving the cell cycle. [4] The restriction 
checkpoint is controlled by the retinoblastoma tumor suppressor protein (pRb). [17] During 
G1 phase hypophosphorylated pRb binds and inactivates consequently the E2F transcrip-
tion factor, which is important for S phase genes. As cells progress in cell cycle CDK4 and 
CDK6 as well as cyclin D are synthesized. Active complexes composed of CDK4-cyclinD 
or CDK6-cyclinD phosphorylate pRb at three critical residues. However, only the phos-
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phorylation at a fourth serine residue by the active CDK2-cyclinE complex leads to induc-
tion of S phase genes by releasing E2F. The restriction checkpoint is passed. [25] 
 
 1.1.3.4.2. G1/S checkpoint 
DNA damage of endogenous o exogenous source induces G1/S, intra-S and G2/M check-
points. [26] 
Depending on type of DNA lesions responsive ATM/ATR and downstream Chk1/Chk2 
kinases are activated. This leads to phosphorylation of the tumor suppressor and transcrip-
tion factor p53, which induces consequently p21Cip1/Waf1 expression. [27] p21Cip1/Waf1 is 
known to inhibit G1 kinases. [17] However it represents a slow mechanism of counteracting. 
A much more rapid way constitutes the downregulation of cdc25A phosphatase thus inhib-
iting important CDK-cyclin complexes (CDK2-cyclinE and CDK2-cyclinA). [27] 
 
 1.1.3.4.3. intra-S checkpoint 
The intra-S checkpoint is an exception forasmuch as it only results in a temporally delay of 
cell cycle progression. Presumably two parallel mechanisms are involved in the inhibition 
of the replication initiation at different sites. One of them coincides with the ATM-
phosphatase cdc25 pathway described above, the other one includes ATM activation and 
phosphorylation of NBS1, a DNA repair protein. [27] The overall result is a slower DNA 
replication thus lengthening the S phase. [4] Nevertheless far too few knowledge exists 
about this checkpoint.  
 
 1.1.3.4.4. G2/M checkpoint 
Upon DNA damage the same components as in G1/S checkpoint are activated in G2 phase 
(referring to ATM/ATR and checkpoint kinases Chk 1/2), however, their specific down-
stream targets differ. The main purpose of G2 phase arrest upon DNA injury is the inhibi-
tion of the CDK1-cyclinB mitosis promoting factor. Checkpoint kinases phosphorylate the 
cdc25C phosphatase at Ser216 thus promoting its association with 14-3-3 proteins and se-
questration in the cytoplasm. Under favourable conditions active cdc25C would normally 
dephosphorylate the CDK1-cyclin B complex at the inhibitory residues threonine14 and 
tyrosine15 to permit a progression to mitosis phase. Since CDK1-cyclinB complexes are in 
the nucleus, cdc25C phosphatase is blocked and a G2 arrest is induced.  
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Additionally p53 upregulation can indirectly block kinase activity via p21Cip1/Waf1 and in-
duce 14-3-3-σ protein expression. 14-3-3-σ binds to CDK1-cyclinB complexes and retains 
them in the cytoplasm far away from the nucleus. [4] 
 
 1.1.3.4.5. Spindle checkpoint 
The spindle checkpoint resides in metaphase/anaphase of mitosis and assures a correct 
chromosome segregation to prevent cell aneuploidies. It is triggered if the mitotic spindle 
has not formed or not attached properly to sister chromatids.  
During mitosis segregation of chromatids is a coordinated process that takes not place until 
all chromosomes are arranged at the equatorial plate and attached to microtubules. Shortly 
after the APC (anaphase-promoting complex) E3 ligase associates with cdc20 and is phos-
phorylated by CDK1-cyclinB to become active. APC is indispensable for chromosomal 
segregation since it targets the protein securin for ubiquitin mediated degradation. This 
releases the protease separase which in turn cleaves the cohesine rings that hold sister 
chromatids together. Separation of sister chromatids is now feasible. 
Proteins involved in activation of the spindle checkpoints are Mad1/2 (mitotic arrest-
deficient) and Bub1 (budding uninhibited by benzimidazole) proteins. They bind to loosen 
kinetochors of chromatids and inhibit the APC complex (by binding to its regulatory sub-
unit cdc20) thus blocking securin degradation and chromatid segregation. [4] 
 
The overall outcome of activated cell cycle checkpoints is an induced cell cycle arrest with 
a possible DNA repair or in the worst case an induced programmed cell death (apoptosis). 
[28]
 
 
 1.1.4.  Molecular aspects of cell cycle progression 
Somatic cells are capable to react to environmental stimuli as well as to intracellular sig-
nals and to correctly link the response to these. The molecular mechanisms behind are out-
lined in the following detailed view. 
Somatic cell division is initiated by a receptor mediated signalling pathway, called the 
MAPK (mitogen-activated protein kinase) signalling pathway (see Fig. 5). It is a conserved 
mechanism which controls cellular growth, proliferation, differentiation and survival of 
cells. Due to stimulation (e.g. growth factors, stress, hormones etc.) of receptor tyrosine 
kinases in the cellular plasma membrane small GTP-binding molecules consequently acti-
vate three downstream kinases. These kinases, termed MAPKKK (MAPKK kinase), 
MAPKK (MAPK kinase) and MAPK sequentially phosphorylate each other: MAPKKK 
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phosphorylates and activates MAPKK, MAPKK phosphorylates and activates MAPK. [29] 
Thus activated MAP kinase phosphorylates and activates transcription factors or other ser-
ine/threonine kinases which induce specific cellular responses. [30] 
Three distinct MAPK signal transductions are well-known, the Erk, Jnk and p38 MAPK 
pathway, whereas the Raf-MEK1/2-ERK1/2 pathway is the most frequent one (Fig. 5). 
Although activation of all three pathways follows the same principle, the type of stimula-
tion and outcome differ. [30] 
 
 
Fig. 5:  a. General MAPK signal transduction pathway step by step, b. Raf-MEK/1/2-ERK1/2 pathway in 
detail  [31] 
 
So in response to extracellular signals cells activate the Raf-MEK1/2-ERK1/2 pathway to 
synthesize type D cyclins (cyclin D1, D2 and D3) and thus to turn on cell cycle. [22] Cyclin 
D forms complexes with CDK4/6 travelling that way to the nucleus to become fully acti-
vated by CAK kinase. Thereby the type of cyclin D seems not to be relevant. However due 
to the short-lived properties of D-type cyclins it is of great importance that cells receive 
continuously mitogenic signals for a permanent cyclin D synthesis. Otherwise the cell cy-
cle would be interrupted and cells enter quiescence. [32] 
Active CDK4-cyclinD or CDK6-cyclinD complexes phosphorylate the tumor suppressor 
protein pRb at three critical residues (Ser780 and Ser807/811) in order to inactivate it during 
G1 phase. At the beginning of G1 phase pRb is hypophosphorylated (or not phosphorylated 
at all) and tightly bound to the transcription factor E2F, which is important for S phase 
gene expression. [4] pRb masks the transactivation domain of E2F and keeps it inactive by 
that way. Additionally it interacts with histone deacteylases to repress premature transcrip-
tion. [33] As soon as pRb phosphorylation occurs, cyclin E expression is induced. [34] Asso-
ciation of cyclin E with CDK2 in late G1 phase results in pRb phosphorylation (at the 
fourth serine795) and ultimate lost in its growth-inhibitory power. [19] This is the moment 
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when a cell leaves the restriction checkpoint behind and is irreversibly committed to DNA 
replication and cell division (thus not responsive to extracellular signals anymore). [15] As a 
consequence the E2F transcription factor is released from Rb binding and becomes tran-
scriptionally active. [4] Cells proceed to S phase where E2F initiates transcription of impor-
tant genes like cyclin A. [35] At the same time cyclin E is proteolytically degraded to ensure 
just one replication round per cell division. [15] 
Progression through S phase is driven by active CDK2-cyclinA kinases which target pro-
teins specific for DNA replication. Amongst others Rb hyperphosphorylation is kept up 
until mitosis completion. [22] Towards the end of S phase cyclin A rapidly complexes with 
CDK1, whereas CDK1 seems to be poorly phosphorylated at inhibitory residues. [36] Con-
sequently E2F promoted transcription is repressed, resulting in a repressed E2F accumula-
tion and S phase exit. [37] During G2 phase cyclin A-CDK1 kinase enhance activation of 
cyclin B associated CDK1 complexes by inhibiting the kinase responsible for inhibitory 
phosphorylation on CDK1. [36] Cyclin B-CDK1 complexes regulate the transition through 
the G2/M checkpoint and the mitosis phase. [15] Initiation of mitosis requires phosphoryla-
tion of CDK1 at threonine161 and removal of phosphate groups from the inhibitory sites by 
cdc25C phosphatase. [8] Cyclin B associated CDK1 kinases influence then several ongoing 
processes during mitosis, like chromosomal condensation, centrosome separation, break-
down of nuclear lamina and guide through mitotic progression. [15] 
Finally, an appropriate exit from mitosis necessitates inactivation of CDK1-cyclinB com-
plexes, which is performed by APC during metaphase. [15] APC ubiquitinates cyclin B, thus 
it triggers its proteosomal degradation. Concomitantly, CDK1 undergoes a conformational 
change which leads to its complete inactivation. [38] 
Figure 6 outlines CDK-cyclin complexes important in cell cycle progression.  
 
 
Fig. 6: Cyclin-CDK complexes responsible for cell cycle progression [4] 
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 1.2.  Programmed cell death  
Together with cellular proliferation organisms harbour a mechanism for programmed cell 
death (apoptosis). To keep the balance between both processes is indispensable to life. 
Disorders in both events may lead to autoimmunity, cancer and other diseases. [39] 
Apoptosis is a physiological process of natural cell suicide in order to eliminate damaged, 
dangerous or a surplus of cells. [40] It is an active, controlled process which in contrast to 
necrosis (also believed to be a form of cell death) does not trigger any inflammatory re-
sponse. Supplementary it does not cause any harm to the organism. [41] Apoptosis plays an 
immense role in tissue homeostasis, defense against pathogens, elimination of unnecessary 
cells and generally in the development of organisms. Typical, common morphological fea-
tures are cell shrinkage, chromatin and cytoplasm compaction and DNA fragmentation, [40] 
all ending in the generation of apoptotic bodies which are then removed by phagocytosis. 
Apoptotic bodies are fragments/vesicles surrounded by intact membranes to prevent leak-
age of cellular contents, which otherwise would trigger an immune response. [42] 
There are two alternative pathways of apoptosis induction, the mitochondrial and the re-
ceptor-mediated pathway. For both pathways caspases (cysteine aspartic proteases) are 
important mediators [39], which lead to a complete degradation of cellular components. [43]  
 
 1.2.1.  Cystein aspartic proteases (caspases) 
Caspases are proteases stimulated by pro-apoptotic signals to induce a downstream caspase 
cleavage cascade ending in degradation of the cell. These proteases are synthesized as in-
active precursors (pro-caspases) and proteolytically cleaved to active enzymes (by them-
selves or by other proteases), whereas once activated no return is possible. [44] Caspases are 
usually made up of a large and a small subunit linked to a pro-domain. After proteolysis (at 
aspartat residues) the prodomain is displaced and caspases form heterodimers with other 
caspases, in which the small subunits face each other (Fig. 7). [45]  
 
 
Fig. 7: Caspase zymogens forming heterodimers when activated [46] 
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Two families of caspases can be distinguished, namely the inflammatory and the apoptotic 
caspases, whereas the latter include initiator and effector caspases. Initiator caspases (cas-
pase-2, -8, -9 and -10) are recruited in multiplicity via adaptor proteins and auto-activated 
due to close vicinity. These caspases initiate the caspase cascade leading to the activation 
of downstream effector caspases. Effector caspases (caspase-3, -6 and -7) cleave cellular 
proteins thus dismantling cells. [47]  
 
 1.2.2. Receptor-mediated pathway (extrinsic pathway) 
This apoptosis pathway is triggered when corresponding ligands (e.g. FAS – a transmem-
brane protein) bind to specific cell surface receptors belonging to the tumor necrosis factor 
(TNF) family due to death stimuli (Fig. 8). [48] TNF receptors trimerize upon activation, [49] 
thus recruiting the adaptor protein FADD (Fas-associated death domain protein) to their 
cytoplasmic death domain. FADD binds then the initiator caspases, pro-caspase-8 and pro-
caspase-10, to form the death-inducing signalling complex (DISC). [39] The result is auto-
proteolytic cleavage of caspase-8/10 and activation of downstream effector caspases (e.g. 
caspase-3). [49] 
 
 
Fig. 8: Schematic view of the extrinsic and the intrinsic apoptosis pathway [50] 
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 1.2.3.  Mitochondrial pathway (intrinsic pathway) 
Due to apoptotic signals pro-apoptotic proteins belonging to the Bcl-2 family experience 
modifications which activate and translocate them to mitochondria to induce the intrinsic 
apoptotic pathway (Fig. 8). [48] The consequence is disruption of the mitochondrial mem-
brane and loss of the electrochemical potential following a release of cytochrome c, 
Smac/DIABLO and apoptosis-inducing factor (AIF). Cytochrome c forms the apoptosome 
by interacting with Apaf-1 (apoptotic protease activating factor-1), ATP and pro-caspase-9 
in the cytosol. Subsequent activation of caspase-9 leads to the initiation of the caspase cas-
cade. [43] 
 
The type of signals cells receive determines which pathway is switched on. Extracellular 
signals like growth factors, hormones, cytokines and toxins elicit the extrinsic pathway, 
whereas hypoxia, oxidative stress, heat shock, DNA damage, viral infections and radiation 
trigger the intrinsic pathway. However, a cross-talk between both pathways exits. [51] In 
some cell types caspase-8 is insufficient to induce the receptor-mediated pathway. Thus 
interaction with the mitochondrial pathway is a way out of the misery. Activated caspase-8 
cleaves the pro-apoptotic Bcl-2 member Bid, which travels to mitochondria and induces 
cytochrome c release. [39] 
 
Both pathways join the same final route to cell death. Caspase-8 or -9 in the case of the 
mitochondrial pathway activate pro-caspase-3, an effector caspase, which in turn activates 
caspase-6 and caspase-7. Cellular targets are proteins like nuclear lamins, the cytoskeletal 
protein actin, DNA repair proteins like PARP-1, Bcl-2 family members, transcription fac-
tors (e.g. NF-κB) and cell cycle regulators (e.g. pRb). The final result is organized cellular 
death. [52] 
 
 1.2.4.  Regulation of apoptosis 
Referring to the regulation of apoptosis the same as for cell cycle regulation is valid. 
Proper regulation is a strict necessity, whereas control is executed at the level of caspases, 
involving the FLIP and Bcl-2 family, as well as inhibitors of apoptosis (IAPs) as important 
regulatory proteins. [40] Although there are many other regulatory levels, not all will be 
mentioned here. 
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 1.2.4.1. FADD-like ICE inhibitory proteins (FLIPs) 
FLIP proteins are involved in the receptor-mediated pathway and bind to the FADD adap-
tor protein thus blocking the caspase binding site. Alternatively they are also able to bind 
to pro-caspase-8/10 directly to inhibit their own binding to FADD. DISC formation and 
apoptosis are impeded. [52] 
 
 1.2.4.2.  Bcl-2 family 
The Bcl-2 family includes anti-apoptotic (e.g. Bcl-2, Mcl-1, Bcl-XL) as well as pro-
apoptotic (e.g. Bax, Bad, Bim) factors which are important in the control of the mitochon-
drial membrane permeability. [48] They decide whether apoptosome formation takes place 
or not, whereas an imbalance of one of both protein members is decisive. [50]  
Anti-apoptotic proteins reside usually in the outer mitochondrial membrane of healthy cells 
[53] inhibiting the conformational change of pro-apoptotic proteins, thus avoiding mito-
chondrial breakdown. When pro-apoptotic proteins, activated by death signals, undergo a 
conformational change they travel to the surface of mitochondria and bind to their Bcl-2 
counterparts. The result is inactivation of anti-apoptotic proteins and pore formation. [39] In 
spite of everything the concrete Bcl mechanism is still unclear. [54] 
Bad is a typical pro-apoptotic protein kept inactive in healthy cells by phosphorylation. Its 
sequestration in the cytosol is mediated by binding to 14-3-3 protein. Upon apoptotic 
stimulation dephosphorylation and translocation of Bad to the mitochondria induces apop-
tosis. [39] 
 
 1.2.4.3.  Inhibitors of apoptosis (IAPs) 
Inhibitors of apoptosis (e.g. survivin, XIAP, c-IAP1/2) are proteins affecting both apop-
totic pathways. [52] They directly interfere with caspase-3, -7 and -9 and inhibit their prote-
olytic procession required for full caspase activity. Admittedly it was not reported that 
other caspases are affected. [55]  
Smac/DIABLO (second mitochondria-derived activator of caspases), a protein released 
together with cytochrome c from mitochondria during apoptosis, is a typical IAP antago-
nist. Apparently it blocks the IAPs thereby promoting caspase cascade and apoptosis. [39] 
Due to the fact that IAP proteins contain a RING finger domain, typical for E3 ligases, and 
it is conceivable that they might target themselves or caspases for proteosomal degrada-
tion. [56] 
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Survivin is an essential inhibitor of apoptosis with cell cycle regulatory functions during 
mitosis at the same time. In contrast to other IAPs survivin has an unusual structure con-
taining only one typical BIR domain. [57] During the spindle checkpoint in mitosis phase 
survivin is phosphorylated at threonine34 by CDK1-cyclinB complexes. Thus active sur-
vivin controls the formation of the mitotic spindle by binding to microtubules and centro-
meres and prevents apoptosis at the same time. [58] Concerning its apoptotic functions it 
affects indirectly caspases, it is able to bind to XIAP and to prevent its Smac inhibition 
(thus promoting mitosis at the same time) and it can block apoptosome formation thus 
promoting survival. [59] 
 
 
 1.3.  Necrosis 
Necrosis is in contrast to apoptosis a form of uncontrolled cell death induced by accident. 
Typical characteristics are cellular swelling and loss of membrane integrity with a con-
comitant release of cytoplasmic content. Thereby adjacent cells are affected and inflamma-
tion occurs eventually. Usually treatment of cells with high cytotoxic agents provokes ne-
crosis. In literature necrosis is often termed as oncosis. [41] 
 
 
 1.4.  Cancer 
Cancer or malignant neoplasm as it is called medically is a genetic disease which can be 
traced back since mankind exists. [60] In consequence of deregulation of cell cycle cancer 
cells display a common uncontrolled proliferation and can be distinguished from healthy 
cells by several traits. [61] 
 
 1.4.1.  Characteristics of cancer 
In contrast to normal, healthy cells tumor cells acquire particular properties summarized in 
Figure 9, thus making them different. According to Hanahan and Weinberg one of the six 
characteristic features of cancer cells is escape from dependency on growth factors. On 
the one hand cancer cells are independent of mitogenic signals generating their own stimuli 
to overcome cell cycle repression. On the other hand malignant cells are deaf to inhibitory 
signals. A farther cancerous property is evasion from apoptosis by affecting the tumor 
suppressor protein p53, thus promoting survival. The unlimited replicative potential of 
tumor cells comes from their ability to activate telomerase to maintain telomere length and 
to prevent that way cellular aging. In order to expand, cancer cells induce angiogenesis 
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(blood vessel growth into the tumor), an ingenious trick which provides them enough oxy-
gen and nutrients. At this stage cells are finally capable of invading tissues and spreading 
all over the body forming metastasis, a crucial step to consecrated downfall. [62] 
 
 
Fig. 9: Properties of cancer cells [63] 
 
 1.4.2.  Malignant transformation leading to cancer 
Malignant transformation refers to the stage-wise development from healthy to tumori-
genic cells towards cancer. Independent of the cancer type a common sequence of events 
can thereby be observed. 
Cancer results from spontaneous (e.g. replication errors) or environmental induced (e.g. 
UV radiation, chemicals) genomic mutations in important regulatory genes. These muta-
tions include point mutations, frame-shift mutations, chromosomal mutations as well as 
epigenetic modifications (and many more). [64, 65] However, a simple mutation per se is 
only harmful when propagated and anchored in the progeny’s genome. Nevertheless, this 
does not immediately lead to the development of cancer, but it is a step forward to it. 
Clonal expansion of cells, which harbour a mutated gene, increases the chance for another 
mutation to occur. [65] After accumulation of several mutations in different genes – until 
now it is not known how many of them are required to induce malignant transformation – 
DNA damage, altered gene expression and protein function cause genomic instability. [65] 
Thus, according to different reports many cancer types display chromosomal aneuploidies. 
[64, 66]
 Although cells have certain DNA repair mechanisms, they seem to fail in most of the 
cases over the length of time. [65] Anyway, besides somatic mutations hereditary transmit-
ted germline mutations represent a risk factor for cancer development as well. [64] 
Altogether cancer obviously seems to be a complicated multi-step process of malignant 
cell transformation during a long time span. 
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Two major gene classes seem to contribute to malignant transformation to a very great 
part: proto-oncogenes and tumor suppressor genes. [67] Alterations in these genes lead to 
development of cancer. [68] 
 
 1.4.2.1.   Proto-oncogenes 
Proto-oncogenes are genes encoding proteins important in cellular stimulation regarding 
promotion of cell division and inhibition of apoptosis. [65] In spite of a tight gene regulation 
mutations in proto-oncogenes resulting in a “gain-of-function” cause cellular transforma-
tion. Such mutations often imply protein overexpression, constitutive activation or failure 
in switching off protein expression. [30] Due to a dominant nature, a mutation in a single 
allele is enough to enhance oncogene stimulatory properties. [65] Aberrant activated proto-
oncogenes are then called oncogenes. [30] 
Different transcription factors, chromatin remodelers, growth factors and their receptors, 
signal transducers (e.g. Ras) and apoptosis regulators (e.g. Bcl-2 family) are counted 
among oncogenes. [68] 
 
 1.4.2.1.1.  Ras oncogene 
One of the most famous oncogenes is the Ras oncogene. Ras is a small GTP binding mole-
cule residing in the inner plasma membrane. It is involved in transducing a mitogenic sig-
nal from a receptor on cell surface to important downstream kinases, thus mainly activating 
the Raf-MEK1/2-ERK1/2 MAP kinase pathway. This activation is a prerequisite for cells 
to enter G1 phase of the cell cycle. Other Ras targets are Ral-GEFs and PI3-K (phosphati-
dylinositol-3-kinase) which are important in remodelling the cytoskeleton. [69] 
Ras normally is inactive when bound to GDP (guanosine diphosphate). Due to stimulatory 
signals recognized by cell surface receptors the activated GEF (guanine exchange factor) 
catalyzes the exchange of GDP to GTP (guanosine triphosphate), which is present in a 
higher concentration in the cytoplasm. GTP-bound Ras constitutes its active form and Ras 
can exert its functions. However, Ras activation is short-termed. GAPs (GTPase activating 
protein) stimulate the intrinsic hydrolyzing potential of Ras: upon hydrolysis GTP is con-
verted to GDP and Ras gets again inactivated. [69] 
In many tumor types (about 70 %) Ras is mutated. This leads to its overexpression and/or a 
constitutive activation and in a consequence to enhanced signal transduction and accelera-
tion of the cell cycle progression. Thus Ras contributes to neoplasm formation. [69] 
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1.4.2.2.  Tumor suppressor genes 
Tumor suppressor genes are the adversaries of proto-oncogenes. They have inhibitory ef-
fects on the cell cycle, thus impeding progression if necessary. [65] Mutations in tumor sup-
pressor genes result in their inactivation. Thus important control mechanisms fall away and 
proliferation can unhampered proceed. [30] Unlike in oncogenes, mutations of suppressor 
genes are recessive, this means that a mutation in one allele is not enough to disable the 
affected gene. Nonetheless, it represents a predisposition towards tumor formation. Once a 
mutation in the second allele is acquired the gene is completely inactivated. This observa-
tion has become famous as the two-hit hypothesis proposed for the tumor suppressor pRb 
by Knudson A. in 2001, but is valid for all tumor suppressors. [70, 71, 72] Tumor suppressors 
are usually proteins which are important in controlling checkpoints or programmed cell 
death. [65] 
 
 1.4.2.2.1.  Retinoblastoma protein (pRb) 
The retinoblastoma protein is an important tumor suppressor protein that regulates the tran-
sition of the G1 restriction checkpoint during cell cycle. [73] As depicted earlier pRb is a 
prosperous inhibitor of transcription during S phase of the cell cycle. Hence, its correct 
inactivation is required for cellular proliferation. [74] 
Rb contributes to malignant transformation, if changes affecting the corresponding gene or 
its encoded protein occur. Inactivation of the Rb gene due to mutations (DNA-replication 
or mitotic recombination errors) [73] results in an allelic defect, which can be transmitted 
through the germline. [64] Later during child development a second acquired somatic muta-
tion in the other allele evolves to retinoblastoma. Retinoblastoma is a retina neoplasm in 
the eye. [73] At a very low probability retinoblastoma can also develop due to two separated 
somatic mutation events in both alleles. [30] 
In contrast to mutations which prevent Rb gene expression, alterations regarding the pro-
tein of Rb (phosphorylation, degradation, viral protein interaction) [74] lead to a non-
functional protein unable to bind E2F. The consequence is an uncontrolled proliferation of 
cells contributing to the development of other cancer types than retinoblastoma. [17] 
 
 1.4.2.2.2.  Transcription factor p53 
The transcription factor p53 (TP53) is one of the most important tumor suppressor genes 
which got famous by its second name “the guardian of the genome”. [75, 30] Due to its regu-
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latory functions in cell growth and genomic stability p53 protects cells from malignant 
transformation. [76, 77] 
Under normal conditions p53 is present only at low concentrations due to limited stability. 
It has a short half life (about 20 minutes). [76, 77] In response to DNA damage, hypoxia 
(oxygen deficiency) or other cellular stress stimuli [78] p53 translocates to the nucleus 
where different kinases (e. g. ATM, ATR, DNA kinase), which are induced dependent on 
the kind of stimuli, phosphorylate it on different serine or acetylate it on lysine residues 
(different other modifications can occur as well). [76, 77] These modifications stabilize and 
thus activate p53 subsequently. Its concentration rises and formation of p53 tetramers 
(consisting of two p53 dimers) takes place. p53 is then able to bind to DNA and act as a 
transcription factor. [30] Downstream targets include the CDK inhibitor p21Cip1/Waf1, 
MDM2, GADD45, cyclin G, Bax and IGF-BP3. [77] 
There are two different outcomes of p53 activation. p53 either induces cell cycle arrest or 
programmed cell death. Which process is finally triggered, depends on multiple factors. 
Growth and survival stimuli, pRb overexpression, presence of p21Cip1/Waf1 and cellular con-
centration of p53 itself seem thereby to play an important role in this decision. [79] 
p53 induced upregulation of p21Cip1/Waf1 protein early in cell cycle [30] leads to the inhibi-
tion of cyclin D-CDK4/6 complexes and prevents a further progression through the cell 
cycle. Arrest of cells in G1 phase is the result. [79] In G2 phase p53 cannot induce cell cycle 
arrest, but plays a role in maintaining it. Upon DNA damage p53 targets several down-
stream proteins. p53 negatively affects the cdc25C phosphatase which is important for ac-
tivation of the mitosis promoting factor (MPF), CDK1-cyclinB. [80] Additional upregula-
tion of 14-3-3-σ prevents the correct nuclear localization of MPF thus impeding cell cycle 
progression. [81] p53 induced p21Cip1/Waf1 expression seems to affect CDK1-cyclinB by in-
hibiting its kinase activation by CAK [82] or by sequestering the complex in the nucleus to 
prevent the activating dephosphorylation by cdc25C phosphatase. [83] p53 also activates the 
GADD45 protein (growth and DNA damage protein), which normally interacts with 
PCNA, but which also seems to interact with CDK1 leading to its dissociation from cyclin 
B. [84] 
Cell cycle arrests comprise a perfect chance for cells to switch on various DNA repair 
mechanisms to remediate the induced errors. If the repair was successful, cells can re-enter 
the cell cycle to grow farther. Otherwise apoptosis would be the logical consequence. [85]  
Regarding p53 induced apoptosis, p53 binds to promoters of various pro-apoptotic proteins 
and activate their transcription. Such proteins include Bcl-2 family members (PUMA, 
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NOXA, Bax), p53AIP1 (p53 apoptosis inducing protein), Apaf-1 and Fas. Thus p53 is able 
to influence the extrinsic and intrinsic pathway. [76, 77] However, a transcription independ-
ent mode of p53 action was described as well. p53 is believed to translocate into mito-
chondria [86], where it contributes to the loss of membrane integrity leading to caspase acti-
vation and thus to apoptosis. [87] Other theories say that p53 directly interacts with the pro- 
and anti-apoptotic members of the Bcl-2 family. [76, 77] 
p53 itself is regulated by Mdm2 (mouse double minute 2) protein, an E3 ligase which 
binds to the transactivation domain of p53 and blocks its function. On top of it Mdm2 tar-
gets p53 for polyubiquitination and proteosomal degradation. Mdm2 is a downstream tar-
get of p53 at the same time and thus transcribed by the latter. This negative feedback loop 
assures that p53 levels settle down after a triggered response. [79] The CDK inhibitor 
p14ARF (alternative reading frame protein) in contrast is able to bind to Mdm2 and to pre-
vent p53 degradation. Additionally, all p53 modifications induced upon genotoxic stress 
contribute to a disruption of the interaction with Mdm2. [88] 
In 50 % of all tumors TP53 is mutated, in all other cases, proteins influencing p53 are af-
fected. [89] In particular the DNA binding domain of p53 seems to be very susceptible for 
such mutations, an evidence for its importance in the p53 suppressor functions. [90] Addi-
tionally, TP53 germ line mutations occur. They got well known as the Li-Fraumeni syn-
drome in which affected persons develop a tumor at a juvenile age and have a great chance 
to develop secondary carcinomas as well. Apart from occurring mutations p53 can also be 
inactivated by virally encoded proteins. [91] A more detailed description about these 
mechanisms can be found in the next section.  
Hence, p53 is definitely the focus of tumor development and there is a great interest in 
restoring p53 functions by p53-based therapies, like for instance gene therapy or reconsti-
tution of p53 wild type conformation. [91] 
 
 1.4.3.  Other targets of cancer 
In addition to oncogenes and tumor suppressor genes, which are affected most of the time 
in neoplasia, several other deregulations may contribute to malignant transformation. They 
should be mentioned here shortly. In association with the cell cycle overexpression of cy-
clins, aberrant activation of CDKs [92], defective checkpoints and mutated CDK inhibitors 
abrogate the correct cell cycle progression. [10] Overexpression of anti-apoptotic proteins or 
IAPs like survivin, mutations in death receptors [39], failure in DNA repair and virally 
transformed cells are also often observed. [8] Anyway, nearly every protein equipped with 
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regulatory functions seems to be a potent target in cancer. Unfortunately not all of them are 
identified yet, but with the information available anti-cancer treatment are on the advance. 
Last but not least, it should be mentioned that not only internal factors play important roles 
in cancer development. Cancer has a lot to do with lifestyle and attitude, this regards espe-
cially dietary, alcohol consumption and smoking, three main risk factors for developing 
cancer. [93] 
 
 1.5.  Human papillomaviruses (HPV) 
Human papillomaviruses are small, non-enveloped viruses containing a double-stranded, 
circular DNA of 8 kb length. [94] Papillomaviridae display a high affinity for epithelia, in-
fecting dermal or mucosal tissue of the anogenital and oropharyngeal tract. [95] Viruses 
infecting the mucosa can be classified in low-risk and high-risk subtypes. [94] Low-risk 
viruses, including HPV 6, 11, 42-44, 53-55 and 66 [96] cause oral papillomas, skin warts or 
condylomata in the anogenital area and are considered to be inoffensive. [97, 98] In contrast, 
high-risk viruses are able to transform host cells [94], long-term infections thus provoking 
cancer of the vulva, vagina, cervix, anus and penis. [97] HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 55, 56, 58, 59, 68, 73, 82 and 83 are considered as being intermediate or high-risk sub-
types. [99] Bold highlighted numbers represent the most frequent HPV types detected. [96] 
Up to now 200 virus types have been discovered [94], whereas HPV occurs in 20 different 
species for instance in birds. [100] 
 
 1.5.1.  HPV genome structure  
HPV particles encode eight open reading frames (ORFs), which are translated from a poly-
cistronic mRNA. [94] Thereby three different types of genes can be distinguished (Fig. 10). 
The late genes L1 (major capsid protein) and L2 (minor capsid protein) assemble the cap-
sid, a protein coat around the DNA to protect it. [101] The early genes E1, E2, E4 and E5 are 
essential for DNA transcription and replication, whereas the E6 and E7 proteins are impor-
tant for cellular transformation. [98]  And ultimately a non-coding region between the early 
and the late genes, a stretch of 1 kb which is called the upstream regulatory region (URR) 
due to its regulatory functions in gene expression, replication and viral assembly. [101]  
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Fig. 10:  General genome structure of human papilloma viruses – E1, E2, E4-E7 = early transcribed genes, L1 
and L2 = late transcribed genes [101] 
 
 1.5.2.  HPV life cycle 
The life cycle of human papilloma viruses strongly depends on their host, the keratino-
cytes. [94] This is due to the fact that HPV does not encode his own replication proteins and 
therefore parasitically exploits the DNA replication machinery of its host. That means vi-
ruses replicate only when the host is copying its DNA. [102] 
 
 
Fig. 11: HPV infection pathway of keratinocytes [103] 
 
Figure 11 depicts the HPV infection pathway. Human papilloma viruses infect basal stem 
cells of the epithelium, reaching them by small skin injuries. [101] These cells are the only 
type of cells they can enter [102], because of their continuous dividing properties. All other 
epithelial cells, lying over the basal cells, are differentiated and not able to divide anymore. 
Hence, they are useless for viruses. [101]   
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Access to cellular insides is achieved by the binding of viral particles to two different cell 
surface receptors, which enable their uptake. However, until now it is doubtful which re-
ceptors exactly are in charge. Heparan sulfate proteoglycan and α6 integrin receptors are 
thought to be involved. [104] Entry of virions is finally mediated by endocytosis of clathrin 
coated vesicles, which seems to be delayed however. [105] Viral uncoating, a scientific term 
for the release of viral DNA from the capsid, occurs in late endosomes and/or lysosomes. 
The DNA is then imported to the nucleus, where replication can take place. [104] The L2 
protein seems to be involved thereby since it contains a nuclear localizing signal (NLS). [94] 
In basal, undifferentiated cells the viral DNA remains inside the nucleus episomal, that 
means it does not integrate into the genomic DNA of the host. [98] The first genes to be 
transcribed are E1 and E2 [94, 106], both involved in viral replication and episomal mainte-
nance. Initiation of early gene transcription is mediated by cellular transcription factors 
upon binding to the URR. [106, 100] E1 and E2 are expressed at low levels and produce only 
a low copy number of the viral DNA. E6 and E7 expression in basal stem cells seems to be 
in question yet. [100] As being a helicase, E1 has the ability to unwind the DNA and addi-
tionally to interact with DNA polymerase and different accessory proteins to induce repli-
cation. However, its DNA binding is of low affinity. Therefore E2, a DNA-binding protein, 
helps in recruiting E1 to the origin of replication. [94, 100, 104] Besides, E2 displays transcrip-
tional regulatory functions, thus controlling E6 and E7 expression from the early promoter. 
[104]
 
After mitosis of basal stem cells one of the daughter cells normally migrates upwards 
through the various skin layers and starts its differentiation program. This is linked to the 
final exit of cells from the cell cycle and marks the end of their dividing properties. [94, 103] 
At the top cells lose their nuclei [94], get a cornified stratum and replace the old cells, which 
flaked away. This is part of the skin regeneration process in healthy cells. [102] In infected 
cells HPV senses the induced differentiation and renders suddenly its transcription pro-
gram to enhance gene expression. E4, E5, E6 and E7 proteins are now transcribed at high 
levels. Before, hardly any of these proteins were synthesized. [106] Upregulation of E6 and 
E7 proteins leads to a continuous cell proliferation and terminates the differentiation pro-
gram of cells. Cells thus replicate at an accelerated rate. This may cause the formation of 
benign warts. In the worst case however, cells are being transformed by E6 and E7 activi-
ties and as a result exposed to a higher risk to develop cancer. About E4 and E5 proteins 
very little is known. E5 is said to be involved in mimicking growth signals to keep cells 
proliferating [102], whereas E4 helps in disrupting the keratin network in cornified cells at 
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upper cell layers. [104] Eventually expression from the late promoter leads to L1 and L2 
accumulation in cells of the external epidermal layer. This stimulates packaging of new 
progeny viruses, which are then shed together with old skin cells. New viruses escape from 
the cornified stratum assisted by E4. [104]  
Human papillomaviruses evade from immune system by their perfect elaborated strategy to 
survive in keratinocytes. Replication and virus particle packaging is restricted to cells in 
the upper layers of the skin/mucus, far away from any immune competent cells. [102] Like-
wise, HPV oncoproteins can interfere with interferons and reduce the MHC I expression in 
infected cells, thus they are not able to present the antigen to the immune system. [107] So 
the infection may not be observed for a long time. [102] 
 
 1.5.3.  HPV E6 and E7 oncoproteins  
The E6 and E7 proteins are both mainly nuclear proteins [108], expressed relative early dur-
ing the viral life cycle. [104] Their ability to promote continuous cell proliferation by the 
abolishment of the proper cell cycle regulation is of great significance in establishing viral 
pathogenesis. [108] However, only cells infected by high-risk papillomaviruses seem to be at 
risk to develop cancer. [104] Although E6 and E7 from low-risk HPV types drive cells into 
an accelerated progression as well, the result is simply an accumulation of cells forming a 
benign wart, which is restricted to a small area. [98, 102] These oncoproteins become only 
dangerous when the HPV infection persists over years. Then the probability of random 
integration of the viral DNA into the host’s genome increases. It is an event which does not 
provide any benefit for the virus, it is rather contrariwise because most of the genes are lost 
thereby. The infection can usually be cleared, but some of the cells may survive with the 
integrated E6 and E7 oncoproteins in their genome. This would be a devastating conse-
quence, which allows mutations to accumulate. [102]  
E6 and E7 oncoproteins are expressed from a bicistronic mRNA [109] and seem to cooperate 
together. [104] 
      
 1.5.3.1.  E6 oncoprotein 
A step forward to cellular transformation is made by the different interactions of the E6 
oncoprotein with several binding partners inside the cell. These interactions result in the 
inhibition of the proteins. [98] 
The probably most important binding partner of E6 is the tumor suppressor p53, which is 
normally expressed and maintained at low levels in healthy cells. As the viral infection 
occurs, the cell reacts with the upregulation of p53. To impede cell cycle arrest or apop-
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tosis induced by p53, E6 grabs p53 and binds additionally to E6-AP (E6 associated pro-
tein), an E3 ubiquitin ligase, at the same time. This allows the interaction between p53 and 
E6-AP, which normally would not be able to bind to p53 on its own. As a matter of fact 
p53 is ubiquitinated and degraded in the proteasom (Fig. 12). 
However, E6 can inactivate the p53 protein by other mechanisms discovered recently. The 
interaction with p53 occurs in a way that blocks its DNA binding domain thus preventing 
its transcriptional functions. Secondly, E6 can bind and mask the NLS of p53, thereby se-
questering it in the cytoplasm keeping it away from its target action side. A third mecha-
nism is the binding of E6 to CBP/p300, proteins which normally activate p53. [108] E6 also 
targets proteins important for apoptosis like FADD, Caspase-8 and Bak and mediate their 
degradation in order to reduce the probability of an induced apoptosis due to the viral in-
fection. Many other interaction partners involved in chromosomal stability, epithelial or-
ganization, differentiation and transcriptional regulation have been reported as well. [98] 
 
 
Fig. 12: E6 and E7 oncogene interaction with important cellular tumor suppressor proteins [110] 
 
 1.5.3.2.  E7 oncoprotein 
The high-risk E7 oncoprotein leads to immortalization of cells by interacting with the tu-
mor suppressor pRb and its binding partner E2F, outlined in Figure 12. pRb normally con-
trols the G1 restriction checkpoint through inactivating the S phase specific E2F transcrip-
tion factor. Binding of E7 to hypophosphorylated pRb and concomitantly to E2F displays 
the latter from the complex. [111, 112] Subsequently E2F induces transcription of genes im-
portant for DNA replication. [101] Thus, E7 abrogates the restriction checkpoint and medi-
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ates cell cycle progression. However, E7 complements this by the interaction with different 
cellular proteins. Interaction with CDK inhibitors (p21Cip1/Waf1, p27) abolishes their inhibi-
tory function of halting the cell cycle. E7 binding to HDACs (histone deacetylases) allows 
chromatin remodelling processes to take place and to induce gene transcription. Addition-
ally, binding to CDKs, p300/CBP, TBP and AP-1 transcription factor were observed as 
well. [111, 112] 
Anyway, unscheduled S phase activates apoptosis, triggered by p53. At this stage E6 inter-
venes and interacts with p53 directly to prevent undesired cellular changes. [113] 
 
 1.5.4.  Cervical cancer 
Cervical cancer is the abnormal growth of cells in the lower part of the uterus, the so-called 
cervix (neck of uterus). [103] This type of cancer causes very frequently female death world-
wide. [114] 
Human papillomaviruses have been accounted for more than 90 % of all cervical cancers 
[111]
, whereas in particular HPV types 16 and 18 seem to be responsible for 70 % of all 
cases. However, an HPV infection is not sufficient to induce cancer. Several other factors 
like taking hormonal contraceptives over a longer period of time, smoking, various other 
coinfections (e.g. chlamydia, herpes simplex virus) and bad nutrition contribute to tumor 
formation. [101]   
 
 1.5.4.1. Transmission and diagnosis 
Human papillomaviruses are transmitted by skin-to-skin contact, which occurs to a great 
part by sexual intercourse. Thus, frequent changing of multiple sexual partners increases 
the risk of infection. Thereby using condoms seems not to protect entirely because of the 
possible contact to other infected parts of the anogenital tract. [102, 115] Since HPVs are quite 
resistant to environmental impact they are able to survive and to establish a source of in-
fection. [115] Vertical transmission from mother to child through the birth canal is also at 
question. However both occur to a lower extent. [116] 
A majority of the population is infected with various types of HPV without even knowing 
about it. Thus the danger of infection is quite high. One possibility to prevent or at least to 
reduce the outbreak of cancer in most cases is early diagnosis. 
The first method to be used for HPV screening was the Papanicolaou test or shortly Pap 
smear. It is a simple staining method of cells scraped off from the cervix. Examination 
under the microscope allows the differentiation between healthy and abnormal cells, which 
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display enlarged nuclei surrounded by clear rings (Fig. 13). But the visual inspection of the 
cervix is part of the daily routine as well. [102, 115] Since detection of HPV by Pap smear is 
used, 70 % of  cancer mortality could be reduced in the past 50 years in the United States. 
[102]
 However, due to false negative results, which can occur due to clumping of cells, other 
detection methods are additionally performed. [115] 
 
 
 
 
 
 
 
Fig. 13:  Pap smear of cervical cells – Cells on the left are healthy; cells on the right display enlarged nuclei, 
which indicate an HPV infection. [117] 
 
A better and more sensitive detection method is DNA testing, where cervical biopsies are 
taken to extract cellular DNA or RNA. Exposure of the genetic material to special reagents 
generates a positive signal, if HPV DNA/RNA is present. Two methods are generally in 
use: in-situ hybridization and PCR-hybridization. 
During in-situ hybridization the isolated genomic material is exposed to probes which bind 
(hybridize) to specific HPV sequences, if they are present in the sample. Incubation with 
an antibody recognizing the probe itself enables the visualization of a positive signal, if a 
detection reagent is added. PCR-hybridization is a similar technique, which in contrast 
amplifies the extracted genetic material before beginning the hybridization. For this reason 
it is more sensitive than hybridization alone.  
The advantage of these sensitive methods is that infected cells can be detected even before 
any cytological abnormalities occur. [102] 
 
 1.5.4.2. Symptoms and treatment 
HPV infections produce seldom any symptoms [115, 118], although pain and vaginal bleeding 
were reported in very rare cases. [119] The occurrence of warts can be a typical evidence for 
an HPV infection. [118]  
If cytological abnormalities attributed to an HPV infection were detected, appropriate treat-
ment should succeed as soon as possible to impede the further progress. Otherwise the 
situation would only worsen.  
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Normally, a healthy immune system is capable of clearing HPV infections in 1-3 years 
without even to be noticed actually. [115] Should the infection persist and erupt visibly, re-
moval of affected cells by surgery, liquid nitrogen, laser, radiotherapy, chemotherapy, 
chemical burning with salicylic acid or podofilox or by the treatment with antiviral and 
immunomodulatory agents like interferons takes place. [102, 115]  
 
 1.5.4.3. HPV vaccines 
In addition to the above mentioned treatment types, two prophylactic HPV vaccines are 
commercially available since 2006. Gardasil® from Merck and Cervarix® from GlaxoS-
mithKline are both protein subunit vaccines using the L1 capsid protein of HPV. [120, 121] 
L1 is said to self-assemble into virus-like particles (VLPs) and to elicit an adaptive im-
mune response producing neutralizing antibodies. [121] 
Gardasil® is a quadrivalent vaccine containing L1 proteins from HPV 6, 11, 16 and 18 pro-
duced recombinantly in the yeast Saccharomyces cerevisiae. This vaccine is believed to 
protect against 90 % of all genital warts and against 70 % of cervical cancer. Cervarix® in 
contrast is only a bivalent vaccine protecting against HPV 16 and 18 and is produced by 
baculoviral expression in the insect cells Trichoplusia ni. [107, 120] However, both vaccines 
do not protect against persistent HPV infections acquired before vaccination. [120] There-
fore the best time for immunization is during youth, when young women have not become 
sexually active and are not infected yet. Hence, vaccination between 9 and 26 years is rec-
ommended. [122, 123, 124] Currently no one knows if refreshment to boost the immune reac-
tion will be necessary after some time. [107, 118] 
It is claimed that these vaccines are not dangerous to healthy people. That means that even 
though viral material is directly injected, they are not able to initiate an HPV infection 
themselves due to the lack of a viral DNA. Although adverse local reactions after vaccina-
tion were quite common. The majority experienced pain at the injection side, swelling and 
very rare fever. Surprisingly Gardasil® can be used to vaccinate male persons to prevent 
spreading of HPV as well, though it is not admitted everywhere. [125] 
However, due to the yet unknown consequences of vaccination and the with it associated 
high costs young women are often restrained from assuming a risk.  
 
 1.6.  Pharmacological CDK inhibitors as new therapeutic agents 
With all the information acquired so far about cell cycle and its regulation, about pro-
grammed cell death, cancer and its development and viral HPV infections all contributing 
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to tumor progression, it will become obvious that there is more behind cancer prevention 
and therapy. In addition to anti-cancer drugs developed to directly kill tumor cells, the po-
tential of a new approach involving pharmacological CDK inhibitors was discovered re-
cently. These inhibitors are capable of modulating cells in a way that stops the transform-
ing properties of malignant cells and provide a good alternative therapy to vaccines against 
HPV. [10] 
Pharmacological CDK inhibitors are synthetic compounds [43] which act like cellular CDK 
inhibitors. Due to frequent deregulations of cyclin-dependent kinases (CDKs) or their natu-
ral inhibitors during malignant transformation, pharmacological CDK inhibitors, in con-
trast, could offer possible alternatives for therapy. Up to now more than 50 such com-
pounds including flavopiridol, ROSC and olomoucine are investigated in their efficacy to 
fight cancer. [126] 
A common feature of all pharmacological and natural CDK inhibitors is the binding capa-
bility to the ATP binding site of kinases. [10, 126] Thus, blocking the activation of cyclin-
dependent kinases impedes the further cell cycle progression.  
These CDK inhibitors are thought to be highly selective and to have anti-proliferative as 
well as pro-apoptotic effects on cancer cells with a concomitant low cytotoxicity. Some of 
them are already in clinical evaluation (e.g. flavopiridol and ROSC). [10, 14, 43, 126] Recent 
analyses have even discovered that combined therapies with pharmacological inhibitors 
may be of great success due to possible synergistic effects and that CDK inhibition can be 
achieved at greater extents, if cells are synchronized prior to the treatment with pharmacol-
ogical inhibitors. [127] 
However, some of these new anti-cancer drugs are reported to have anti-viral effects as 
well. They are involved in blocking the viral replication not by inhibiting viral proteins, but 
cellular ones. Besides viral transcription can be blocked, whereas the cellular transcription 
is not affected at all. [128] 
So, pharmacological inhibitors constitute a great alternative to highly genotoxic, chemo-
therapeutic drugs or dangerous HPV vaccines and are worth of further investigation. 
 
 
 1.7.  Aims of the present diploma thesis 
Considering the fact that pharmacological CDK inhibitors seem to be very effective agents 
in the treatment of cancer, the question appeared whether small-molecule compounds such 
as ROSC and OLO II would be able to affect cancer cells lacking functional G1/S check-
point. The main purpose of the thesis was to compare the effects of two closely related 
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pharmacological CDK inhibitors on human HeLa and HTB-31 cervical cancer cells differ-
ing in the status of p53 and G1/S checkpoint. Although structure of both CDK inhibitors is 
very similar, their properties slightly differ. Therefore, it was of interest to compare their 
action and to monitor in detail the changes in the expression and functional status of the 
most important cellular factors regulating cell cycle progression and apoptosis. Moreover, 
it was important to prove whether cell cycle status of cancer cells prior to the onset of 
treatment might have any effect on the efficacy of therapy. Following issues were raised: 
 
1. Assessment of the anti-proliferative effects of the two closely related tri-substituted 
purines roscovitine (ROSC) and olomoucine II (OLO II) on human HeLa and HTB-
31 cervix carcinoma cells 
2. Determination of pro-apoptotic effects of the two closely related tri-substituted 
purines roscovitine (ROSC) and olomoucine II (OLO II) on human HeLa and HTB-
31 cervix carcinoma cells 
3. Examination of the impact of the p53 status on the outcome of treatment of HeLa 
cells (dysfunctional wt p53 protein) and HTB-31 cells (mutated p53) 
4. Determination of the importance of the functional status of cancer cells prior to the 
onset of treatment for the outcome of therapy 
a. Effect of CDK inhibitors on asynchronously growing cancer cells after short 
(10h) and long (22h) recovery period after plating 
b. Effect of CDK inhibitors on G1-arrested cervix cancer cells released from 
TSA block 
5. Characterization of the changes in the levels and functional status of major regula-
tors of cell cycle and apoptosis induced after administration of CDK inhibitors 
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 2. MATERIALS & METHODS 
 
 2.1. Materials 
 
2.1.1. Cell lines 
 
 2.1.1.1.  HeLa S3 
 
 
Organism homo sapiens 
Organ cervix 
Cancer type cervix carcinoma 
Morphology epithelial 
Medium RPMI 1640 
Fetal bovine serum 10 % 
CO2 Atmosphere   5 % 
Temperature 37°C 
Special characteristics wt p53, HPV-18 positive,  
lack of G1 restriction checkpoint 
 
Tab. 1: Short résumé of HeLa S3 cell characteristics [129] 
 
 
Human HeLa cells are epithelial cells derived from a primary cervical carcinoma tumor. 
They are adherent and have the ability to pile up due to loss of contact inhibition. Their 
population doubling time is approximately 24 hours. Their characteristics are summarized 
in Table 1, whereas Figure 14 shows an image of asynchronously growing HeLa cells ex-
amined under light microscope.  
The human HeLa S3 cervical carcinoma cell line was cultured in RPMI-1640 medium sup-
plemented with 10 % fetal bovine serum (FBS) and phenol red as a pH indicator. Passag-
ing of cells occurred twice a week in a ratio varying between 1:6 to 1:10. To maintain 
physiological conditions as realistic as possible no antibiotics were used for cell culture. 
This cancer cell line established from primary tumor is transformed by the high-risk human 
papillomavirus 18 (HPV 18): multiple copies of HPV 18 DNA are integrated into the host 
DNA. [130] Two of the expressed viral HPV 18 oncoproteins, namely E6 and E7, interfere 
with important tumor suppressor proteins in HeLa cells. The E6 protein inactivates the p53 
protein by enhancing of E6-AP-mediated ubiquitination and degradation in protea-   
somes. [21] The E7 protein binds to the hypophosphorylated pRb, leads to its inactivation 
and the release of E2F transcription factors, promoting S phase. Thus, the G1 restriction 
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checkpoint in HeLa cells is lacking. In general terms, virally encoded proteins abolish cell 
cycle arrest and induce permanent cell cycle progression. 
 
               a.           b.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 14:  HeLa cells in cell culture flasks - a. a phase contrast image under light microscope, b. photography 
using the Hoffman modulation contrast                                                         
 
 
 2.1.1.2. HTB-31 (C-33A) 
 
 
Organism homo sapiens 
Organ cervix 
Cancer type cervix carcinoma 
Morphology epithelial 
Medium MNP 
Fetal bovine serum 10 % 
CO2 Atmosphere   5 % 
Temperature 37°C 
Special characteristics mutant p53 and pRb, HPV nega-tive 
 
Tab. 2: Short résumé of HTB-31 cell characteristics [131] 
 
 
Human HTB-31 cells are, like HeLa cells, epithelial cells derived from a primary cervical 
carcinoma tumor. Table 2 describes their characteristics features, Figure 15 shows their 
specific morphology. 
These cells were cultured in MEME medium supplemented with 10 % fetal bovine serum 
(FBS), natriumpyruvate, non-essential amino acids and phenol red. Passaging of cells oc-
curred twice a week in a ratio varying between 1:4 to 1:8.  
Unlike HeLa cells, HTB-31 cells are negative for any human papillomavirus DNA or 
RNA, but harbour a p53 “loss-of-function” mutation. A point mutation in its conserved 
region at codon 273 (Arg → Cys substitution) results in a higher p53 expression. Moreover 
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retinoblastoma genes are also mutated (G → A nucleotide substitution). This results into an 
in-frame deletion in the pRb protein leading to a truncated form, which is not able to asso-
ciate with other cellular proteins anymore. As a consequence pRb is hypophosphorylated. 
[114]
 Both mutations contribute to an improper cell cycle progression leading to malignant 
transformation of cells. 
 
               a.           b. 
 
 
 
 
 
 
 
 
 
 
Fig. 15:  HTB-31 cells in cell culture flasks - a. a phase contrast image under light microscope, b. photogra-
phy using the Hoffman modulation contrast                                                         
 
In general terms, the inactivation of the tumorsuppressor proteins pRb and p53, either by 
mutation or by inactivation mediated by HPV-encoded oncoproteins, is an important step 
in human cervical carcinogenesis. [114] 
 
2.1.2.  Drugs 
 
 2.1.2.1. Doxorubicin 
 
 
 
Fig. 16: Molecular structure of doxorubicin hydrochloride [132] 
 
Doxorubicin (DOX) is an anthracycline antibiotic derived from the bacteria Streptomyces 
var. caesius, its molecular structure is depicted in Figure 16. [133] DOX displays several 
cytotoxic properties: Doxorubicin DNA intercalation or inhibition of DNA Polymerase 
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leads to a DNA/RNA synthesis inhibition, interference with DNA unwinding processes, 
inhibition of topoisomerase II and the generation of free radicals can lead to DNA da-  
mage [134], but DOX also affects electron transport chains in mitochondrial membranes, 
thus disrupting them. [135] According to the mentioned above action, cellular response to 
DOX depends on the dosage. At lower DOX concentrations cells undergo a strong G2 ar-
rest, whereas at higher doses DOX triggers apoptosis. [134] 
Doxorubicin is highly cardiotoxic and not selective at all, healthy and malignant cells are 
affected equally. Subsequent secondary effects are severe, thus other more selective and 
potent anti-cancer drugs are investigated. [134] 
 
 2.1.2.2. Olomoucine II 
 
 
 
Fig. 17: Molecular structure of OLO II [136] 
 
Olomoucine II (OLO II) is a new pharmacological CDK inhibitor that belongs to the 
purine family, especially inhibiting CDK1 and CDK2. However, it also affects transcrip-
tion by indirect modulation of the carboxy-terminal domain (CTD) of RNA Polymerase II 
through CDK7 and CDK9. Although OLO II occupies the active site of CDK2, which is 
almost the same binding position of ROSC, it seems to be more potent than ROSC itself. 
Comparing their molecular structures (shown in Fig. 17 and 18) there is a huge similarity, 
the only difference existing in an additional hydroxyl group at the benzyl ring increasing 
OLO II’s efficiency. OLO II is said to have anti-proliferative effects, blocking the cell cy-
cle and inducing elevated p53 gene expression at higher concentrations. [137] 
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 2.1.2.3. Roscovitine 
 
              a.              b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: a. Crystal structure of CDK2 in complex with (R)-ROSC, illustrating the position of (R)-ROSC in 
the ATP-binding pocket, b. Atoms involved in H-bond (R)-ROSC-CDK2 binding [138] 
 
R-ROSC (known also under commercial names Seliciclib or CYC202) is a potent and se-
lective CDK2, CDK1, CDK5 and CDK7 inhibitor. [138] ROSC, a tri-substituted analogue 
belongs to the family of purine CDK inhibitors and is, like OLO II, an ATP-like molecule. 
In other terms, it competes with ATP for CDK binding. [21] Figure 18 a. shows the crystal 
structure of (R)-ROSC in the ATP-binding pocket of CDK2. Fig. 18 b. shows the molecu-
lar structure of ROSC and the atoms, which are involved in hydrogen bonding to CDKs. 
In most cell lines two major ROSC effects were observed: a cell cycle arrest and an induc-
tion of apoptosis (programmed cell death). Inhibition of the cell cycle progression can oc-
cur directly by binding of ROSC to CDKs or indirectly either by interacting with CAK and 
therefore inhibiting the CDK activating phosphorylation or by stabilizing p27Kip1 and en-
hancing CDK inhibition. [138] 
 
 2.1.2.4. Mimosine 
 
 
 
 
Fig. 19: Molecular structure of mimosine [139] 
 
Mimosine (MIMO) is a non-proteinogenic, toxic amino acid isolated from the plant mi-
mosa pudica (Fig. 19). [140] Due to its ability to form iron chelate complexes MIMO seems 
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to repress the synthesis of deoxyribonucleotids and therefore to inhibit DNA replication 
(mechanism not fully elucidated). Hence, this compound can be used to synchronize cells 
in late G1 phase of the cell cycle. [141] This effect depends on the MIMO concentration and 
treatment period, but is completely reversible. [142] 
 
 2.1.2.5. Trichostatin A 
 
 
 
Fig. 20: Molecular structure of trichostatin A [143] 
 
Trichostatin A (TSA), an antifungal antibiotic, is a mammalian histone deacetylase inhibi-
tor with chromatin loosening effects (molecular structure is shown in Fig. 20). [144] Chro-
matin remodelling processes are responsible for transcriptional regulation of genes, 
whereas histone acetylases (HAT) and histone deacteylases (HDAC) are major key play-
ers. Acetylation is usually linked to the activation of gene expression. TSA plays an impor-
tant role in regulation of acetylation status of histones and therefore also in permanent tran-
scriptional activation of genes. However, acetylation seems to be reversible. Although not 
all genes respond to TSA treatment. [145] TSA has also synchronizing effects, arresting cells 
in G1 or G2 phase of the cell cycle, influencing cellular differentiation and causing apop-
tosis. [146] 
 
2.1.3.  Media 
 
RPMI 
 400 ml  RPMI 1640 (containing L-Glutamine)  Sigma R6504 
     10 %   FBS PAA Laboratories  
   phenol red   
 
MNP 
400 ml  MEME Sigma    
    10 %  FBS PAA Laboratories  
non-essential amino acids PAA Laboratories 
    natriumpyruvate 
             phenol red   
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For both media phenol red was used as a pH indicator. Due to a change from a red to a 
yellow medium colour, overgrown or contaminated cells could be immediately spotted. 
Storage of media occurred at 4°C in the dark. 
 
 
 2.2. Methods 
 
 
2.2.1. Cell culture 
 
Material 
 
Cell counting chamber (depth 0.100 mm, 0.0025 mm2)                    Bürker-Türk 
Cell culture bottles (T25, T75, T162)                     Corning Inc. 
FBS (heat inactivated fetal bovine serum)  PAA Laboratories GmbH 
CO2 Incubator                 New Brunswick 
Microtiter plates (96-well and 384-well)               Greiner Bio-One 
Petri dishes (ø10cm, ø6cm, ø3.5cm)                      Corning Inc. 
Trypsin/EDTA Difco Laboratories            
 
For all experiments cells were cultured to 70–80 % confluence in an atmosphere of 5 % 
CO2 at 37°C using clear cell culture dishes. It was always a prerequisite to work sterile 
under a laminar flow in order not to contaminate cells with bacteria or funghi, which would 
completely influence experimental results. Likewise the medium colour was checked and 
the cells were examined under the microscope, that refers to cellular morphology, density 
and adherence status as well as possible contaminations.  
For passaging of cells the old medium was removed and cells were incubated for 5 minutes 
with trypsin/EDTA (limited proteolysis). Thus, detached cells were collected in a sterile 
falcon tube and centrifuged at 200 x g for 3 minutes at 20°C. Afterwards the old medium 
was discarded and cells were resuspended in fresh medium. To maintain the cell culture, an 
appropriate cell amount was transferred to cell culture bottles of different size, containing 
fresh medium (depending on desired experimental yield: 
 T25   7 ml medium 
 T75 15 ml medium 
 T162 30 ml medium).  
To allow a quantitative comparison between different treatments of the same cell line an 
equal cell number in each experiment was essential. Therefore, the rest of the cell suspen-
sion was always diluted to 5 x 104 cells/ml in the case of HeLa cells, whereas HTB-31 cells 
were plated to 8 x 104 cells/ml (counted in a Bürker-Türk chamber). Differences in cell 
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density resulted from the fact that HTB-31 cells, also known as C-33A cells, grow slower 
than HeLa cells (resulted from growth curve analysis, data not shown). So to achieve a 
reasonably yield of protein amount for subsequent analysis, the cell number was modified. 
The proper diluted cell suspension was split to cell culture dishes: 
  ø  10 cm PDs  12 ml of cell suspension 
 ø    6 cm PDs    4 ml of cell suspension 
 ø 3.5 cm PDs    2 ml of cell suspension 
 1 well (  96 well plate) 100 µl of cell suspension 
 1 well (384 well plate)     50 µl of cell suspension 
           (2.5 x 104 cells/ml) 
Approximately nineteen hours after plating cells were treated with drugs as indicated.  
 
 2.2.2.  Medications 
 
Material 
 
 
Sterile filter 0.20 µm (RC15, RC25) Sartorius 
Syringe, 5 ml and 20 ml BD DiscarditTm 
 
All drugs used for medical treatment were available as powder and had to be diluted to 
stock solutions, whereas different concentrations were chosen (Tab. 3). Aliquots were than 
stored at -20°C. 
 
 
Drug 
 
Concentration  
of stock solution 
 
DOX 
 
5 mM 
 
MIMO 
 
5.5 mM 
 
OLO II 
 
100 mM 
 
ROSC 
 
50 mM 
 
TSA 
 
4.4 µg/ml 
 
Tab. 3: List of drug stock solutions and their concentrations 
 
Before each treatment drugs were diluted with adequate medium to a required lower con-
centrated mastermix and filtered sterile through filters of 0.20 µm thickness. Out of this 
mastermix all subsequent lower concentrations needed, were diluted with sterile medium. 
Due to a loss of volume during sterile filtration mastermixes were always prepared with 
600 µl of volume additionally. 
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The drug volume used for treatment depended on the cell culture dishes used and can be 
seen in Tab. 4. 
 
 
Cell culture dish 
 
Drug volume used [µl] 
 
ø  10 cm PD  
 
500 
 
ø    6 cm PD  
 
300 
 
ø 3.5 cm PD  
 
200 
 
well (96 well plate) 
 
100 
 
well (384 well plate) 
 
50 
 
Tab. 4: List of added volumina of drug stock solutions 
 
Experimental conditions regarding drug concentration and treatment period differed in 
each case, whereas treatment always occurred at the same time. 
 
 2.2.3.  CellTiter-Glo® Luminescent Cell Viability Assay 
The CellTiter-Glo® Viability Assay is a simple and fast method of determining the number 
of viable cells after treatment. It is based on the measurement of the ATP level produced 
by viable cells in culture taking advantage of the luciferase reaction (Fig. 21). After the 
cells are lysed, ATP released in the supernatant is used by the enzyme luciferase to convert 
the substrate luciferin to oxiluciferin thereby generating light. The luminescent signal can 
be measured and is proportional to the ATP level and therefore to the cell number. [147] 
This assay provides information about the proliferation status of cells after treatment and 
allows to assess the drug cytotoxicity by calculating the IC50. The IC50 is the inhibitory 
concentration of a drug needed to kill 50 % of all cells. 
 
 
Fig. 21: Luciferase reaction [147] 
 
Assay Kit  Promega 
 
CellTiter-Glo® Buffer 
CellTiter-Glo® Substrate (lyophilized) 
stored at -80°C, thawed and mixed together, stored than at -20°C 
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After cellular treatment for different incubation times the microtiter plate was centrifuged 
at 200 x g, 3 min at 20°C to allow cells to accumulate at the subsurface of wells. The me-
dium was reduced to three-quarter of the volume and the buffer-substrate mix was added in 
a 1:1 ratio. An incubation period of 30 minutes at 37°C (incubator, dark environment) as-
sures cellular lysis and luciferase reaction to take place. The cell suspension was then 
transferred to a white microtiter plate to avoid light interference from neighbouring adja-
cent wells and luminescence was measured in a plate reader. [147] 
 
 2.2.4. Measurement of the DNA content in single cells stained with propidium 
iodide by flow cytometry 
Cells are stained with propidium iodide (PI), a fluorescent dye, for measuring their DNA 
content in order to determine their cell cycle phase distribution. Propidium iodide interca-
lates into the DNA strands. Upon excitation DNA-PI complexes generate fluorescence. 
The intensity of emitted fluorescence is directly proportional to the DNA concentration. It 
means that cells in G1 phase have haploid DNA, cells in G2 phase have diploid DNA and 
cells with an undefined DNA amount (higher than haploid and lower than diploid) are in S 
phase. Cells undergoing apoptosis possess partially degraded DNA and generate weaker 
fluorescence than G1 cells. They are termed as sub-G1 or hypoploid cells. [148] 
For measurement cells are absorbed through a fine capillary tube into the fluorescence-
activated cell sorter, where only room for one cell after another (thus generating a single 
cell suspension is important and essential) exists. Each time a stained cell passes the laser 
light it scatters the light, its dye is excited to a higher wave length and the cell is counted as 
one event. Detectors quantify the achieved information. The forward scatter gives informa-
tion about the cell size, the side scatter about the particle’s complexity (nucleus shape, cy-
toplasmic granulation). The intensity of the emitted fluorescence is proportional to the 
DNA amount of cells. [149] 
The flow cytometry studies allow determination of changes in cell cycle phase distribution 
as well as in rate of apoptosis in response to the used drugs. 
 
Material 
 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
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Trypsin/EDTA  Difco Laboratories  
Stock solution (pH 7.6) 
           20.4 mM Tri-Sodium citrate x 2 H2O  Merck 
   0.6 % (v/v) NP-40  US. Biochem. Corp.   
           9 mM Spermine tetrahydrochloride Sigma 
           3 mM Tris AppliChem   
  stored at -20°C 
Solution A 
                 9 mg Trypsin 250 (Difco) BD 
                50 ml stock solution (pH 7.6) 
 stored at -20°C 
Solution B 
             150 mg Chicken Egg White  Sigma 
 (type II-0, trypsin inhibitor) 
           30 mg Ribonuclease A Sigma 
  (boiled for 3 minutes before use) 
                50 ml stock solution (pH 7.6) 
 stored at -20°C 
Solution C 
               4.9 mg Propidium iodide Sigma 
        69.6 mg Spermine tetrahydrochloride Sigma 
            10 ml stock solution (pH 7.6) 
  stored at 4°C 
 
Cells were harvested by limited trypsinization at 37°C for 5 minutes. After inhibition of 
trypsin activity (using medium) cells were washed twice with 1x PBS for 3 minutes at 900 
x g (4°C). The cell pellet was resuspended in 100 µl 1x PBS and transferred to tubes suit-
able for flow cytometry. To permeabilize cell membranes the single cell suspension was 
incubated with 75 µl of solution A containing trypsin and incubated for 10 minutes at room 
temperature. Adding 75 µl of Solution B containing RNase and trypsin inhibitor followed 
for another 10 minutes. RNase guarantees degradation of RNA (which otherwise would 
also be stained by propidium iodide) and the trypsin inhibitor stops excessive protein deg-
radation. Finally, cells were stained with 63 µl of Solution C containing propidium iodide. 
Staining proceeded for at least 30 minutes at 4°C in the dark. [150] Fluorescence measure-
ment was performed with the flow cytometer Becton Dickinson FACScan. Results are 
shown as DNA histograms. 
 
 2.2.5. Caspase-Glo® 9 Assay 
The Caspase-Glo® 9 Assay allows the measurement of caspase-9 activity in treated cells or 
cellular supernatants. Caspases play a pivotal role in apoptosis and are activated by several 
environmental stimuli. Caspase-9 is involved in the activation of a whole cleavage cascade, 
recognizing and cleaving especially the LEHD amino acid sequence (Leu-Glu-His-Asp) of 
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target proteins, among others pro-caspase-3. As a final consequence of the activation of 
proteolytic cascade, cells die. 
Treated cells are lysed by the assay buffer and the released initiator caspase cleaves the 
provided substrate, which contains an LEHD sequence. This specific sequence is cleaved 
and amino-luciferin is generated. The enzyme luciferase uses ATP to convert luciferin to 
light (Fig. 22). The luminescence generated is proportional to caspase-9 activity. [151] 
 
 
Fig. 22:  Caspase-Glo® 9 Assay – Cleavage activity of caspase-9 results in luminescence emission by taking 
advantage of the luciferase reaction [151] 
 
Assay Kit Promega 
 
Caspase-Glo® 9 Buffer 
Caspase-Glo® 9 Substrate (lyophilized) 
MG-132 Proteasome Inhibitor 
stored at -20°C, thawed and mixed together 
 
Cells are plated into white microtiter plates with a transparent bottom. After a particular 
treatment period, the microtiter plate was centrifuged at 200 x g, 3 min at 20°C. The me-
dium was reduced to three-quarter of the volume. The buffer-substrate mix was added in a 
1:1 ratio and incubated at room temperature in the dark. Luminescence was measured after 
one and after two hours, ensuring maximal measuring output. Besides untreated controls, 
medium had to be analysed as well, because of background luminescence. [151] 
If desired, the supernatant can be transferred to another white microtiter plate and analyzed 
in the above described manner. At higher drug concentrations majority of cells may die 
and subsequently release caspases into the surrounding medium. To detect this caspase 
activity as well, the supernatant may be interesting for analysis. 
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The recorded relative luminescence units (RLU) during caspase measurement are meaning-
less until data is normalized to the cell number determined in viability assays. This applies 
for all performed caspase assays.  
 
 2.2.6. Apo-ONE® Homogeneous Caspase-3/7 Assay 
The Apo-ONE® Homogeneous Caspase-3/7 Assay is a good method for detection of cas-
pase-3 and -7 activity. Caspase-3 and -7 recognize and cleave especially the DEVD amino 
acid sequence (Asp-Glu-Val-Asp) of target proteins (e.g. PARP-1).  
Treated cells are lysed by the assay buffer. Released effector caspases can then cleave the 
provided chemical substrate rhodamine R110 containing the DEVD sequence. The DEVD 
sequence is cleaved and excitation of rhodamine at 499 nm results in a green fluorescence 
(emission at 521 nm, Fig. 23). There is a strong correlation between emitted fluorescence 
and activated caspase-3/7. [152]  
 
 
Fig. 23: Apo-ONE® assay principle – Cleavage activity of caspase-3/7 results in a fluorescence emission [152] 
 
Assay Kit Promega 
 
Apo-ONE® Homogeneous Caspase-3/7 Buffer 
1:100 Caspase Substrate Z-DEVD-R110 
stored at -20°C, thawed and mixed together 
 
To perform Apo-ONE® assay cells were plated in black microtiter plates with a clear bot-
tom. The clear bottom ensures microscopical examination for contaminations, the black 
plate avoids cross-interference of fluorescent light in adjacent wells. 
After a treatment period the microtiter plate was centrifuged at 200 x g, 3 min at 20°C and 
the medium was reduced to three-quarter of the volume (if desired, the supernatant can be 
transferred to another black microtiter plate and analyzed in the same manner). The buffer-
substrate mix was added in a 1:1 ratio and incubated at 37°C in the dark (CO2 may disturb 
the reaction). Fluorescence measuring occurred after 30 minutes, one hour, three hours, six 
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hours and 18 hours to measure even minimal increase of enzymatic activity. Just in the 
same way as mentioned before medium had to be measured again. [152] 
 
 2.2.7. Caspase-Glo® 3/7 Assay 
 
Assay Kit Promega 
 
Caspase-Glo® 3/7 Buffer 
Caspase-Glo® 3/7 Substrate (lyophilized) 
stored at -20°C, thawed and mixed together 
 
The Caspase-Glo® 3/7 Assay measures like the Apo-ONE® Assay the activity of caspase-
3/7, but in contrast to this assay the chemical reaction is based on the generation of a lumi-
nescent signal (which is more sensitive than fluorescence).  
After cell lysis released caspase-3/7 cleaves the provided substrate, whereas the chemical 
reaction is exactly the same like for the Caspase-Glo® 9 Assay, the only difference being in 
the cleavage sequence recognized (DEVD instead of LEHD). The luminescence generated 
is proportional to caspase-3/7 activity. The assay procedure is exactly the same as for Cas-
pase-Glo® 9 Assay. [153] 
All assays detecting effector caspases are important tools for detecting ongoing apoptosis 
after medical treatment. Withal, achieved results can be analyzed for an inversed correla-
tion to viability assays. 
 
 2.2.8. 7-Aminoactinomycin D Dye Exclusion Test 
7-Aminoactinomycin D, a fluorescent dye similar to propidium iodide, is able to intercalate 
into DNA strands. Staining cells with 7-AAD is a simple and fast method to distinguish 
healthy from damaged cells and to quantify the latter. One of the attributes of damaged 
cells is a disrupted cell membrane, which is an indication for ongoing necrosis. 7-AAD 
easily passes the disrupted membrane of damaged cells and stains their DNA, whereas vi-
able cells with an intact membrane exclude the dye (Fig. 24). In the cell sorter each cell is 
excited with the same wave length and analyzed for emitting fluorescence. Thus cells can 
be classified as fluorescence positive (damaged cells) or negative (healthy cells). Results 
are evaluated for cell viability and drug cytotoxicity. The higher a drug concentration is the 
more likely poisoning of cells occurs and cause necrosis. [148] 
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Fig. 24: Dye exclusion test principle using 7-AAD as fluorescent dye 
 
Material 
 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
Trypsin/EDTA  Difco Laboratories  
7-AAD 
     1 mg 7-AAD Sigma 
     50 µl abs. EtOH Austr. Alco. Österr. 
   950 µl 1x PBS 
 
After treatment cellular supernatant was transferred to a Falcon tube and cells were washed 
with 1x PBS, which was then also transferred to the Falcon. Cells were detached from the 
underground by adding trypsin and washed twice with 1x PBS at 900 x g, 3 minutes at 
4°C. The cell pellet was resuspended in 500 µl 1x PBS and transferred to tubes suitable for 
flow cytometry. Staining of cells occurs with 5 µl of 7-AAD for 20 minutes at room tem-
perature in the dark. Immediately afterwards flow cytometric measurement has to be car-
ried out. The wave length for excitation is at 555 nm, emission at 655 nm. 
 
 2.2.9. In situ M30 CytoDEATH staining 
In situ CytoDEATH staining is an immunofluorescence technique for determining caspase-
dependent apoptosis in cells. During the switch-on of programmed cell death a couple of 
effector caspases are activated. They lead to the degradation of several proteins with the 
purpose to eliminate the cell. Among one of the first cleavage substrates is the cytoplasmic 
cytokeratin 18, a cytoskeleton protein. A specific antibody (clone M30 CytoDEATH) rec-
ognizes and binds to the cleaved cytokeratin product (Fig. 25). The antibody is coupled to 
the fluorescein (FITC), a green fluorochrom, and can be visualized under the microscope 
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or alternatively, can be measured by flow cytometry. In healthy cells no cytokeratin cleav-
age product is generated thus no antibody binding occurs and cells cannot be stained. Posi-
tive stained cells show a speckled green fluorescence in the cytoplasm. [154] 
 
 
Fig. 25:  Cytokeratin 18 cleavage by caspases during apoptosis – M30 CytoDEATH antibody recognizing the 
cleavage product [155] 
 
Material 
 
Lab-Tek® Chamber Slide System (4-well, sterile) Nunc Internat. Corp. 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
1x PBS-Tween – 1L 
10x PBS diluted 1:10 with ddH2O 
      0.1 % (v/v) Tween-20 Sigma 
 stored at 4°C 
MeOH Carl Roth GmbH 
Triton-X 100 US. Biochem. Corp. 
3 % BSA Blocking Solution 
     1.2 mg BSA Amresco 
       40 ml 1x PBS 
  stored at 4°C 
1 % BSA Blocking Solution 
     0.4 mg BSA Amresco 
       40 ml 1x PBS 
  stored at 4°C 
 
Cells were plated into a 4-well slide chamber (cell number 5 x 104 cells/ml, 600 µl of cell 
suspension plated) and treated for indicated periods of time. The medium was discharged 
and cells were washed twice with 1x PBS. Cells were covered with ice-cold methanol       
(-20°C) for 30 minutes in order to fix them. Afterwards cells were washed carefully three 
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times with 1x PBS-Tween. For permeabilization of the cell membrane cells were incubated 
with 0.2 % Triton-X 100 for 20 minutes. Again washing of cells with 1x PBS-Tween oc-
curred (thrice). Blocking of cells with 3 % BSA/PBS for 30 minutes eliminates unspecific 
antibody binding and improves the staining quality. Cells were washed thrice with 1x PBS-
Tween and then incubated with 150 µl of the M30 CytoDEATH antibody (diluted 1:400 in 
1 % BSA/PBS) overnight. Finally, cells were washed three times with 1x PBS und in-
spected under the microscope. To visualize all cells (not only the apoptotic ones) nuclei 
were stained with DAPI afterwards. 
 
 2.2.10. DAPI staining 
DAPI staining represents a typical method for counterstaining in fluorescence microscopy. 
DAPI is a fluorescent dye binding to the DNA and therefore staining the nucleus. It is ex-
cited by ultraviolet light (extinction at 345 nm), displays a blue colour (emission at 455 
nm) and passes even intact cell membranes. Hence cells have not to be fixed to be visual-
ized. [156] 
 
Material 
 
DAPI stock solution 
      10 mg DAPI DAKO Corporation 
         2 ml DMF Sigma 
DAKO® Fluorescent Mounting Medium  DAKO Corporation 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
 
DAPI solution is prepared by diluting DAPI stock solution 1:100 in 1x PBS. The obtained 
solution is further diluted 1:50 in Mounting Medium. DAKO® Fluorescent Mounting Me-
dium prevents a rapid fading of the fluorescence. [157] 
Fixed or viable cells are covered with DAPI solution for 10 minutes in the dark and 
washed then with 1x PBS. Cells are kept in 1x PBS to avoid drying-out. Inspection under 
the microscope can proceed. 
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 2.2.11. Determination of the potential of mitochondrial membrane by JC-1 staining 
JC-1 is a cationic, lipophilic dye with fluorescent properties used as a substrate for deter-
mination of the integrity of mitochondrial membrane. During early stages of apoptosis its 
collapse is observed. Due to the release of cytochrome c (a caspase activator) from the mi-
tochondria the electron transport is disrupted and apoptosis is triggered.  
JC-1 enters the mitochondria of healthy cells, which usually possess a high membrane po-
tential, and forms J-aggregates of red fluorescence. Apoptotic cells with a low membrane 
potential fail to accumulate JC-1 in the mitochondria, thus it remains monomeric and emits 
a green fluorescence. [158] 
Cells can be stained in situ and visualized under a fluorescence microscope or quantified 
by flow cytometry. 
 
Material 
 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
10 mM JC-1 Solution 
        5 mg JC-1 Alexis 
      766 µl DMSO Sigma 
Trypsin/EDTA  Difco Laboratories 
 
a. In situ staining 
Treated cells were washed with warm (37°C) 1x PBS and stained with 20 µM JC-1 for 20 
minutes in the dark at 37°C. Thereafter, cells were washed to remove free dye and could 
then be analyzed under the fluorescence microscope. 
 
b. Staining for flow cytometric measurement 
Treated cells were washed carefully with warm 1x PBS and harvested by trypsinization. 
After three more washing steps (centrifugation at 300 x g, 5 minutes, 20°C) cells were re-
suspended in 490 µl warm 1x PBS and transferred to tubes suitable for flowcytometric 
measurements. JC-1 stock solution (10 mM) was diluted 1:10 with warm 1x PBS. 10 µl (cE 
= 20 µM JC-1) of this solution were used to stain the cells for 20 minutes at 37°C in the 
dark. Ultimately cells were washed four times with warm 1x PBS and analyzed flow cy-
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tometrically using two channels: green fluorescence – Ex/Em 510/527 nm, red fluores-
cence – Ex/Em 585/590 nm. Obtained results are quantitative. 
 
 2.2.12. Whole cell lysates 
Whole cell lysates are prepared to acquire intracellular proteins for further analyses. Cellu-
lar lysis is accomplished by using detergents, which lead to the disruption of the cell mem-
brane without affecting proteins. Cells reject their whole content. Sonification of cells en-
sures after a centrifugation step the separation of DNA and cell debris from proteins, which 
are in the supernatant. 
 
Material 
 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
Cell scraper                             Sarsted 
RIPA buffer 
   50 mM Tris/HCl (pH 7.4)      
   500 mM NaCl Merck 
     1 % (v/v) NP-40 US. Biochem. Corp. 
    0.5 % (w/v) Na-Doc Carl Roth GmbH  
    0.1 % (w/v) SDS Carl Roth GmbH 
      0.05 %  NaN3 Sigma 
  stored at 4°C  
20mM Pefablock® SC 
      12 mg Pefabloc (protease inhibitor) Merck 
       50 ml ddH2O 
0.1 M PMSF Calbiochem/Sigma 
200 mM NaF 
200 mM NaVO3  
Stock solution for SDS sample buffer (pH 6.8) 
  6.006 g Tris AppliChem 
      0.4 g SDS Carl Roth GmbH 
    0.01 g NaN3 Sigma 
 fill up to 100 ml ddH2O 
 stored at RT 
2x SDS sample buffer
 non-stained, non-reduced 
      0.5 g SDS Carl Roth GmbH 
  1.25 ml Stock solution for SDS-SB (pH 6.8) 
   2.5 mg  EDTA Merck 
      5 mg NaN3 Sigma 
       5 ml Glycerol Amresco 
  fill up to  25 ml ddH2O 
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Cells were scraped off with a cell scraper and washed twice with 1x PBS for 3 minutes at 
900 x g. Depending on the pellet size cells were resuspended in between 100 µl and 200 µl 
RIPA buffer containing the protease inhibitors Pefabloc (1:100) and PMSF (5:100), 
200µM natrium vanadate and 200µM natrium fluoride. For some lysates 2x SDS-SBnon-
stained, non-reduced containing 1:100 PMSF was used to resuspend the cell pellet. Cells were 
kept on ice for 30 minutes thus making the buffer effective. Afterwards a triple sonification 
of cells for 10 seconds ensures a DNA free protein suspension after centrifugation at 1500 
x g for 5 minutes (cells were kept on ice to avoid heating up). The supernatant was used for 
further analysis or stored at -20°C. 
 
 2.2.13. Cell fractionation - Isolation of nuclei 
Cell fractionation is a method for separating cellular components like mitochondria, nuclei 
and so on. Cells are disrupted with a hypotonic buffer containing ionic and non-ionic de-
tergents and by mechanical pottering. By centrifugation at a higher gravitation nuclei are 
separated from cytoplasm. In this special case RSB buffer is used to isolate nuclei to study 
nuclear components. 
 
Material 
 
10x PBS – 1 L 
 Dulbecco’s phosphate buffered saline (DPBS)                                                                   Sigma 
 powder without calcium chloride 
 diluted to 1 L ddH2O 
 stored at RT 
1x PBS – 1 L 
 10x PBS diluted 1:10 with ddH2O 
 stored at 4°C 
RSB buffer  
   10 mM Tris/HCl (pH 7.4)      
   10 mM NaCl Merck 
  1.5 mM MgCl2 Carl Roth GmbH 
 stored at 4°C 
10 % Na-Doc 
      0.1 g Na-Doc    Carl Roth GmbH 
    0.9 ml  ddH2O 
10 % NP-40 
    0.1 ml  NP-40    US. Biochem. Corp. 
    0.9 ml  ddH2O 
RIPA buffer 
   50 mM Tris/HCl (pH 7.4)      
   500 mM NaCl Merck 
     1 % (v/v) NP-40 US. Biochem. Corp. 
    0.5 % (w/v) Na-Doc Carl Roth GmbH  
    0.1 % (w/v) SDS Carl Roth GmbH 
      0.05 %  NaN3 Sigma 
  stored at 4°C  
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After treatment cells were harvested by scrapping them off and washed three times with 1x 
PBS. Subsequently the cell pellet was resuspended in 2 ml ice-cold (-20°C) RSB buffer 
(around ten times higher volume than pellet) and cells were left to swell for 15 minutes on 
ice. Detergents (0.25 % NP-40 and 0.15 % NaDoc) were added slowly to the cells, vor-
texed quickly and kept 5 more minutes on ice. Cells were pottered approximately 20 times 
and then centrifuged at 4500 x g for 20 minutes at 20°C. The supernatant representing the 
cytoplasmic fraction was discarded and stored in Eppendorfer tubes at -20°C. The pellet 
containing the membrane bound fraction including nuclei was resuspended in RIPA buffer 
and stored at -20°C as well. 
 
 2.2.14. Determination of protein concentration 
For a quantitative determination of protein concentration in different samples DC assay 
from Bio-Rad Laboratories was used, whereas bovine serum albumin (BSA) served as a 
standard. Standards are usually dilution series of known concentrations of one and the 
same protein. Their absorbance values are plotted against the corresponding concentration 
and the generated regression line enables to calculate the concentration of unknown protein 
samples from the measured absorbance. 
The DC assay is a modified Lowry assay based on a two-step colorimetric reaction. Pro-
teins react with an alkaline copper tartrate solution (solution A) to reduce a Folin reagent 
(solution B) resulting in a blue colour change. Aromatic amino acids like tyrosine and tryp-
tophan (to a less extent cysteine and histidine) are responsible for the colour development. 
[159]
 
Quantification of protein concentration in different samples assures that the same protein 
amount is used for further analysis. This allows comparative statements about protein ex-
pression and their modification status (like in for instance treated and untreated cells). 
 
Material 
 
BSA stock solution [50 µg/µl] 
      50 mg  BSA Amresco 
         1 ml ddH2O 
Microtiter plate (96-well)               Greiner Bio-One 
DC Protein Assay Bio-Rad 
 reagent A 
 reagent B 
 
The DC assay was performed in 96-well microtiter plates using following procedure. The 
BSA standard dilution was prepared as specified, thereby using the corresponding buffer 
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utilized for preparing the sample (Tab. 5). Each sample was diluted twice with ddH2O in 
order to obtain a statistical mean value. The reagents were added (25 µl reagent A and 200 
µl reagent B) and after an incubation time of 15 minutes at room temperature absorbance 
was measured at 750 nm in a plate reader. 
Determined protein concentrations have a unit of µg/µl and every protein amount needed 
can be calculated. 
 
BSA [µg] Vol. H2O [µl] Vol. Buffer [µl] 
Vol. BSA         
[2 µg/µl] 
Vol. BSA       
[10 µg/µl] 
     
 4.0 1.0 - - 
 4.0 1.0 - - 
1 3.5 1.0 0.5 - 
2 3.0 1.0 1.0 - 
3 2.5 1.0 1.5 - 
3 2.5 1.0 1.5 - 
5 1.0 1.0 2.5 - 
7 0.5 1.0 3.5 - 
7 0.5 1.0 3.5 - 
 
    
10 3.0 1.0 - 1.0 
15 2.5 1.0 - 1.5 
20 2.0 1.0 - 2.0 
20 2.0 1.0 - 2.0 
25 2.5 1.0 - 2.5 
 
    
     
 BSA stock solution [50 µg/µl]  
BSA 
[10 µg/µl] 1:5 
10 µl + 40 µl 
ddH2O BSA [10 µg/µl] 
BSA  
[2 µg/µl]   1:5 
10 µl + 40 µl 
ddH2O 
     
 
Vol. H2O [µl] Vol. Sample [µl]   
 4.0 1.0   
 4.0 1.0   
 
Tab. 5: Protein determination – Pipetting scheme [159] 
 
 2.2.15. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gel electrophoresis is the separation of proteins in an electric field, whereas proteins mi-
grate through a net of acrylamide according to their size. Proteins with a higher molecular 
weight do not migrate as far as low molecular proteins since they cannot pass a certain 
acrylamide pore size. The acrylamide pore size is dependent on the used acrylamide con-
centration and the amount of cross-linkers (APS and TEMED). Varying these specifica-
tions allows the analysis of different molecular weight ranges. 
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To ensure that migration occurs only by size and not by charge, proteins are treated with 
SDS. SDS denatures the protein’s secondary/tertiary structure (at a high temperature), thus 
facilitating the migration through the gel. Additionally it masks the protein’s own charge 
giving them a uniform negative charge. Proteins migrate that way to the positive charged 
pole, the anode. Treatment with DTT reduces disulfide bonds also helping in dissolving the 
protein’s structure. Finally the sample is mixed with glycerol, which weighs the sample 
down to a well of a gel, and with bromphenol blue to visualize it during migration (to 
avoid running out). 
A gel usually consists of an upper stacking gel and a lower separation gel. The stacking gel 
is composed of a low acrylamide concentration with a large pore size. Its function is to 
concentrate all proteins at the same front-line for optimal separation. The separation gel 
has a smaller acrylamide pore size (thus a higher acrylamide concentration) and is used to 
separate the proteins. [160] 
 
Material 
 
Gel cassettes 1.5 mm, Novex Invitrogen 
Acrylamide/bis-Acrylamide 30 % Solution Sigma 
1M Tris/HCl, pH 6.8 
2M Tris/HCl, pH 8.7 
20% SDS 
       20 g SDS Carl Roth GmbH 
     100 ml ddH2O 
  stored at RT 
10 % APS 
             1 g APS Carl Roth GmbH 
       10 ml ddH2O 
TEMED Carl Roth GmbH 
Combs (10 and 12 wells, 1.00 mm thick) Invitrogen 
2x SDS sample buffer
 stained, reduced 
      0.5 g SDS Carl Roth GmbH 
  1.25 ml Stock solution for SDS-SB (pH 6.8) 
   2.5 mg  EDTA Merck 
      5 mg NaN3 Sigma 
      5 mg Bromphenol blue US. Biochem. Corp. 
       5 ml Glycerol Amresco 
      20 µl 2.6 M DTT Sigma 
BSA/Carbo marker for protein gels (20µl/slot) 
   20 µg/µl BSA Amresco 
   20 µg/µl Carbonic anhydrase I Sigma 
       120µl 2x SDS-SBstained/reduced 
Carbo/Cytochrome C marker for protein gels (20µl/slot) 
   20 µg/µl Carbonic anhydrase I  Sigma 
   20 µg/µl  Cytochrome C 
       120µl 2x SDS-SBstained/reduced 
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10x Electrophoresis buffer – 2 L 
     288 g  Glycine Carl Roth GmbH 
       60 g Tris AppliChem 
       20 g SDS Carl Roth GmbH 
      fill up to  2 L ddH2O 
  stored at RT 
1x Electrophoresis buffer – 1 L  
 10x Electrophoresis buffer diluted 1:10 with ddH2O 
  stored at RT 
Electrophoresis Chamber, Novex-X-cell II Invitrogen 
 
First of all separating gels of various acrylamide concentrations were prepared by mixing 
the required solutions together being careful to add APS and TEMED at last (otherwise the 
gel would polymerize to fast to be poured). Table 6 is showing the gel ingredients and the 
mixing instruction. 
 
Separation gel 8 % 10 % 12 % 15 % Stacking gel 4 % 
30 % acrylamide 2300 µl 2900 µl 3480 µl 4350 µl 30 % acrylamide 320 µl 
2M Tris/HCl, pH 
8.7 1650 µl 1650 µl 1650 µl 1650 µl 
1M Tris/HCl, pH 
6.8 300 µl 
SDS 20 % 44 µl 44 µl 44 µl 44 µl SDS 20 % 12 µl 
APS 10 % 39.6 µl 39.6 µl 39.6 µl 39.6 µl APS 10 % 12 µl 
TEMED 6.6 µl 6.6 µl 6.6 µl 6.6 µl TEMED 2.4 µl 
Bidest. H2O 4759.8 µl 4160 µl 3579.8 µl 2710 µl Bidest. H2O 1753.6 µl 
total 8.8 ml 8.8 ml 8.8 ml 8.8 ml total 2.4 ml 
 
Tab. 6: SDS-PAGE – ingredients for stacking and separation gel [161] 
 
The separation gel was poured into the cassette up to three-fourths of its height and over-
layed with 1 ml of ddH2O. It should prevent fissuring of the gel due to oxygen perturba-
tion. After the gel polymerized for approximately 45 minutes the water was removed and 
the stacking gel was poured above. Insertion of a comb created the wells (10 or 12 wells). 
The stacking gel polymerized for another 45 minutes and the cassette was then fixed into 
the electrophoresis chamber, which was filled up with 1x electrophoresis buffer as an elec-
trolyte. 
30 µg of proteins were dissolved in reduced and stained 2x SDS-sample buffer to an end 
volume of 25 µl, boiled up at 95°C for 3 minutes and cooled down on ice. After spinning 
down samples were loaded onto the gel (markers were used occasionally). Standard run-
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ning time was 2 hours at 130 volt. After separation of proteins they were blotted onto a 
membrane. 
 
 2.2.16. Electroblotting (Western Blot) 
Electroblotting is the electric transfer of separated proteins from a polyacrylamide gel to a 
membrane. The electric field is thereby established perpendicular to the gel, whereas the 
gel has tight contact to the membrane. Thus proteins are able to migrate due to their nega-
tive charge to the membrane (placed on anode side). They irreversibly bind due to hydro-
phobic interactions to the membrane and keep their separation arrangement. This technique 
enables further protein analysis by antibodies. 
 
Material 
 
MeOH Carl Roth GmbH 
10x Blotting buffer – 2 L 
     288 g Glycine Carl Roth GmbH 
       60 g  Tris AppliChem 
         4 g SDS Carl Roth GmbH 
      fill up to  2 L ddH2O 
 stored at RT 
1x Blotting buffer – 2 L 
   200 ml 10x Blotting Buffer 
   400 ml Methanol Carl Roth GmbH  
 1400 ml  ddH2O 
         pH 8.3 
  stored at 4°C 
Hybond-P PVDF membrane, Westran S Whatman 
Nitrocellulose membrane, Optiran Ba-s Whatman 
Sponges for Blotting 
Blotting Chamber, Trans-Blot Cell Bio-Rad 
Cooling system, refrigerated circulator LTD 6G Grant 
Magnetic stirrer 
 
After running a gel electrophoresis the cassette was broken up to get access to the gel to 
assemble the blotting sandwich (see Fig. 26 a.). In a gel holder blotting cassette a sponge, 
soaked in 1x blotting buffer, was placed on the cathode side. The gel was positioned on 
three Whatman papers on the sponge (right orientation is important!) and the membrane, 
activated in methanol (or water in the case of nitrocellulose), was placed on top of it. It was 
a prerequisite to prevent introducing bubbles between the gel and the membrane since they 
would affect the transfer quality. Again two Whatman papers were carefully put on the 
membrane and a second sponge completed the sandwich. Every part of the sandwich was 
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soaked in 1x blotting buffer and kept wet over the whole preparation time. Afterwards the 
blotting cassette was closed and fixed in the trans-blot cell. The cell was filled up with 1x 
blotting buffer and connected to a power supply (Fig. 26 b.). Blotting took place at 30 volts 
over night at 4°C using a cooling system and a magnetic stirrer.  
Due to a high binding specificity and mechanical stability PVDF and improved nitrocellu-
lose membranes were used. 
 
              a.                 b. 
 
 
 
 
 
 
 
 
 
Fig. 26: a. Western Blot assembly, b. Position of gel and membrane regarding the poles in a blotting cell [162] 
 
 2.2.17. Ponceau S staining 
Ponceau S staining is a fast mode of reversibly staining immobilized proteins on a mem-
brane. It does not interfere with the subsequent immunodetection, but it is not quantitative 
as well. However, the efficiency of blotting and equal protein loading can be checked very 
easily. 
 
Material 
 
Ponceau S 
      0.1 % (w/v) Ponceau S Merck 
          5 % (v/v) Acetic acid Fluka Chemika 
 fill up to 50 ml ddH2O 
MeOH Carl Roth GmbH 
 
After blotting and disassembling the membrane was activated in methanol (water) and 
stained in Ponceau S solution for 15 minutes. Methanol/Water was used to wash out the 
surplus of colour and the membrane was dried. Stained membranes were scanned for docu-
mentation and either used for immunodetection or stored at room temperature protected 
from light. 
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 2.2.18. Immunodetection 
Immunodetection is a method using specific antibodies to detect a desired protein on a 
membrane. Therefore a membrane is first incubated with a primary antibody targeting one 
or several epitopes on the designated protein. Following incubation with a secondary anti-
body, which specifically recognizes the Fc part of the primary antibody, allows a detection 
reaction to take place when a substrate is provided. In our case used secondary antibodies 
were coupled to two different molecules leading to different reactions. 
 
a. Horseradish peroxidase coupled secondary antibody 
If the secondary antibody is directly coupled to the enzyme horseradish peroxidise (Fig. 27 
a.), it will immediately oxidize luminol (the provided substrate) generating luminescence. 
The luminescence signal is proportional to the amount of bound primary antibody and the 
amount of protein present. [163] 
 
b. Biotin coupled secondary antibody 
In contrast, a secondary antibody can also be linked to the vitamin biotin (vitamin B7, Fig. 
27 b.). Streptavidin, a bacterial protein, is coupled to HRP and used to detect biotin. Strep-
tavidin exhibits four binding sites for biotin thus resulting in a high affinity binding and 
signal amplification. [164] 
                    a.                  b. 
 
 
 
 
 
 
 
 
 
Fig. 27:  a. Chemiluminescence reaction of HRP coupled secondary antibodies [165], b. Immunodetection 
using Biotin coupled secondary antibodies and streptavidin [166] 
 
To visualize the generated chemiluminescence sensitive autoradiographic films or a 
Chemi-SmartTM system are used. If utilizing films, the membranes have to be placed in an 
autoradiograph cassette and overlayed with a film for a chosen exposition time. Protein 
bands are visible, were antibodies had bound. Chemi-SmartTM on the other hand is a 
chemiluminescence imaging system allowing a fast autoexposure of membranes with a low 
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background signal. Images are recorded by a CCD camera and protein bands can be quan-
tified afterwards by the analysing software Bio-1D Advanced. [167] 
 
Material 
 
10x TBS – 2 L 
    28.4 g Tris  AppliChem 
     160 g NaCl Merck 
      fill up to  2 L ddH2O 
         pH 7.4 (with HCl) 
  stored at RT 
1x TBS-Tween – 2L 
   200 ml 10x TBS 
 1800 ml ddH2O 
       2 ml Tween-20 (0.1 %) Sigma 
 stored at RT 
5 % Milk Blocking Solution 
     2.5 mg milk powder Fixmilch Instant 
    50 ml 1x TBS-Tween 
  stored at 4°C 
3 % BSA Blocking Solution 
     1.2 mg BSA Amresco 
       40 ml 1x TBS-Tween 
  stored at 4°C 
NaN3 
ECL Plus Western Blotting Detection Reagents Amersham Biosc. 
        25 µl solution A 
    1000 µl solution B 
Super Signal® West Dura Extended Duration Substrate  Pierce   
     500 µl Peroxide Buffer 
     500 µl Luminol Enhancer Solution 
X-Omat Blue XB-1 Kodak 
 
To avoid unspecific antibody reactions with parts of the membrane others than proteins 
themselves, membranes were saturated for at least 1 hour with 5 % milk (for total proteins) 
or 3 % bovine serum albumin (BSA) in the case of phosphorylated protein detection after 
Ponceau S staining. Membranes were then incubated with specific antibodies over night at 
4°C on a shaker (except elsewise indicated by company). They are normally diluted 
1:1,000 in 3 % BSA solution supplemented with 1:50 NaN3 to prolong their stability. Pri-
mary antibodies were always re-used and stored at 4°C. The membrane was washed four 
times with 1x TBS-Tween to dispose the excess of antibody (for about 10 minutes). Anti-
body-antigen complexes were then detected with appropriate secondary antibodies diluted 
most of the time 1:10,000 (for total proteins) or 1:5,000 to account phosphorylated pro-
teins. Incubation time was 1.5 hours. Afterwards the membrane was properly washed as 
described before and incubated with the enhanced chemiluminescence detection reagent 
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ECL-Plus for 3 minutes on a shaker. ECL mix was prepared shortly before applied, accord-
ing to distributor by diluting the solutions 1:40 (25 µl Solution A mixed with 1 ml solution 
B). To achieve better signal-noise ratio, the SuperSignal® from Pierce was sometimes used 
(incubation time: 5 minutes). Signal detection occurs as mentioned previously. 
Usually proteins were first checked for their phosphorylation status and then for total pro-
tein amount. This allows predictions about their activity and protein expression. Mem-
branes were incubated several times with distinct antibodies of various molecular weights. 
Ultimately equal protein loading was additionally checked by incubation with antibodies 
against the housekeeping protein actin or against the GTP binding protein Ran. 
 
 2.2.19. Stripping of membranes 
Stripping of membranes removes the primary and secondary antibody from a probed mem-
brane thus facilitating successive detection of several proteins on the same blot. Addition-
ally, elimination of unspecific signals can be reduced. Such signals are produced especially 
when the same secondary antibodies in different sequential detection series are used. How-
ever, it is very important to optimize stripping conditions in order not to remove the mem-
brane bound protein, although a small amount will always be lost. This may result in a re-
duced sensitivity. Nevertheless it is a fast and time saving method. [168] 
 
Material 
 
Stripping buffer 
   100 mM DTT Sigma 
        2 % SDS Carl Roth GmbH  
  62.5 mM Tris/HCl (pH 6.7)        
fill up to 100 ml ddH2O 
10x TBS – 2 L 
    28.4 g Tris  AppliChem 
     160 g NaCl Merck 
      fill up to  2 L ddH2O 
         pH 7.4 (with HCl) 
  stored at RT 
1x TBS-Tween – 2L 
   200 ml 10x TBS 
 1800 ml ddH2O 
       2 ml Tween-20 (0.1 %) Sigma 
 stored at RT 
3 % BSA Blocking Solution 
     1.2 mg BSA Amresco 
       40 ml 1x TBS-Tween 
  stored at 4°C 
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Prior to stripping the membrane, it is activated in MeOH and washed twice with 1x TBS-
Tween for 10 minutes. Incubation in pre-heated stripping buffer for 20 minutes at 60°C at 
rotational movement removes the antibody complexes. Afterwards the membrane is 
washed thrice in 1x TBS-Tween buffer and blocked in 3 % BSA for one hour. The same 
membrane can then be re-probed with other antibodies.  
 
 2.2.20. Statistical evaluation 
 
Software 
 
GraphPad Prism 5 
 
Biostatistical evaluation of achieved results was performed with the GraphPad Prism 5 
software. Sigmoidal inhibitory dose-response curves are generated by plotting drug con-
centrations logarithmically on the x-axis against response values in percent on the y-axis 
using the nonlinear regression curve. Using row statistics, mean values and standard devia-
tion from all results of the same data set were calculated. Dose-response curves permit the 
determination of the inhibitory concentration of a specific drug. 
Significances of different drug concentrations were analyzed using one-way ANOVA with 
Dunnett’s post test, which compares all columns to the control column. It was presumed 
that all data show a Gaussian distribution.  
For such significance analysis a null hypothesis is assumed to describe a measured data set 
statistically. The assumption is valid until the data rebuts the hypothesis proving the con-
trary. It is up to the p-value to characterize how likely the null hypothesis is. The p-value 
indicates the probability of observing the same (or greater) differences in random samples 
as the one achieved in a recent experiment. It is always a value between 0 and 1. Values 
close to 0 invalidate the null hypothesis, that means differences in samples are not random, 
whereas 1 represents no difference between random samples. The lower a p-value the big-
ger is the significance of a measured data set, disabling the null hypothesis. A p-value for 
instance smaller than 0.01 represents the probability of 99 % that occurring differences are 
not random, but real and a probability of 1 % that differences are random. To be more con-
crete, in our specific case the null hypothesis is: All populations have identical mean val-
ues. Hence, the used drugs are ineffective. If data display small p-values, it is unlikely that 
observed differences are due to random sampling. The null hypothesis is unlikely, the veri-
fied conclusion is that the tested drug is effective. For experiments the chosen significance 
threshold p-value was 0.05 %. Asterisks in figures represent the estimated significances 
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due to p-values, whereas p < 0.001 corresponds to ***, p < 0.01 corresponds to **, p < 
0.05 corresponds to *. 
Statistical evaluation is of great importance to make reliable and real conclusions which 
are not based on coincidences. [169, 170] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
The diploma thesis is based on results published in two original papers and on a contribu-
tion presented during minisymposium during AACR 100th Annual Meeting 2009 (No. 
3862), Denver, Colorado: 
 
 
1. Józefa Węsierska-Gądek, Andreea Borza, Eva Walzi, Vladimir Krystof, Margarita 
Maurer, Oxana Komina and Stefanie Wandl. Outcome of Treatment of Human 
HeLa Cervical Cancer Cells With Roscovitine Strongly Depends on the Dos-
age and Cell Cycle Status Prior to the Treatment. Journal of Cellular Bioche-
mistry, 2009, 106: 937-955. 
 
 
2. Józefa Węsierska-Gądek, Andreea Borza, Oxana Komina and Margarita Maurer. 
Impact of Roscovitine, a Selective CDK Inhibitor, on Cancer Cells: Bi-
functionality Increases Its Therapeutic Potential. Acta Biochimica Polonica, 
2009, 56 (3): 1-7. 
 
 
3. Józefa Węsierska-Gądek, Andreea Borza, Eva Walzi, Margarita Maurer, Oxana 
Komina and Stefanie Wandl. Dual Action of Roscovitine, a Selective CDK In-
hibitor, on Human HeLa Cervical Cancer Cells: Inhibition of Phosphorylation 
of Cell Cycle Regulators and Repression of HPV-encoded Proteins. AACR 100th 
Annual Meeting 2009 (No. 3862), Denver, Colorado 
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 3.  RESULTS 
 
 3.1.  Effects of ROSC, OLO II and DOX on the proliferation of hu-
man HeLa and HTB-31 cervix carcinoma cells  
As previously mentioned, roscovitine (ROSC) and olomoucine II (OLO II), relative new 
pharmacological cyclin-dependent kinase inhibitors, are in the centre of interest due to 
their high potential in modulating cell cycle in cancer cells. The effect of both inhibitors on 
two human cervical carcinoma cell lines differing in the p53 tumor suppressor and cell 
cycle status was examined. 
In HeLa cells wt p53 protein is not functional and the G1 restriction checkpoint is abro-
gated due to the expression of E6 and E7 viral oncoproteins, respectively. In contrast, 
HTB-31 cells are not virally infected, but they instead harbour mutations in TP53 and RB 
tumor suppressor genes, which consequently affect their functionality. In the light of above 
mentioned facts and considering the circumstance that ROSC and OLO II inhibit primarily 
CDK2 the question appeared, whether they would be able, if at all, to block cell cycle pro-
gression. 
To assess the impact of CDK inhibitors on proliferation of HeLa and HTB-31 cells lumi-
nescent viability assays were performed. At least three independent experiments, each in 
quadruplicate were done (exact procedure can be taken from methods part 2.2.3.). Treat-
ment with different drug concentrations permitted the generation of dose-response curves 
and the determination of IC50 values. Hence, it was possible to analyze, if the displayed 
effects were relevant/real or not and to compare them to other drugs. Additionally, signifi-
cant analyses of different drug concentrations were performed. All values in the figures 
stated below represent mean experimental values, whereas standard deviations are shown 
as error bars in both directions. 
OLO II is structurally very similar to ROSC – they differ in only one hydroxyl group. 
Therefore it was interesting to compare the action of both inhibitors with each other and 
additionally with doxorubicin, a strong cytostatic drug. Unlike pharmacological CDK in-
hibitors, DOX is not selective and exerts high cytotoxicity towards normal and transformed 
cells. 
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 3.1.1.  Anti-proliferative effects of ROSC in HeLa cells are time- and dose-
dependent, the cell cycle status prior to the onset of treatment may influence 
the outcome  
To determine the efficacy of ROSC several experiments were performed in parallel. 
Scheme of treatment of HeLa cells with different ROSC concentrations was constant. 
However, other parameters like the duration of continuous treatment, time period between 
plating and the start of treatment as well as post-incubation after treatment in a drug-free 
medium varied. This experimental approach allowed to evaluate not only direct action of 
the drugs, but additionally at the same dosage their long-term effects. Viability assays were 
performed immediately after treatment. 
 
 
 
Fig. 28:  Dose-response curves for ROSC. Exponentially growing HeLa cells were plated in 96-well micro-
titer plates and let to settle down for either 10h (left panel) or 22h (right panel) prior to the onset of 
treatment. Exposure of cells to ROSC for 12h or 24h clearly reduced the number of viable cells in 
comparison to untreated controls.  
 
ROSC inhibits proliferation of HeLa cells in a time- and dose-dependent manner (shown in 
Fig. 28). [Paper No. 1] As the ROSC concentration increases, the cell number decreases visibly. 
Lower ROSC concentrations (starting at 10 µM) are able to reduce the cell number, al-
though the reduction is statistically not significant. A reduction of the cell number ob-
served after 12h of the action of 40 µM ROSC is in contrast highly significant and occurs 
already after treatment in both cases. The observed effect is even stronger after 24h, if IC50 
values are considered. Treatment of 24h reveals an inhibitory concentration of about 32 
µM for both dose-response curves. However, a comparison between the left and the right 
panel in Fig. 28 demonstrates differences between the efficacy of treatment depending on 
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the period after plating that precedes the onset of treatment, especially for the 12h treat-
ment at lower ROSC concentrations. 
Thus, above results show lower sensitivity of HeLa cells to medications at 10h after plating 
as compared to cells at 22h post-plating and indicate that human HeLa cells need a recov-
ery period of approximately 20h prior to the administration of drugs. Therefore, based on 
these observations, we decided to start the treatment of cells in all subsequent experiments 
only after full recovery period. 
 
 3.1.2.  Long-term effects of ROSC  
In the next experiments the continuous and discontinuous treatment modi were compared. 
Since experiments showed that ROSC definitely acts over time, longer treatment periods 
become of great interest. Cells were exposed to ROSC for 24h and 48h or, alternatively, 
cells were treated for 24h and then after a medium change (MC) post-incubated in a drug-
free medium for the next 24h. 
 
 
 
Fig. 29:  Dose-response curve for ROSC upon varying the exposure time. HeLa cells were plated in 96-
well microtiter plates. After a 20h recovery period before the onset of treatment cells were incubated 
with different ROSC concentrations for 24h or 48h. Alternatively, after ROSC treatment for 24h the 
medium was changed and cells were post-incubated for the further 24h in a drug-free medium.  
 
According to expectations treatment of HeLa cells for 48h succeeded in reducing the cell 
number at much lower concentrations when compared to the short-term incubation (Fig. 
29). [Paper No. 2] Surprisingly, a medium change after 24h of ROSC treatment is even more 
potent than the continuous treatment itself. Comparison of IC50 values evidenced the dif-
ference between each treatment. At the same dosage, the post-incubation of treated cells 
increased the anti-proliferative efficiency by more than 50 % (43 vs. 20 µM ROSC). This 
indicates that this kind of treatment reflecting the effect of the drug after in vivo admini-
stration seems to be very effective and quite promising for the near future. 
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 3.1.3.  Higher ROSC concentrations are statistically highly significant 
 
 
 
Fig. 30:  Statistical significances of the reduction of the number of living cells after ROSC treatment. 
To evaluate which ROSC concentration reduced the proliferation of HeLa cells at a relevant grade, 
statistical analyses were performed.  The effect of different ROSC concentrations was compared to 
that of untreated cells, considering thereby various incubation times. Statistical analyses was per-
formed using one-way ANOVA with Dunnett’s post test. 
 
Statistical analyses indicate that ROSC at higher concentrations (40 µM and 60 µM 
ROSC) exhibit highly significant anti-proliferative effects (p < 0.001) observed directly 
after treatment for 24h, 48h and after 24h with a 24h post-incubation period (Fig. 30). [Paper 
No. 1]
 Remarkably, the 24h treatment at 20 µM ROSC followed by a post-incubation in a 
drug-free medium is very significant despite a relatively high SD value. The variation of 
measurement values seems to be attributable to varying adherence of treated cells to the 
substratum (bottom of plates). 
 
 3.1.4.  OLO II is a more potent CDK inhibitor than ROSC 
In order to compare the effectiveness of OLO II with that of ROSC, HeLa cells were 
treated with OLO II in the same experimental modus. 
 
  
 
82 
 
 
Fig. 31:  Dose-response curves for OLO II. Exponentially growing HeLa cells were plated into 96-well 
microtiter plates and let to settle down for either 10h (left panel) or 22h (right panel) before the onset 
of treatment. OLO II was administered at different concentrations for 12h and 24h respectively. 
 
OLO II inhibits proliferation of HeLa cells in a time- and dose-dependent manner (Fig. 
31). The marked reduction of the cell number occurred at low doses thereby indicating that 
OLO II is a very efficient agent. In comparison to ROSC similar inhibitory effects were 
observed at an approximately four-fold lower concentration. Thus the IC50 of OLO II aver-
ages 10 µM after 24h. It means that lower OLO II concentrations are sufficient to induce 
exactly the same effects as achieved by ROSC. Even the treatment with OLO II after 12h 
seems to be effective. OLO II at lower concentrations, however (1 µM and 2 µM OLO II, 
respectively), does not affect the cell number. Taken together OLO II is a more potent anti-
proliferative CDK inhibitor than ROSC. 
Differences in the sensitivity of cells to OLO II depending on the length of period after 
plating that precedes the onset of treatment, especially for the 12h treatment, were ob-
served. This result is consistent with previous data on ROSC and indicates that HeLa cells 
need a longer period to recover from stress induced by procedures connected with plating 
(trypsinization, centrifugations etc.). 
 
 3.1.5.  Time course of OLO II action 
As mentioned, OLO II acts like ROSC in a time- and dose-dependent manner. Experiments 
were designed to analyze the course of time of OLO II action, investigating a 24h and 48h 
continuous treatment as well as the 24h treatment with a post-incubation phase for an addi-
tional day. 
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Fig. 32:  Dose-response curve for OLO II after varying the exposure time. HeLa cells were plated into 
96-well microtiter plates. After a 20h recovery period OLO II was added to final concentrations as 
indicated. Cells were incubated with the drug for 24h or 48h, respectively. Alternatively, after treat-
ment with OLO II for 24h the medium was changed and cells were post-incubated for the further 
24h in a drug-free medium. 
 
Our results revealed the same trend like after ROSC treatment (Fig. 32). The most efficient 
reduction of the cell number was observed after treatment for 24h with a subsequent me-
dium change and post-incubation for 24h.  
The drug concentration sufficient for the 50 % inhibition of cell proliferation in the treat-
ment modus with the post-incubation phase was approximately half (6 µM) of that after 
24h treatment. 
In conclusion, both CDK inhibitors (ROSC and OLO II) have delayed effects in cells, sug-
gesting that a block of cell cycle or alternatively other processes persist for 24h even in the 
absence of the drug. 
Statistical analyses prove significance of the obtained results: only effects at higher OLO II 
concentrations (5 µM and 10 µM) are statistically relevant in each approach. At lower drug 
concentrations nearly all cells (about 96 %) were still viable (Fig. 33).  
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Fig. 33:  Statistical significances of the diminution of the number of viable cells upon treatment by 
OLO II. To evaluate the effect of different OLO II concentrations on the number of viable cells, sta-
tistical analyses using one-way ANOVA with Dunnett’s post test were performed.   
 
 3.1.6.  Anti-proliferative effects of ROSC and OLO II as compared to effects ex-
erted by DOX, a highly cytotoxic drug 
 
 
 
Fig. 34:  Comparison of treatment of HeLa cells with ROSC, OLO II and DOX. In addition to ROSC and 
OLO II HeLa cells were also treated with DOX for the indicated periods of time. Proliferation as-
says were performed as described earlier. Statistical analyses were performed using one-way 
ANOVA with Dunnett’s post test. 
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DOX is known to be a highly cytotoxic drug and was used in the present experiments as a 
control for the treatment with CDK inhibitors.  
Figure 34 shows the tremendous power of DOX. After treatment for 24h DOX at low dose 
(2 µM) is able to reduce the cell number to approximately a quarter. This effect is strongly 
enhanced after longer treatment (48h or 24h/MC/24h). Only 1 % of all cells remained vi-
able (Tab. 7). Hence, DOX is, without any doubt, a highly cytotoxic agent acting very effi-
ciently already at low doses.  
Unlike DOX, tested pharmacological CDK inhibitors are not so effective. However, it 
should be underlined that DOX is cyto- and genotoxic. 
Our results show that both tested pharmacological CDK inhibitors exerted delayed effects. 
The post-incubation of cells treated in the absence of drugs for 24h was more efficient than 
continuous treatment for 48h. Taken together, all obtained results are statistically highly 
significant.  
 
Mean of the number of viable cells [% of control] 
 
24h 24h/MC/24h 48h 
Co 100.0 100.0 100.0 
40 µM ROSC 52.0 15.0 23.0 
60 µM ROSC 32.0 9.0 13.0 
10 µM OLO II 52.0 17.0 19.0 
2 µM DOX 26.0 1.0 2.0 
 
Tab. 7: Reduction of the number of viable cells after treatment with examined drugs. 
 
 3.1.7.  HTB-31 cells are less susceptible to ROSC treatment 
Due to the promising effects achieved by ROSC in HeLa cells, investigation of HTB-31, a 
human cervical carcinoma cell line, regarding the same treatment as in HeLa cells took 
place.  
Experiments were performed according to the same experimental protocol as for HeLa 
cells. 
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Fig. 35:  Dose-response curve for the action of ROSC in HTB-31 cells. HTB-31 cells were seeded 20h 
before the onset of treatment. The same ROSC concentrations as for HeLa cells were applied to 
HTB-31 cells for the indicated periods of time. Subsequently CellTiter-Glo® Luminescent cell vi-
ability assays were performed as described earlier. 
 
In contrast to HeLa cells, HTB-31 cells are more resistant to ROSC treatment. After treat-
ment for 24h a much higher ROSC concentration (90.37 µM) was needed to inhibit cellular 
proliferation by 50 %, this constitutes the two- or three-fold dose needed for HeLa cells 
(Fig. 35). Even a medium change or a treatment for a longer period did not diminish the 
cell number as efficient as in HeLa cells, although 40 µM and 60 µM ROSC reduced the 
cell number with a high significance (data not shown).  
Post-incubation of treated HTB-31 cells in a drug-free medium was also more efficient 
than continuous treatment for 48h. This result is of great importance because this mode of 
treatment mimics the action of drugs in vivo administered to patients. 
 
 3.1.8.  OLO II affects HTB-31 cells more strongly than ROSC 
Furthermore HTB-31 cells were exposed to OLO II.  
 
 
 
Fig. 36:  Dose-response curve for OLO II in HTB-31 cells. HTB-31 cells were treated with different OLO 
II concentrations as indicated. 
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A 24h treatment of HTB-31 cells with OLO II is not as potent as in HeLa cells (Fig. 36). 
The inhibitory concentration needed to reduce the number of living cells by 50 % averaged 
about 15 µM. Surprisingly, both long-term treatments (continuous and discontinuous) are 
in HTB-31 cells as effective as in HeLa cells: showing nearly the same IC50. In the case of 
the treatment with the post-incubation phase OLO II at a final concentration of 5 µM is 
sufficient to reduce the cellular proliferation by 50 %.  
OLO II at a final concentration of 10 µM reduces the cell number to 20 % when it acts 
longer than 24h (Fig. 37). This substantiates that OLO II is a generally more potent agent 
and its effect is independent of the cell line. 
 
 
 
Fig. 37:  Significances of OLO II treatment of HTB-31 cells. Statistical analyses of the effects of OLO II 
treatment on the number of living human HTB-31 cells were performed using one-way ANOVA 
with Dunnett’s post test.  
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 3.1.9.  DOX treatment is not so effective in HTB-31 cells 
Finally, it was interesting to examine the effect of DOX on HTB-31 cells.  
 
 
 
Fig. 38:  Comparison of the efficacy of the ROSC and OLO II action with that of DOX in human HTB-
31 cells. HTB-31 cells were treated with ROSC, OLO II and DOX as indicated. Proliferation assays 
were performed as for the other treatments described earlier. Statistical analyses were performed us-
ing one-way ANOVA with Dunnett’s post test. 
 
As depicted in Fig. 38, HTB-31 cells are less sensitive to DOX than HeLa cells. Even after 
longer treatment periods about 11 % of cells remain viable (compared to 1 % in HeLa 
cells). Nevertheless, DOX is still more cytotoxic than ROSC and OLO II. If maybe higher 
concentrations of CDK inhibitors were chosen, the same effect could be hit. However, this 
was not further tested, since DOX only served as a control drug. 
HTB-31 cells seem to be generally more resistant to the action of conventional cytostatics 
and CDK inhibitors. 
 
 3.2.  Effects of ROSC and OLO II on the cell cycle progression in 
HeLa and HTB-31 cancer cells  
ROSC and OLO II strongly affected the cellular proliferation in both examined cancer cell 
lines. In the next step their action on the cell cycle was examined. 
Asynchronously growing HeLa and HTB-31 cells were treated either with ROSC or OLO 
II at two concentrations and stained with propidium iodide to measure their DNA content 
by flow cytometry (see propidium iodide staining procedure at 2.2.4.). The generated DNA 
profiles provided good information about the distribution of cells in G1, S and G2/M phase 
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of the cell cycle. Moreover, the ratio of cells containing DNA concentration lower than 
cells in G1 phase, so-called hypoploid or sub-G1 cells, were also shown. Sub-G1 cells rep-
resent usually apoptotic cells. 
At each time point control cells were analyzed in order to monitor spontaneous changes in 
the distribution of cells in distinct cell cycle phases.  
At least three independent experiments were performed. DNA histograms were chosen to 
illustrate a representative experiment. Moreover, results of at least three independent ex-
periments were additionally shown. Bar graphs showing mean values ± SD were generated 
using the GraphPad Prism 5 software.  
 
 3.2.1.  ROSC induces a G2/M arrest in HeLa cells accompanied by a high apop-
tosis rate 
Results from proliferation assays showed that ROSC only at higher concentrations is able 
to efficiently reduce the cell number. Therefore cells exposed to higher ROSC concentra-
tions (20 and 40 µM ROSC) were analyzed by flow cytometry. 
 
 
Fig. 39: DNA profiles of control and ROSC-treated HeLa cells 
 
As shown in Figs. 39 and 40, the effect of ROSC on the cell cycle was concentration-
dependent. [Paper No. 1] At lower ROSC concentration (20 µM) increased the frequency of the 
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G2/M population and concomitantly diminished that of G1 phase. After 18h of treatment a 
transient increase of S phase was observed. Six hours later the G2/M population reached its 
highest value of 32.7 %, clearly representing a G2/M arrest. Concomitantly, a population of 
sub-G1 cells appeared (10 %). 
ROSC at a twofold dosis resulted in a stronger increase of G2/M cells appearing already 
after 12 hours of treatment and was accompanied by a reduction of S phase. Remarkably, 
the G1 population remained almost unaffected and was nearly the same as in untreated 
cells. Moreover, the frequency of hypoploid cells representing cells undergoing apoptosis 
constituted approximately 20 % of all diploid cells after 12h and increased to 30 % after 
the next 12 hours. DNA profiles shown in Fig. 39 definitely visualize both effects in re-
sponse to ROSC treatment: increase of G2/M cell population and sub-G1 cells. 
 
 
Fig. 40:  Distribution of cell cycle phases in HeLa cells after ROSC treatment. HeLa cells were treated 
with 20 µM or 40 µM ROSC for increasing periods of time, as indicated. After trypsinization of 
cells, the generated single cell suspension was stained with propidium iodide. DNA content was 
measured in the flow cytometer.  
 
 3.2.2.  OLO II arrests HeLa cells at G2/M at low dosis  
Effect of OLO II on the cell cycle of HeLa cells was also investigated. Cells were exposed 
to 5 µM and 10 µM OLO II for 12h and 24h. 
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Fig. 41:  Distribution of cell cycle phases in HeLa cells after OLO II treatment. HeLa cells were treated 
with 5 µM or 10 µM OLO II for 12h and 24h. Cells prepared as a single cell suspension were 
stained with propidium iodide and DNA content was measured by flow cytometry.  
 
At a final concentration of 5 µM, OLO II induced after 12h an accumulation of cells in S 
phase and a reduction of the G1 cell population. These changes were transient (Fig. 41). 
Surprisingly, the frequency of cells in G2 phase remained unchanged at this time point. 
After treatment for 24h an increase of G2/M cells (~ 25 %) associated with a reduction of S 
phase cells was observed.  
In contrast, the effect of OLO II at the twofold dosis on HeLa cells becomes evident after 
treatment for 24h. Cells were arrested in G2/M phase and apoptosis at a moderate rate ap-
peared. In summary, OLO II modulates the cell cycle progression of HeLa cells in a simi-
lar way and with the comparable efficiency as ROSC, but at much lower concentrations.  
 
 3.2.3.  ROSC rapidly arrests HTB-31 cells in G2/M phase but pro-apoptotic effects 
are delayed 
Proliferation assays revealed that HTB-31 cells display a lower susceptibility to ROSC 
treatment. Therefore experimental protocol in this case was set up in a manner which al-
lowed the monitoring of the cell cycle over a longer period of time. At first cells were 
stained with propidium iodide every 6h and later every 12h up to two days.  
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Fig. 42:  DNA profiles of HTB-31 cells treated with ROSC for 36h and 48h. The Co showed in the left 
panel (36h) was obtained from cells at 24h. 
 
Treatment of HTB-31 cells with 20 µM ROSC leads to the accumulation of cells in G2 
phase already after 12h, reaching its highest value of about 30 % after 24h of treatment 
(Fig. 42). These effects were similar to those observed for HeLa cells.  
The ratio of G2 phase cell population slightly decreased after 36h and 48h of treatment. 
Concomitantly, the frequency of G1 cell population was reduced beginning with 18h. Inter-
estingly, ROSC at a final concentration of 20 µM did not induce cell apoptosis. 
When treated with 40 µM ROSC, HTB-31 cells arrested stronger in G2/M phase. After 36h 
an increase to almost 40 % of G2 phase occurred (very impressive shown in Fig. 42). [Paper 
No. 1]
 This seemed to be at the expense of G1 cells. Exposure of HTB-31 cells to 40 µM 
ROSC for the further 12h resulted in diminution of S phase cells and an appearance of hy-
poploid cells. The flow cytometric analyses indicate that onset of apoptotic response to 
ROSC is much weaker and delayed than in HeLa cells. Moreover, it proceeds very slowly. 
The ration of sub-G1 cells appeared at 36h and increased only by approximately 5 % dur-
ing the next 12h. 
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Fig. 43:  Distribution of HTB-31 cells in distinct cell cycle phases after ROSC treatment. HTB-31 cells 
were treated with 20 µM or 40 µM ROSC up to 48h, as indicated. After trypsinization of cells, the 
generated single cell suspension was stained with propidium iodide. DNA content was measured in 
the flow cytometer. (Statistical data were not obtained for each time point) 
 
 3.2.4.  Increase of the ratio of G2/M cell population after OLO II treatment 
The next experiments were performed to determine the effect of OLO II on cell cycle pro-
gression in HTB-31 cells. 
 
 
Fig. 44:  DNA profiles of control HTB-31 cells and cells treated with OLO II for the indicated time 
points. 
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It is not surprising at all that OLO II is also able to induce accumulation of cells in G2/M 
phase in HTB-31 cells (Figs. 44 and 45). OLO II at both concentrations (5 µM and 10 µM 
OLO II) induced the G2/M arrest with the same efficiency as ROSC starting at 12h. The 
lower concentration increased the G2/M phase at the expense of G1 cells, leaving the S 
phase unchanged as in controls after 24h of treatment. In contrast, 10 µM OLO II induced 
the G2/M arrest at the account of S phase cells. 
OLO II did not induce apoptosis in HTB-31 cells within 24h. Considering the fact that 
HTB-31 cells were relatively resistant to triggering apoptosis by ROSC, it cannot be ex-
cluded that after treatment for the further 24h apoptosis could be induced.  
 
 
Fig. 45:  Distribution of HTB-31 cells in distinct cell cycle phases after OLO II treatment. Treatment of 
HTB-31 cells with OLO II was performed at the same concentrations and conditions as for HeLa 
cells.  
 
In summary, all experiments performed so far evidence that inhibition of CDKs by ROSC 
and OLO II strongly affects the distribution of examined human cervical carcinoma cells in 
distinct cell cycle phases. Both inhibitors arrested asynchronously growing cells in the 
G2/M phase. Moreover, both CDK inhibitors at higher dosage triggered apoptosis. How-
ever, unlike HeLa cells, HTB-31 cells were relative resistant to apoptosis and responded to 
the treatment with a delay. 
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 3.3.  Modulation of the major cell cycle regulators upon treatment 
with selective CDK inhibitors 
Anti-proliferative and cell cycle modulatory effects of both examined CDK inhibitors in 
HeLa and HTB-31 cells evoked the question by which mechanism the drugs induce the 
observed changes. To address this issue it was necessary to perform detailed analysis of 
major cell cycle regulators, including cyclin-dependent kinases, by immunoblotting. For 
this purpose whole cell lysates (WCLs) from control HeLa and HTB-31 cells as well as 
cells treated with ROSC and OLO II at indicated concentrations were prepared. After pro-
tein separation by electrophoresis and subsequent electroblotting onto membranes, distinct 
proteins including their phosphorylated forms were detected with specific antibodies. 
Comparison of the expression and optionally phosphorylation status of distinct proteins 
provided information on their changes upon ROSC/OLO II treatment. 
The equal protein loading and proper transfer was always checked by Ponceau S staining. 
Equal protein loading was additionally verified by incubation of immunoblots with actin, a 
housekeeping protein that normally does not oscillate in cells upon treatment. 
 
 3.3.1.  ROSC prevents the activating phosphorylation of CDK2 and CDK1 
In the fist step, the functional status of the major cell cycle regulators was analyzed. CDK2 
and CDK1 are potential targets of both CDK inhibitors and have been inspected first. 
CDK2 would normally assemble with cyclin E to active complexes and phosphorylate the 
tumor suppressor pRb to move cells into S phase. CDK1 associates with cyclin B and pro-
motes M phase.  
As shown in Fig. 46 ROSC decreased the activating phosphorylation of CDK2 at Thr160 
within the T-loop in a time- and concentration-dependent manner (compared to untreated 
control cells and to the amount of total CDK2 protein). [Paper No. 1] This indicates that ROSC 
inhibits the activity of CDK2. Already after 12h CDK2 was inactivated by preventing its 
activating phosphorylation at Thr160. This was additionally evidenced by further analysis of 
the modification status of nucleophosmin (NPM), a specific CDK2 substrate, whose phos-
phorylation at Thr199 depends on CDK2. Loss of phosphorylation of NPM occurs after 
treatment for 12h at 40 µM ROSC and after the further 12h at 20 µM ROSC. Surprisingly, 
at this time point the phosphorylated form of NPM appeared (Fig. 47). The relevance of 
this unexpected effect has to be elucidated. 
Consequently, one would expect that inactive CDK2 would be unable to phosphorylate 
pRb and would stop cell cycle progression in G1 phase. However, considering the fact that 
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in HeLa cells the E7 oncoprotein is present, the prevention of pRb phosphorylation could 
not induce cell cycle arrest at the G1/S border. 
 
 
 
Fig. 46: Abolishing of CDK2 and CDK1 activating phosphorylation after ROSC treatment of HeLa 
cells. Whole cell lysates from control and ROSC-treated HeLa cells were loaded onto 12 % SDS-
PAGE gels, blotted onto PVDF membranes and incubated afterwards with CDK specific antibodies.  
 
 
 
Fig. 47:  Decrease of NPM phosphorylation is an evidence for CDK2 inactivation by ROSC. HeLa cells 
were treated with ROSC and lysed. Proteins were loaded onto 10 % SDS-PAGE gels. Immunoblot-
ting analyses was performed using NPM specific antibodies and anti-actin sera to check the equal 
protein loading. 
 
Regarding the phosphorylation and activation status of CDK1, obtained results reveal 
changes of its phosphorylation at three important residues. [Paper No. 1] Phosphorylation at 
Thr161 prepares CDK1 for its activation, whereas phosphorylation of Thr14 and Tyr15 car-
ried out by Wee/Myt1 kinase leads to its inhibition. The obvious increase of the phos-
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phorylation of CDK1 at two inhibitory sites beginning after 12h evidenced the inactivation 
of CDK1 in ROSC-treated HeLa cells. Although the activating phosphorylation of CDK1 
slightly increased after 18h as well, it has no importance until no dephosphorylation at in-
hibitory sites occurs. Inactivation of CDK1 is a main mechanism by which ROSC induces 
the G2/M arrest in HeLa cells. 
 
 3.3.2.  Repression of cdc25C phosphatase correlates with an accumulation of 
phosphorylation of CDK1 at inhibitory sites 
Analysis of the expression and functional status of cdc25C phosphatase that is responsible 
for dephosphorylation of CDK1 at Thr14/Tyr15 revealed that ROSC modulated the phos-
phorylation status of cdc25C at Ser216. The increase of site-specific phosphorylation of 
cdc25C upon ROSC treatment at a final concentration of 40 µM for 12h and 18h correlates 
with the phosphorylation of CDK1 at the inhibitory sites. [Paper No. 1] After treatment for 24h 
at both ROSC concentrations the amount of phosphorylated and total cdc25C phosphatase 
significantly decreased (Fig. 48). 
Another important player in maintaining the ROSC-induced G2 arrest is LATS-1, a relative 
new tumor suppressor protein. LATS-1 was discovered to negatively regulate CDK1, when 
phosphorylated at Ser909, thus inhibiting its kinase function. Thus, ROSC affects CDK1 by 
three different ways to assure that no cell cycle progress will occur.  
 
 
Fig. 48: Cellular levels and phosphorylation status of cdc25C phosphatase and LATS-1 tumor suppres-
sor protein in control and ROSC-treated HeLa cells. HeLa cells were treated with ROSC as indi-
cated and proteins were analyzed by immunoblotting using specific antibodies, as indicated. 
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 3.3.3.  ROSC prevents pRb phosphorylation 
Loss of CDK2 activation should clearly affect pRb phosphorylation. Therefore, the phos-
phorylation status of the retinoblastoma protein at three different residues after ROSC 
treatment was investigated. 
ROSC diminished the phosphorylation of pRb protein at Ser780 and Ser807/811 in a time- and 
dose-dependent manner, leading to a reactivation of pRb protein functions as a tumor sup-
pressor (Fig. 49). [Paper No. 1] However, it was unclear whether this event would be able to re-
establish the G1 restriction checkpoint since HeLa cells express HPV-encoded E7 oncopro-
tein.  
 
 
Fig. 49:  Reduction of the site-specific pRb phosphorylation. Whole cell lysates obtained from controls 
and ROSC-treated HeLa cells were loaded onto 10 % SDS-gels and blotted onto PVDF membranes. 
Afterwards, the protein level and site-specific phosphorylation of pRb was monitored using specific 
antibodies recognizing pRb phosphorylated at distinct sites as well as total pRb protein irrespective 
of its modification.  
 
 3.3.4.  Inactivation of CDK7 mediated by ROSC 
Further analyses were performed to determine the current state of CDK7 in untreated con-
trol and ROSC-treated HeLa cells. CDK7 is a kinase responsible for the activation of the 
major cell cycle-related kinases like CDK2 and CDK1 and regulates simultaneously dis-
tinct steps in transcription.  
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Fig. 50:  Abolishing of site-specific phosphorylation of CDK7 in response to ROSC treatment. Site-
specific phosphorylation of CDK7 and its total levels were determined in control and ROSC-treated 
HeLa cells by immunoblotting using specific antibodies. 
 
The functional involvement of CDK7 in the cell cycle and transcription is regulated by a 
phosphorylation at Ser164/Thr170. When HeLa cells were exposed to ROSC, a reduction of 
the site-specific phosphorylation of CDK7 occurred already after 12h of treatment and de-
creased to a minimum after the further 6h (Fig. 50). [Paper No. 1 and 2] After a continuous 
treatment for 24h, phosphorylation of CDK7 at the critical residues slightly increased. 
However, it seems that a weak increase of phosphorylation is attributable to the elevation 
of total CDK concentration. These results indicate that reduction of site-specific phos-
phorylation of CDK7 upon ROSC treatment might correlate with its reduced activity nec-
essary to regulate transcription. 
 
 3.3.5.  ROSC and OLO II repress the function of RNA polymerase II in HeLa cells 
necessary for global transcription 
One would expect that the prevention of site-specific phosphorylation of CDK7 might 
strongly affect its functions in the regulation of transcription. CDK7 regulates the activity 
of RNA polymerase II during transcription. CDK7 catalyzes the phosphorylation of RNA 
polymerase II at Ser5 within the heptapeptid repetitive motif respectively, localized in the 
carboxy-terminal domain (CTD). 
To gain more insight, the functional status of RNA polymerase II was examined in control 
HeLa cells and cells treated with ROSC as well as OLO II at their most effective concen-
trations. Whole cell lysate as well as subcellular fraction (isolated nuclei and cytosolic 
fractions; according to RSB fractionation, section 2.2.13.) were analyzed by immunoblot-
ting. This should facilitate the detection of RNA polymerase II accumulated in nuclei, 
where transcription occurs.  
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Fig. 51:  ROSC and OLO II abolish the phosphorylation of RNA polymerase II at specific serine resi-
dues critical for regulation of transcriptional progression. HeLa cells were treated with ROSC 
and OLO II as indicated. Whole cell lysates and subcellular fractions (nuclei and post-nuclear su-
pernatant representing a crude cytosolic fraction) were loaded onto 8 % SDS-PAGE gels and blotted 
onto PVDF membranes. Site-specific phosphorylation of the CTD of RNA polymerase II was ana-
lyzed by immunoblotting using phosphospecific antibodies from Abcam. Twin blots were used for 
detection of the phosphorylation of Ser2 and Ser5. Subsequently, total RNA polymerase II was de-
tected. 
 
The immunblotting analysis revealed that exposure of HeLa cells to both CDK inhibitors 
markedly reduced the phosphorylation of RNA polymerase II at Ser5 after 12h and this 
persisted at 24h after action of OLO II (Fig. 51). [Paper No. 2] Interestingly, the phosphoryla-
tion of RNA polymerase II at Ser2 was completely reduced after 24h (Fig. 51) thereby indi-
cating that the function of RNA polymerase II in the elongation and processing of primary 
transcripts was inhibited. 
 
 3.3.6. Increase of p53 levels upon ROSC treatment 
Immunoblotting analysis of whole cell lysates prepared from control and ROSC-treated 
HeLa cells revealed an increase of p53 protein levels in response to ROSC treatment be-
ginning at 12h. [Paper No. 2] As depicted in Fig. 52, ROSC-mediated enhancement of p53 pro-
tein was time and concentration dependent. The highest increase of p53 levels was detected 
after 24h at a final concentration of 40 µM. In contrast, p53 protein was barely detectable 
in lysates prepared from untreated control cells. These results indicate that the blockage of 
global transcription in HeLa cells upon treatment with CDK inhibitors has no effect on the 
cellular levels of p53 protein. Considering the fact that p53 expression in HeLa cells is 
primarily controlled by the regulation of protein stability that is determined by HPV-
encoded E6 oncoprotein. The upregulation of p53 protein under conditions of the block of 
global transcription would indicate that both pharmacological CDK inhibitors reduced the 
expression of HPV-encoded E6 oncoprotein. 
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Fig. 52:  Increasing levels of p53 protein after ROSC treatment. HeLa cells were treated with ROSC at 
two different concentrations. Whole cell lysate samples were monitored by immunoblotting for p53 
levels. The specific monoclonal DO-1 antibody was used to detect p53.  
 
 3.3.7.  Repression of E6 and E7 viral oncoproteins in HeLa cells 
The viral genome is usually transcribed using tools of host cells and one would expect that 
blockage of global transcription after inhibition of RNA polymerase II might also affect 
the expression of the oncogenic proteins E6 and E7, which are integrated into the genome 
of HeLa cells and co-expressed with other cellular genes. The fact that p53 protein ap-
peared in HeLa cells after treatment with both CDK inhibitors despite blockage of global 
transcription implicates that the treatment facilitated p53 protein to escape from its E6-
mediated degradation. Therefore, it was of importance to prove the effect of both CDK 
inhibitors on the cellular concentration of HPV-encoded oncoproteins. For this purpose, 
control and ROSC-treated cells were analyzed for the presence of HPV-encoded proteins. 
Analysis of whole cell lysate samples revealed the reduction of E7 oncoprotein levels after 
ROSC treatment for 18h (Fig. 53). [Paper No. 1] However, the intensity of E7 signal on im-
munoblots was relatively weak. Therefore, we decided to fractionate cells to enrich the 
antigens. Since both oncogenic proteins are localized primarily in the nucleus, cells were 
fractionated yielding the nuclei and post-nuclear supernatant designated as a cytosolic frac-
tion. Then both subcellular fractions (cytosol and nuclei) were analyzed by immunoblot-
ting to detect E6 protein. 
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Fig. 53:  Repression of E7 oncoprotein by ROSC. HeLa cells were treated with ROSC for 12h and 18h. 
Whole cell lysates were loaded onto 15 % SDS-PAGE gels. After blotting, E7 was detected using 
specific anti-E7 antibodies from Abcam.  
 
The repression of HPV 18-encoded E6 protein influenced by ROSC and OLO II treatment 
is demonstrated in Fig. 54. [Paper No. 2] As expected, E6 oncoprotein was detected in the nu-
clei isolated from untreated control cells, but not in the cytosolic fraction. The level of E6 
oncoprotein was markedly reduced in the nuclei isolated from cells treated with CDK in-
hibitors. The diminution of E6 protein in whole cell lysates was also observed in samples 
after treatment for 24h but not at 12h. However, in WCL prepared from untreated control 
cells at 12h no E6 positive signal was detected. Therefore, it is not possible to evaluate this 
observation. Both CDK inhibitors repress the E6 protein after 12h and 24h of treatment 
very effective. 
 
 
Fig. 54:  Repression of E6 oncoprotein expression by ROSC and OLO II. Controls and ROSC and OLO 
II-treated HeLa cells were lysed yielding whole cell lysates of fractionated nuclei. Proteins were 
separated onto 15 % SDS-PAGE gels and blotted onto PVDF membranes. E6 specific antibodies 
from Abcam allowed the detection of the oncoprotein. To prove the authenticity of the cytosolic 
fraction and the equal protein loading detection of Ran, a small GTPase, occurred. Ran was only de-
tected to low levels in nuclei, a fact which may be influenced by its ability of shuttling between cy-
tosol and nuclei at any time.  
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We conclude that ROSC and OLO II clearly display anti-viral activity. They are definitely 
able to inactivate the oncogenic E6 and E7 proteins in HeLa cells by modulating the RNA 
polymerase II functional status and in consequence the global transcription. 
 
 3.3.8.  Site-specific phosphorylation of CDK7, but not that of CDK2 is affected in 
HTB-31 cells 
Unlike HeLa cells, HTB-31 cells were less sensitive to the action of CDK inhibitors. 
Therefore it was unclear, which cell cycle regulators might be affected by ROSC and OLO 
II.  
 
 
Fig. 55:  Effect of ROSC and OLO II on the functional status of CDK7 and CDK2 in human HTB-31 
cells. HTB-31 cells were treated with ROSC and OLO II at two different concentrations for 12h and 
24h. Whole cell lysates were generated and analyzed for the presence of an activating phosphoryla-
tion in CDK2 and CDK7. The sample obtained from the treatment with 20 µM ROSC for 24h was 
overloaded and for this reason it has not been considered at all. The reactivity of endogenous CDK2 
in HTB-31 cells with monoclonal anti-CDK2 antibodies was reduced as compared to that in other 
human cancer cells. 
 
Immunoblotting experiments revealed that both tested CDK inhibitors did not reduce the 
site-specific phosphorylation of CDK2 at Thr160 (Fig. 55). Surprisingly, after exposure of 
HTB-31 cells to ROSC the phosphorylation of CDK2 at Thr160 increased. This unexpected 
effect became evident especially after treatment for 24h. 
In contrast, both CDK inhibitors were able to reduce the activating phosphorylation of 
CDK7. Decrease of the phosphorylation of CDK7 occurred only at higher ROSC concen-
tration (Fig. 55). These results show that the functional status of both examined kinases 
was differentially modulated by tested CDK inhibitors.  
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 3.3.9. Transcriptional regulation in HTB-31 cells is affected by OLO II  
Decrease of site-specific phosphorylation of CDK7 in response to CDK inhibitors indicates 
that they might interfere with cellular transcription. Therefore, the functional status of CTD 
of RNA polymerase II was examined in HTB-31 cells exposed to CDK inhibitors. 
 
 
Fig. 56:  Repression of cellular transcription in HTB-31 cells by OLO II. HTB-31 cells were treated with 
ROSC and OLO II at the indicated concentrations for 12h and 24h. Whole cell lysates were ana-
lyzed for the phosphorylation of RNA polymerase II using specific antibodies. However, there were 
some problems with the detection of the total RNA polymerase protein. 
 
As expected, decrease of the phosphorylation of CDK7 at sites promoting its affinity to 
CTD template also affected the phosphorylation of RNA polymerase II at Ser2 and Ser5 in 
HTB-31 cells. However, only OLO II was able to strongly reduce the modification of RNA 
polymerase II (Fig. 56). Abrogation of the phosphorylation at Ser2 was induced by OLO II 
at a concentration of 10 µM already after 12h and maintained for further 12h. 5 µM OLO 
II was able to diminish the same phosphorylation only after 24h of treatment. This indi-
cates that lower OLO II concentrations need a longer time to exert their functions on HTB-
31 cells. Regarding the phosphorylation at Ser5, only the highest OLO II concentration 
reduced it significantly.  
ROSC seems to have a low, if any, effect on RNA polymerase II in HTB-31 cells. ROSC 
at a final concentration of 40 µM decreased the phosphorylation at Ser2 after 12h very 
well, but this effect was transient. These results show that both CDK inhibitors differen-
tially affect their major cellular targets in HTB-31 cells.  
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 3.3.10. Neither ROSC nor OLO II affects p53 levels in HTB-31 cells 
In further tests the effect of medication on p53 levels in HTB-31 cells was monitored. 
These cells harbour a p53 mutation which causes the accumulation of the malfunctioned 
protein, which is then unable to induce cell cycle arrest.  
 
 
Fig. 57: ROSC and OLO II treatment does not affect levels of p53 protein in HTB-31 cells. HTB-31 
cells were treated with ROSC and OLO II at two different concentrations. Whole cell lysates were 
monitored for p53 levels by immunoblotting. The specific monoclonal DO-1 antibody was used to 
detect p53. The sample obtained after treatment with 20 µM ROSC for 24h was overloaded due to 
an underestimation of protein concentration and was not taken into consideration. 
 
As shown in Fig. 57, treatment of HTB-31 cells with ROSC and OLO II did not affect p53 
levels at all. Intensity of p53 protein band remained nearly constant throughout the treat-
ment period. This result indicates that mutated p53 expressed in HTB-31 cells has pro-
longed stability and remains unaffected by treatment with tested CDK inhibitors.  
 
 3.3.11. ROSC induced upregulation of NF-κB in HTB-31 cells 
NF-κB is a transcription factor usually induced upon environmental stress (e.g. infection, 
inflammation etc.) capable of activating downstream genes to reprogram gene expression. 
Besides its functions in mounting the innate immune response, it is known to be involved 
in promoting survival that contributes to carcinogenesis as well. However, the biological 
function of NF-κB seems to depend on the cellular context. Thus, in some cases repression 
of NF-κB prevents tumor formation. [171] 
As shown in Fig. 58 the phosphorylation status of NF-κB protein changed during cultiva-
tion of control HTB-31 cells. At 12h after the onset of the experiment Ser536 was unmodi-
fied and after further 12h a strong phosphorylation of NF-κB at Ser536 was detected. Inter-
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estingly, exposure of HTB-31 cells to ROSC for 12h and 18h strongly enhanced the site-
specific phosphorylation of the NF-κB protein. However, at 24h the intensity of NF-κB 
protein phosphorylated at Ser536 in control and ROSC-treated cells was comparable. Unlike 
the phosphorylated form, the total level of NF-κB was not affected by ROSC. These results 
indicate that ROSC-mediated enhancement of site-specific phosphorylation of NF-κB pro-
tein observed at 12h and 18h modulates its activity and not its steady-state. This event 
might be linked to its pro-apoptotic functions involving FAS/FAS ligand-mediated path-
way.  
 
 
Fig. 58: ROSC enhanced site-specific phosphorylation of NF-κB in human HTB-31 cells in a time- and 
concentration-dependent manner. HTB-31 cells were treated with ROSC and analyzed for the ac-
tivity of NF-κB protein after 12h, 18h and 24h.  
 
The systemic analysis of the changes of the major cell cycle regulators in HeLa and HTB-
31 cells after treatment provided more insight into the mode of action of the pharmacologi-
cal inhibitors ROSC and OLO II. In comparison to HeLa cells, HTB-31 cells are less sensi-
tive to these inhibitors.  
 
 3.4.  Apoptosis-promoting effects induced by the CDK inhibitors 
ROSC and OLO II in HeLa and HTB-31 cells  
DNA profiles (section 3.3.), showing the changes in the cell cycle progression after treat-
ment, clearly show the appearance of a hypoploid cell population after medication, which 
seems to represent cells undergoing apoptosis. To prove the assumption, distinct assays 
allowing to detect cells undergoing apoptosis were performed in HeLa and HTB-31 cells. 
Moreover, it was of interest to determine by which mechanisms CDK inhibitors would be 
able to induce apoptosis. 
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 3.4.1.  Detection of caspase-3-cleaved cytokeratin 18 in cancer cells exposed to 
CDK inhibitors 
Cleavage of cytokeratin 18, a component of cytoskeleton, mediated by activated effector 
caspase-3 is a characteristic feature of epithelial cells undergoing apoptosis. HeLa cells 
were treated with ROSC and OLO II at concentrations used before. After fixation the sam-
ples were stained with the FITC-coupled monoclonal M30 CytoDEATH antibody recog-
nizing solely caspase-3-cleaved cytokeratin 18. This technique provides an easy and fast 
way to detect ongoing apoptosis in situ. Normal healthy cells remain unstained. However, 
in cells with activated caspase cascade a characteristic punctuated staining pattern appears 
in the cytoplasm, an indication for the presence of the truncated form of cytokeratin 18. 
Compared to controls, which simply display a weak diffuse green fluorescent background, 
treated HeLa cells definitely show a strong green speckled fluorescent staining pattern 
(Fig. 59). Counterstaining with DAPI evidenced that not all cells in the field were reactive 
with M30 CytoDEATH antibody. Generally, the higher ROSC and OLO II concentrations 
seem to induce cell death at a higher rate than the lower dose. In contrast, in response to 
DOX treatment, the majority of cells exhibited positive reaction with M30 CytoDEATH 
indicating that DOX induced massive cell death. Unlike in HeLa cells, DOX had a very 
weak effect on HTB-31 cells. The results revealed by M30 CytoDEATH staining correlate 
with DNA histograms and confirm previous assumption that inhibition of cellular CDKs 
by pharmacological antagonists induced apoptosis in HeLa cells but not in HTB-31 cells. 
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Fig. 59: Detection of caspase-3-cleaved cytokeratin 18 in human cervix carcinoma cells exposed to 
drugs. Control and drug-treated HeLa and HTB-31 cells were fixed with MeOH and permeabilized 
using Triton-X 100. Thereafter specimens were overnight incubated with M30 CytoDEATH anti-
body. Chromatin was visualized after staining with DAPI. Pictures were taken at the 40x magnifi-
cation obiective. 
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 3.4.2.  Loss of J-aggregate formation upon treatment of HeLa and HTB-31 cells 
indicate the collapse of the mitochondrial membrane 
In the further experiments the effect of drugs on the potential of mitochondrial membrane 
was examined. Control and treated cells were stained with the fluorescent dye JC-1. The 
reaction was evaluated in two independent approaches. First, the aggregation of the dye 
was assessed in situ by immunfluorescence microscopy. Secondly, the emitted fluores-
cence was analyzed in two channels by flow cytometry. JC-1 provides information on the 
integrity of mitochondrial membrane potential. Using JC-1 dye for staining, the collapse of 
the mitochondrial membrane, an early event in apoptosis, can be detected and quantified. 
Normally, JC-1 forms J-aggregates generating punctuated red fluorescence accumulating at 
the charged mitochondrial membrane in intact cells. Apoptotic cells, however, display a 
reduced membrane potential, where JC-1 fails to form dimers and remains monomeric, 
thus emitting a green fluorescence. 
In situ staining of HeLa cells was performed after a 24h treatment with OLO II or DOX 
using 20 µM JC-1 (see section 2.2.11.). Immunfluorescence images are depicted in Fig. 60. 
Cells were first visualized by the Hoffman modulation contrast and then the generated 
fluorescence was analyzed. Cells displaying the normal potential of mitochondrial mem-
brane are stained red, whereas apoptotic cells appear to be green. Apparently, the red fluo-
rescence is quite strong and shines in the green light channel as well. This facilitates the 
discrimination between intact and apoptotic cells. In comparison to controls, treated cells 
clearly display a higher frequency of apoptotic cells, that are green stained due to dissipa-
tion of the potential of the mitochondrial membrane. 
 
  
 
110 
 
Fig. 60:  Accumulation of monomeric JC-1 dye upon collapse of mitochondrial membrane after OLO II 
and DOX treatment. HeLa cells were treated with OLO II and DOX at different concentrations for 
24h and stained with 20 µM JC-1. By changing the excitation light, green and red fluorescence were 
recorded. Pictures were taken at the 40x magnification objective. DOX is a DNA-intercalating dye, 
which upon intercalation and excitation emits red fluorescence. Therefore, red fluorescence in DOX-
treated HeLa cell images represents its own fluorescent properties, since J-aggregates are barely ac-
cumulated. However, DOX fluorescence was not independently determined.  
 
The staining procedure for determination of the potential of the mitochondrial membrane 
by flow cytometry is very similar to that used for evaluation under immunfluorescence 
microscopy. HeLa and HTB-31 cells were simply incubated with JC-1 at a final concentra-
tion of 20 µM for 20 minutes, carefully washed and afterwards immediately measured to 
avoid bleaching over time. Flow cytometric measurement of JC-1-stained cells allows 
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quantification of the rate of apoptosis mediated via the mitochondrial pathway. Usually at 
least 20,000 cells were measured.  
In HeLa cells DOX at a concentration of 2 µM clearly disturbed the membrane potential in 
50 % of all stained cells leading to the collapse of the mitochondrial membrane (Fig. 61). 
Thus, DOX triggered apoptosis very efficiently already after 24h. After continuous treat-
ment for 48h even the tenfold lower DOX concentration induced apoptosis at a high rate. 
The apoptosis was triggered with similar frequency also after a discontinuous treatment 
modus (Fig. 61, diagram in the middle).  
In contrast, ROSC and OLO II are less potent than DOX. However, they are also capable 
to induce apoptosis via mitochondrial pathway at higher doses. ROSC at a final concentra-
tion of 40 µM induced apoptosis up to 15 % within 24h. This ratio slightly increased after 
longer incubation periods. The pro-apoptotic effect of OLO II was weaker than that of 
ROSC.  
 
 
Fig. 61:  Loss of J-aggregate formation upon treatment of HeLa cells. HeLa cells were treated with 
ROSC, OLO II and DOX for the indicated periods of time and then stained with JC-1. Emitted fluo-
rescence was measured in two channels. Quantification analyses of apoptotic cells were performed 
by flow cytometry. No statistical analyses have been done for results after discontinuous treatment 
(24h/MC/24h).  
 
Considering that fact that after treatment of HTB-31 cells with DOX, a strongly cytotoxic 
agent, for 24h a sub-G1 population was barely detectable, the duration of the treatment 
scheme was slightly modified. The treatment was constricted to extended time periods. 
Flow cytometric results shown in Fig. 62 confirm once again the higher resistance of HTB-
31 cells to distinct drugs. DOX at the highest concentration induced apoptosis after 48h in 
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approximately 26 % of cells. At this time point only OLO II exerted comparable effects. 
Thus, unlike in HeLa cells, in HTB-31 cells OLO II was generally more effective than 
ROSC. 
 
 
Fig. 62: Loss of J-aggregate formation upon treatment of HTB-31 cells. HTB-31 cells were stained with 
JC-1 at a final concentration of 20 µM. Emitted fluorescence was measured in two channels. Quanti-
fication analyses of apoptotic cells were performed by flow cytometry. No statistical analyses have 
been done for results after discontinuous treatment (24h/MC/24h).  
 
Taken together, the above described experiments revealed a weak to moderate effect of 
both examined CDK inhibitors on the potential of the mitochondrial membrane of HTB-31 
and HeLa cells, respectively. The very strong effect of DOX on the potential of the mito-
chondrial membrane in HeLa cells reflects very well its highly cytotoxicity and evidences 
that the method satisfyingly worked.  
 
 3.4.3.  Intracellular accumulation of 7-AAD as an evidence for the loss of the 
plasma membrane integrity  
Previously performed assays revealed that ROSC and OLO II are able to induce apoptosis 
in HeLa and in a lower rate in HTB-31 cells. In the next experiments we addressed the 
question whether both examined CDK inhibitors are cytotoxic. For this purpose the dye 
exclusion test was performed. Very potent drugs that damage DNA and generate free radi-
cals are highly cytotoxic resulting in necrosis and not apoptosis. A typical property of ne-
crosis is the loss of the plasma membrane integrity. In contrast, cells in early stages of 
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apoptosis still display an intact membrane. The status of the cell membrane may be 
checked by the simple incubation of cells with dyes that are excluded by those with the 
intact plasma membrane. Dyes like 7-AAD, after entering cells, accumulate in the nucleus 
and intercalate into DNA allowing the quantification of cells with a leaky plasma mem-
brane by flow cytometry (procedure see 2.2.8.).  
HeLa and HTB-31 cells were both tested for the necrotic properties of certain drugs. 
 
 
Fig. 63: Uptake of 7-AAD is an evidence for the loss of the membrane integrity. HeLa and HTB-31 cells 
were treated with the indicated drugs for 24h and thereafter stained with 7-AAD for 20 minutes. 
Samples were measured by flow cytometry.  
 
The dye exclusion test revealed a high cytotoxicity of DOX at a higher concentration, 
whereas both examined CDK inhibitors even at high concentrations impaired the plasma 
membrane only in a low number of cells (Fig. 63).  
Considering the fact that the rate of ROSC and OLO II induced apoptosis exceeds that of 
7-AAD accumulation, it seems that they did not generate necrosis in HeLa and HTB-31 
cells. 
 
 3.4.4.  ROSC and OLO II initiate caspase-depedent apoptosis in HeLa cells 
So far performed cell-based assays showed that CDK inhibitors induce a programmed cell 
death in HeLa cells. The detection of cleavage of cytokeratin 18 in HeLa samples treated 
with both CDK inhibitors pointed out that they induce caspase-dependent apoptosis. A 
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second indication was provided by the fact that CDK inhibitors induced apoptosis by the 
mitochondrial pathway. Dissipation of the potential of the mitochondrial membrane result-
ing in a release of cytochrome c is known to trigger the activation of caspase-cascades. 
 
 
Fig. 64:  Activation of initiator caspase-9 in control and drug-treated HeLa cells. HeLa cells were treated 
with different ROSC and OLO II concentrations for different time points. The activity of caspase-9 
was determined using the Caspase-Glo® 9 assay from Promega. The caspase-9 activity was deter-
mined as relative luminescence units (RLU) and normalized to the number of viable cells assessed 
by proliferation assays as earlier described. Results obtained for 2 µM OLO II after a 24h/MC/24h 
treatment seemed not to match with the other results, thus they were not taken into consideration. 
 
Determination of enzymatic activity revealed that ROSC and OLO II induce caspase-9 
activity in a concentration- and time-dependent manner. Both drugs activated caspase-9 at 
higher doses (Fig. 64). Interestingly, the strongest activation of caspase-9 was not observed 
after a long continuous but after a discontinuous treatment modus (treatment for 24h with a 
subsequent medium change and a post-incubation for 24h in a drug-free medium). How-
ever, the continuous treatment for 48h was of advantage only in the case of OLO II. As 
expected, DOX strongly activated the initiator caspase-9 in HeLa cells already after short 
treatment (data not shown).  
To substantiate the obtained results, the activity of downstream effector caspase-3 and -7 
was performed using two different assays. This should offer the possibility to obtain 
method-independent results. Additionally, caspase-3/7 activity was measured in cells as 
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well as in their culture medium (supernatant) to find out at which time point plasma mem-
brane becomes permeable resulting in leakage of activated caspases into the culture me-
dium. 
 
 
Fig. 65:  Enhancement of caspase-3/7 activity after treatment of HeLa cells with CDK inhibitors. ROSC 
and OLO II treatment of HeLa cells was performed as indicated. Caspase-3/7 activity was measured 
in treated cells using Promega’s Caspase-Glo® 3/7, and independently in culture medium using Apo-
ONE® assay. The caspase-3/7 activity was stated as relative luminescence units (RLU) or alterna-
tively as relative fluorescence units (RFU) and normalized to the number of viable cells assessed by 
CellTiter-Glo® luminescent cell viability assay. 
 
Fig. 65 demonstrates the strong correlation of results regarding the activation of caspase-9 
and caspase-3/7. In samples with elevated caspase-9 activity, induction of caspase-3/7 ac-
tivity was also detected. Likewise, caspase-3/7 accumulation is strongest after a 24h treat-
ment with a subsequent medium change and a post-incubation in a drug-free medium. This 
applies to both CDK inhibitors. Thus, ROSC and OLO II show their potency towards cas-
pase-3/7 induction, confirming ROSC to be the more potent inducer.  
After a longer treatment period (48h) the release of effector caspases into the culture me-
dium was observed (results obtained for supernatants from 40 µM ROSC after a 
24h/MC/24h treatment were not taken into consideration, since they appear to be strange). 
Caspase-3/7 accumulation was threefold higher in supernatants than in ROSC-treated cells 
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and nearly sevenfold higher in OLO II supernatants compared to OLO II-treated cells. The 
other treatments barely discharged any caspases to the medium. 
 
In conclusion, ROSC and OLO II induce caspase-dependent apoptosis by an approximately 
fourfold activation of initiator and effector caspases over the levels observed in control 
cells already after 24h of treatment. The long-term effects of CDK inhibitors became evi-
dent, when caspases were released into the culture medium.  
 
 3.4.5.  Phosphorylation of Bad and survivin contributes to ROSC-induced apop-
tosis 
Further experiments were performed to investigate by which mechanisms ROSC induces 
apoptosis. Control and ROSC-treated HeLa cells were therefore lysed and the expression 
as well as the functional status of selected cell death regulators, amongst others Bad and 
survivin, were analyzed. 
The first two proteins detected were pro-caspase-3 and poly [ADP-ribose] polymerase-1 
(PARP-1), its nuclear downstream substrate. Pro-caspase-3 represents the inactive pro-
zymogen of caspase-3, which in turn of apoptotic signals becomes proteolytically cleaved. 
ROSC at a concentration of 40 µM clearly reduced the levels of inactive pro-caspase-3 
after 18h and 24h of treatment thereby indicating its cleavage and following activation 
(Fig. 66). These results are in concordance with those delivered by caspase assays. Like-
wise, analysis of PARP-1 confirmed the activation of effector caspases, since levels of full-
length PARP-1 protein decreased after 24h. However, it is quite surprising that no other 
cleavage product of PARP-1 could be detected. The monoclonal C-210 anti-PARP-1 anti-
body recognizes an epitope at the NH2-terminal part of the 85 kDa cleaved fragment. Addi-
tionally, it is puzzling why PARP-1 is not depleted after 18h of treatment. 
Further investigations revealed a decrease of the inhibitory phosphorylation of the Bad 
protein at Ser112 after 12h. [Paper No. 1] Its phosphorylation was completely abolished after 
further 12h of treatment. Thus, ROSC obviously targets Bad for reactivation to het-
erodimerize with Bcl-2 pro-survival proteins. This inhibits consequently their function and 
promotes cell death by mitochondrial breakdown. Concomitantly, the amount of 14-3-3-θ/τ 
protein, the sequestering partner of phosphorylated Bad, decreased already after 12h. Both 
proteins (Bad and 14-3-3- θ/τ) show these effects, when exposed to 40 µM ROSC. 
Lastly, survivin, an inhibitor of apoptosis, was examined. ROSC at a higher dose reduced 
its phosphorylation as well, an effect observed after 18h of treatment. Since this site-
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specific modification modulates survivin’s stability, its protection from apoptosis was 
compromised. 
 
 
Fig. 66:  ROSC affects several regulators of apoptosis. Control cells and ROSC-treated HeLa cells were 
lysed. Protein samples were analyzed by immunoblotting for the presence of major mediators of 
apoptosis like pro-Caspase-3, Bad or survivin. 
 
The analyses revealed by which mechanisms ROSC promotes apoptosis in HeLa cells. 
Activation of selected pro-apoptotic proteins as well as repression of some pro-survival 
factors caused by modulation of their phosphorylation status in response to ROSC treat-
ment preceded the onset of apoptosis.  
 
 3.4.6.  Short-term ROSC treatment does not have any impact on apoptosis media-
tors in HTB-31 cells  
Cell cycle analyses of HTB-31 cells demonstrated the complete absence, in the case of 
OLO II, or a delayed appearance of hypoploid cells in the case of ROSC. These findings 
were at least partially confirmed by the above depicted apoptotic assays. Additionally, 
HTB-31 cells were analyzed for the status of several apoptosis mediators after ROSC treat-
ment. 
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Fig. 67:  ROSC has no effect on regulators of apoptosis in HTB-31 cells. HTB-31 cells were treated with 
ROSC at different concentrations and time points. Regulators of apoptosis were analyzed by im-
munoblotting.  
 
Independent of the ROSC concentration used, HTB-31 cells did not show any temporal 
change in pro-caspase-3 levels, suggesting its inactive state (Fig. 67). [Paper No. 1] Indeed, 
some modifications concerning PARP-1 cleavage were observed after 24h of treatment, a 
fact which was quite mysterious. 
In addition, neither Bad nor survivin phosphorylation were affected by the ROSC treat-
ment. However, Bad proteins seem to be expressed at low levels in HTB-31 cells.  
 
In summary, ROSC does not display any apoptotic effects on HTB-31 cells, at least not 
during short treatment periods.  
 
 3.4.7. OLO II activates initiator and effector caspases in HTB-31 cells 
Further investigations concerning the determination of caspase-9 activity lead us to two 
essential facts, which were already predicted earlier. 
On the one hand results depicted in Fig. 68 clearly show that ROSC indeed does not affect 
apoptosis during short-term treatments in HTB-31 cells. However, it exerts temporally 
delayed apoptotic effects. During longer treatment periods ROSC induced accumulation of 
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caspase-9 was vey effective and most notably when the medium was changed and cells 
were post-incubated in a drug-free medium. OLO II in contrast is even more potent than 
ROSC, thus triggering caspase-9 activation already after 24h of treatment very signifi-
cantly. This effect is enhanced once again after 48h of treatment, being sixfold higher than 
in control cells.  
 
 
Fig. 68:  OLO II leads to accumulation of caspase-9 in HTB-31 cells already after 24h of treatment. 
Control and drug-treated HTB-31 cells were investigated for caspase-9 activity using Caspase-Glo® 
9 assay from Promega. The caspase-9 activity was stated as relative luminescence units (RLU) and 
normalized to the number of viable cells assessed by proliferation assays as earlier described. 
 
Additional analyses of caspase-3/7 activity in human HTB-31 cells confirmed caspase-9 
achieved results. Likewise, caspase-3/7 accumulation is induced only by OLO II already 
after 24h (Fig. 69). Longer treatment periods display an increase in caspase activation me-
diated by ROSC and OLO II, the latter being more efficient.  
Interestingly, effector caspases were released to the culture medium already after 24h of 
OLO II treatment and increased over time to an eighteenfold amount than observed in con-
trols. Even long-term effects of ROSC induced such a release, however at much lower ex-
tents. 
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Fig. 69:  Activation of effector caspases by OLO II in HTB-31 cells. HTB-31 cells were treated as indi-
cated and tested for Caspase-3/7 activity either in cells or in their culture medium. Thereby used 
Caspase-Glo® 3/7 for cells and Apo-ONE® assay for supernatants were achieved from Promega. The 
caspase-3/7 activity was stated as relative luminescence units (RLU) or alternatively as relative fluo-
rescence units (RFU) and normalized to the number of viable cells assessed by proliferation assays. 
 
Caspase assays showed the higher resistance of HTB-31 cells towards certain anti-cancer 
drugs in contrast to HeLa cells. Nevertheless, HTB-31 cells were affected by OLO II or by 
ROSC after treatment for longer periods of time. 
 
 3.5.  Synchronization of HeLa cells by mimosine and trichostatin A  
All experiments performed so far were done on asynchronously growing HeLa and HTB-
31 cells. This means that the cell population used for experiments comprises cells in dis-
tinct cell cycle phases, some of them being more proliferative than others and therefore 
faster in running through the cell cycle. In some cases, however, it might be of advantage 
to synchronize cells before the medication. Synchronization can be achieved by certain 
chemical compounds and refers to the process which retains cells in the same cell cycle 
phase at the same time. 
Mimosine, a plant amino acid, and trichostatin A, an antibiotic, are known to have such 
synchronization effects in some cancer cell lines. Our ambition was to assess, whether 
HeLa cells could be synchronized by the latter and if this would provide an enhancement 
of ROSC treatment.  
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 3.5.1.  ROSC does not efficiently arrest cell cycle, when HeLa cells were previously 
synchronized by mimosine 
As reported by Torsten Krude, HeLa cells can be synchronized with mimosine at a final 
concentration of 0.5 mM. [142]  
Indeed, when treatment of HeLa cells was carried out with the specified MIMO concentra-
tion, a strong G1-arrest (80 %) was observed (Fig. 70). This was accompanied by the re-
duction of the S phase population to one third, whereas the frequency of G2 cell population 
remained unaffected. Once cells were released into a drug-free medium, they re-entered the 
cell cycle resulting in a transient accumulation of S phase cells. Surprisingly, after 12h of 
recovery the ratio of hypoploid cells increased. After 24h the initial distribution of cell 
cycle phases was re-established. Thus, MIMO-induced G1 synchronization of HeLa cells is 
reversible. Shortly after removal of MIMO cell cycle progresses. 
When Mimo-synchronized HeLa cells were released from the block into medium supple-
mented with ROSC, its effect differed from that achieved with asynchronously growing 
cells. ROSC at lower dose dramatically increased the population of S phase cells after 12h 
at the expense of G1 cells. This effect was only transient since a treatment with ROSC for 
24h resulted in a G2 arrest. The higher ROSC concentration did not affect G2 cell popula-
tion, but re-established the initial distribution of cell cycle phases already after 12h. Thus, 
exposure of MIMO-synchronized cells to ROSC did not maintain the G1 arrest. However, 
ROSC at the higher dosage increased the apoptosis rate to 60 %. Thus, our results showed 
that HeLa cells released from MIMO-mediated G1 arrest respond to ROSC very similar to 
asynchronously growing cells except their stronger apoptotic capability. Therefore, syn-
chronization of HeLa cells by MIMO prior to the onset of ROSC treatment provides very 
limited, if any, benefit. 
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Fig. 70:  ROSC did not maintain mimosine-induced G1 block in HeLa cells. HeLa cells were first treated 
with 0.5 mM mimosine for 24h to synchronize cells. After a medium change cells were either incu-
bated with or without ROSC at two different concentrations for the further 12h and 24h. Cells were 
subsequently harvested and DNA content was measured by flow cytometry. 
 
 3.5.2.  ROSC enhances G1 arrest in TSA-synchronized HeLa cells  
Synchronization of HeLa cells with TSA, an inhibitor of histone deactelyases, leads to the 
hyperacetylation of chromatin, thus enhancing gene expression and affecting DNA replica-
tion at the same time. In most cases this correlates with a permanent activation of certain 
genes. [145, 146] 
How the synchronization of HeLa cells by TSA prior to the ROSC treatment might affect 
the action of the latter was investigated in further experiments. HeLa cells were exposed 
for 24h to 400 ng/ml TSA. The medium was subsequently changed and cells were culti-
vated in the absence or presence of ROSC for the further 12h or 24h.  
Inspection of cells under light microscopy revealed obvious changes of cellular morphol-
ogy appearing after TSA treatment (Fig. 71). HeLa cells growing as an adherent culture 
have normally an oval shape, which changes during cellular division facilitating their de-
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tachment from the substratum. A 24h treatment with TSA, however, completely altered 
their phenotype; they become spindle-shaped with multiple philopodia. 
 
 
Fig. 71:  TSA-induced morphological changes in HeLa cells after 24h of treatment. Images on the left 
were taken at the 10x magnification objective, those on the right were taken at 40x magnification 
objective and represent a three-dimensional view of cells by taking advantage of the Hoffman modu-
lation contrast. 
 
The analysis of the DNA concentration in single cells evidenced that TSA treatment ar-
rested HeLa cells in G1 and G2 phase reducing simultaneously the ratio of the S phase cells 
(Fig. 72). Moreover, TSA induced apoptosis in approximately 20 % of cells. Thus, TSA 
led to modification of chromatin conformation. One might speculate that increase of acety-
lation enhanced expression of genes encoding pro-apoptotic proteins.  
The TSA-induced cell cycle block was maintained even after cells were released into drug-
free medium indicating that recovery of cells in the active cell cycle is a slow process. Af-
ter post-incubation of cells in a drug-free medium, the ratio of hypoploid cells increased, 
reaching up to 50 % after 12h. In the next step, TSA-synchronized cells were released from 
the block in a drug-free medium or alternatively in medium containing ROSC. The short 
exposure (12h) of cells released from G1 arrest to ROSC had a very weak effect on the 
distribution of cells in cell cycle. The ratio of apoptotic cells was reduced at 40 µM by ap-
proximately 50 % as compared to the control. After exposure for 24h a dose-dependent 
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difference became evident. ROSC at a final concentration of 20 µM increased the fre-
quency of S phase cells, whereas ROSC at 40 µM enhanced G1 arrest that was associated 
with a decrease of S phase cells. Moreover, the rate of apoptotic cells increased by ap-
proximately 20 %. 
In the next experimental series TSA-synchronized cells were released from the block in a 
drug-free medium for 1h and then ROSC was added. Interestingly, the maintenance of 
cells in a drug-free medium for 1h had very low impact on the action of ROSC. The trend 
was very similar to that observed after onset of treatment directly after release of TSA-
arrested cells.  
In summary, TSA synchronization of HeLa cells prior to the onset of ROSC treatment en-
hances G1 arrest. However, increase of apoptosis rate seems to be ROSC-independent be-
cause in cells released from the block in a drug-free medium size of apoptotic population 
was comparable.  
 
 
Fig. 72:  Synchronization of HeLa cells by TSA prior to ROSC treatment slightly increases G1 arrest. 
HeLa cells were synchronized for 24h with 400 ng/ml TSA. Thereafter the medium was changed 
and cells were incubated in the absence or presence of ROSC, as indicated. The treatment was done 
directly after release of cells from TSA-mediated block or after 1h of recovery. DNA content was 
determined by flow cytometry. 
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 3.5.3.  ROSC affects cell cycle and apoptosis regulators more efficiently, when 
HeLa cells were previously synchronized by TSA  
Analyses of immunoblots further revealed that ROSC reduces the activating phosphoryla-
tion of CDK7 more efficiently when cells were synchronized with TSA prior to the treat-
ment. The decrease of phosphorylated CDK7 occurred in a time- and concentration-
dependent manner (Fig. 73). Already after 12h of ROSC treatment CDK7 phosphorylation 
was diminished and almost completely disappeared after 24h of 40 µM ROSC. Remarka-
bly, the activating phosphorylation of CDK2 activity was in contrast markedly reduced 
upon TSA treatment and a further incubation with ROSC had a very weak effect.   
 
 
Fig. 73:  Synchronization and ROSC treatment of HeLa cells affect CDK7 activity. HeLa cells were 
synchronized with 400 ng/ml TSA for 24h and after a medium change subsequently treated with 
ROSC. Immunoblots were probed for phosphorylation of CDK2 and CDK7 at activating sites.  
 
The increased hyperacetlyation of histones also affected the apoptosis regulators Bad and 
survivin following ROSC treatment. In the case of Bad protein, its phosphorylation at 
Ser112 was reduced by the higher ROSC concentration already after 12h of treatment and 
almost abolished after further 12h (Fig. 74). At a lower concentration this effect became 
evident only after a longer incubation period. However, the phosphorylation of Bad was 
also reduced in controls after 24h.  
Unfortunately, the cellular levels of total Bad protein were not proven due to technical 
problems. 
Likewise, phosphorylation of survivin protein was affected by the same treatment. ROSC 
reduced its phosphorylation at Thr34 in a time- and concentration-dependent manner. At 
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higher dose the decrease of site-specific phosphorylation of survivin became evident after 
12h, which was additionally continued after 24h of treatment. As seen before, phosphory-
lation of survivin was also diminished in TSA-synchronized cells. Remarkably, the treat-
ment decreased the cellular levels of total survivin protein, indicating that the phosphoryla-
tion determined stability of this protein.  
These results clearly show that functional status of two examined regulators of apoptosis 
was more affected after ROSC treatment, when HeLa cells were synchronized prior to the 
onset of treatment. 
  
 
Fig. 74:  Abrogation of phosphorylation of Bad and survivin after ROSC treatment of G1-arrested 
HeLa cells. HeLa cells were synchronized and treated as usually. Obtained whole cell lysates were 
electrophoretically separated and blotted onto membranes, which were then analyzed by im-
munoblotting as indicated.  
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 4.  DISCUSSION 
 
Deregulation of the proper cell cycle conferring enhanced dividing potential is a major 
hallmark of cancer cells. Moreover, cell death pathways governing the elimination of su-
pernumerary or damaged cells are aberrantly regulated in transformed cells thereby pro-
moting their survival. Thus, in most cancer types cellular factors controlling cell cycle pro-
gression and apoptosis are altered to overcome surveillance. This includes primarily consti-
tutive activation or upregulation of cyclin-dependent kinases, overexpression and aberrant 
cytoplasmic localization of cyclins and inactivation of cellular CDK inhibitors. The ampli-
fied activity of CDKs and/or the concomitant inactivation or loss of cellular CDK inhibi-
tors provided rationale to replenish this deficit by the use of pharmacological inhibitors to 
specifically target CDKs in a novel therapeutic approach. The application of such small-
molecule inhibitory compounds might compensate the occurring deficiencies. Currently, 
very promising pharmacological CDK inhibitors are ROSC and especially OLO II. These 
purine analogues were the focus of interest of this diploma thesis. 
The main purpose of research was to analyze to what extent pharmacological CDK inhibi-
tors may affect proliferation and survival of human cervix carcinoma cells and to assess the 
relevance of the p53 status for the efficacy of the treatment. Therefore, two different hu-
man carcinoma cell lines, harbouring an inactivated p53 protein, were investigated. How-
ever, the way the inactivation is accomplished distinguishes both cell lines. Although HeLa 
cells harbour a wt TP53 gene, its product is unfortunately not functional due to the expres-
sion of HPV-encoded E6 oncoprotein. E6 binds to p53 thereby sequestering it to cellular 
E6-AP ubiquitin E3 ligase complex and in this way targets it for ubiquitin-mediated degra-
dation in the proteasome. Consequently, the G1 restriction checkpoint is abrogated. In con-
trast to HeLa cells, a point mutation in the TP53 gene in HTB-31 cells results in the accu-
mulation of mutated p53 protein. The highly expressed mutant p53 protein in HTB-31 cells 
has no tumor suppressor activity, but it might promote cell survival since some point muta-
tions of TP53 gene are gain of function conferring it new functions. 
Our results showed that HeLa as well as HTB-31 cells are definitely susceptible to the 
treatment with pharmacological CDK inhibitors. A marked reduction of the cell number 
after ROSC or OLO II treatment evidenced their strong anti-proliferative effects exerted on 
both cancer cell lines. However, observed effects are time and concentration dependent. 
ROSC and OLO II showed to be most effective in a discontinuous long-term treatment. 
This reflects their impact after in vivo administration and is of great therapeutical rele-
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vance, since patients naturally degrade the administered drugs over time. Surprisingly, 
OLO II at a fourfold lower dose induced exactly the same effects as achieved by higher 
ROSC concentrations. Thus, OLO II is, despite its structure similarity to ROSC, more po-
tent than the latter. This seems to be cell line-independent, since OLO II also eliminated 
HTB-31 cells more efficiently than ROSC. However, HTB-31 cells were generally more 
resistant to the action of pharmacological CDK inhibitors. 
Further cell cycle analyses revealed the cell cycle modulatory as well as pro-apoptotic ef-
fects of both CDK inhibitors on HeLa and HTB-31 cells. DNA profiles illustrated the dis-
tribution of cell cycle phases in both examined cell lines after treatment and evidenced the 
concentration-dependent outcome. Low concentrations of both pharmacological CDK in-
hibitors arrested asynchronously growing HeLa cells already after 12h of treatment in the 
G2/M phase. In contrast, higher doses accumulated a considerable hypoploid cell popula-
tion (30 %), which most frequently represents cells undergoing apoptosis. Although the 
effects exerted by ROSC and OLO II were similar to those in HeLa cells, HTB-31 cells 
showed a delayed response to the treatment. Moreover, barely any apoptotic cells were 
detected. This confirms the relative resistant nature of HTB-31 cells to cell death.  
Additional analyses of the pro-apoptotic effects of tested CDK inhibitors elucidated the 
mechanism by which apoptosis is triggered. The occurrence of a cleavage product of cy-
tokeratin 18, a cytoskeleton protein and a typical downstream target of caspase-3, led to the 
assumption that caspases might be involved. This was further substantiated by detection of 
activated initiator and effector caspases. ROSC as well as OLO II induced elevated levels 
of caspase-9, which correlated with the increased activity of caspase-3/7 in HeLa cells. 
Likewise, HTB-31 cells were eliminated by caspase-mediated apoptosis, if treatment oc-
curred long enough. Furthermore, extended treatment periods released activated caspases 
into the culture medium, indicating that the cell membrane becomes permeable. After 
staining of cells with the fluorescent JC-1 dye, it became also evident that ROSC and OLO 
II-treated cells fail to accumulate J-aggregates. This indicates the disruption of the electro-
chemical potential of the mitochondrial membrane with a subsequent collapse of the latter. 
Thus, CDK inhibitors induced apoptosis through the release of cytochrome c and promoted 
apoptosome formation. Moreover, ROSC-induced stabilization of the pro-apoptotic protein 
Bad and the concomitant abrogation of survivin phosphorylation, which is necessary for its 
stabilization, preceded the onset of apoptosis in HeLa cells. 
Consequently, the results presented above clearly provide evidence for the bi-functionality 
of ROSC and OLO II, which might increase their therapeutical benefit. 
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Subsequent analyses of the functional status of major cell cycle regulators provided more 
details about the action of pharmacological CDK inhibitors. ROSC mainly affected CDK2 
by preventing its activating phosphorylation at Thr160 and CDK1 by increasing the phos-
phorylation of its inhibitory sites. Thus, inactivated CDK1 contributed to the accumulation 
of cells in G2/M phase. Additionally, CDK7, a dual-specificity kinase involved in cell cy-
cle regulation and transcription, was another target of ROSC. The CDK-activating kinase 
activity of CDK7 is active throughout the cell cycle. However, the kinase activity needed 
for transcription is positively regulated by the phosphorylation at Thr170 and enhances the 
affinity of CDK7 for the RNA polymerase II. CDK7 is then able to phosphorylate Ser5 in 
the heptapeptide repeat of the CTD of RNA polymerase II and thus to induce initiation of 
transcription. [172] ROSC at higher concentrations was shown to diminish the site-specific 
phosphorylation of CDK7 at the aforementioned site thereby affecting the global transcrip-
tion. This was demonstrated by the marked repression of the phosphorylation of Ser5 
within the CTD of RNA polymerase II. A concomitant decrease of the phosphorylation of 
Ser2 within the same heptapeptide repeat was additionally observed and correlated with the 
inability of RNA polymerase II to proceed in elongation and procession of primary tran-
scripts. We demonstrated that OLO II had similar effects on the global transcription in 
HeLa cells and HTB-31 cells, although being weaker in the latter. 
Further analyses of the functional p53 status revealed that ROSC has different effects on 
this protein in HeLa and HTB-31 cells. In response to ROSC treatment a strong upregula-
tion of p53 occurred in HeLa cells and was barely detectable in controls. This result indi-
cates that the blockage of global transcription in HeLa cells upon treatment does not affect 
cellular p53 protein levels. Hence, reactivation of p53 is due to repression of the virally 
encoded E6 oncoprotein. Both CDK inhibitors were shown to efficiently decrease the ex-
pression of HPV-encoded E6 protein at higher concentrations. Subsequently, p53 protein is 
stabilized. One could speculate that increased and reactivated p53 protein contributes to the 
induction of apoptosis and cell cycle arrest. 
However, the p53 reactivation appeared exclusively in HeLa cells. p53 levels in HTB-31 
cells remained constant throughout the treatment period and demonstrated its prolonged 
stability. This constitutes an evidence for the inability of CDK inhibitors to overcome the 
mutation in this protein. 
Interestingly, further experiments on HeLa cells emphasized that the outcome of treatment 
strongly depends on their cell cycle status prior to the onset of treatment. On the one hand, 
this was demonstrated by the fact that the recovery time of cells prior to the onset of treat-
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ment influenced the efficacy of CDK inhibitors. One the other hand, experiments with syn-
chronized HeLa cells released into a post-treatment evidenced enhancement of treatment in 
some cases. Our results showed that ROSC transiently enhanced the induced G1 arrest in 
TSA-synchronized cells. This coincided with the outcome of nocodazole-arrested cells 
treated with ROSC. Thus, cells released from TSA as well as nocodazole-mediated block 
synchronized in early G1 phase and provided a benefit for the treatment. In contrast, cells 
released from serum starvation or MIMO were synchronized in the late stage of G1 phase 
and had no impact on ROSC treatment in HeLa cells.  
In conclusion, ROSC and OLO II are both potent pharmacological CDK inhibitors, which 
are able to re-establish the proper cell cycle regulation in HeLa cervix carcinoma cell lines. 
This is attributed to their pleiotropic effects described above. However, the success of the 
treatment with ROSC or OLO II depends on multiple factors, including the duration of 
therapy, the administered drug concentration and the cell cycle status prior to the admini-
stration. Both pharmacological CDK inhibitors have also pro-apoptotic effects with a con-
comitant low cytotoxicity towards cells. In addition, it was proven that, unlike other drugs 
(DOX or CP), ROSC and OLO II do not damage cellular DNA. [173] This fact makes both 
CDK inhibitors very interesting for targeted therapies. Due to their high selectivity for 
transformed cells ROSC and OLO II may be better tolerated than conventional chemo-
therapeutic drugs. Further investigations of both CDK inhibitors might lead to successful 
anti-cancer drugs with low side-effects.    
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APPENDIX 
 
 I.  List of chemicals or other materials 
 
Centrifuge 3K30  Sigma 
Centrifuge 5417C  Eppendorf 
Chemi-SmartTM 5100  Peqlab Biot. GmbH 
Combitips plus (2.5 ml, 5 ml)  Eppendorf 
Cuvettes 1.5 ml  Bio-Rad 
Digitonine  Sigma 
Doxorubicin  Haiman Pharmaceu- 
   tical Factory 
Eclipse TE300 inverse microscope  Nikon 
Eppendorf tubes 0.6 ml, 1.5 ml, 2 ml  Eppendorf 
Falcons 15 ml, 50 ml (sterile)  Greiner Bio-One 
HCl  Carl Roth GmbH 
Marker, pre-stained benchmark protein ladder  Gibco BRL 
Microplate Reader, Synergy HT  BioTek 
Mimosine  Sigma 
Multilabel-Multitask Plate Counter (Wallac 1420 Victor) Beckman 
Multipette plus  Eppendorf 
NaF  Merck 
NaOH  Carl Roth GmbH 
NaVO3  Sigma 
Olomoucine II  was synthesized and 
provided within a FWF 
project by Prof. Dr. M. 
Strnad and Dr. V. Kry-
stof from Palacký Uni-
versity, Olomouc, Czech 
Republic  
Potter homogenizer 
Power supply, PowerPac 200  Biorad 
Roscovitine  was synthesized and 
provided within a FWF 
project by Prof. Dr. M. 
Strnad and Dr. V. Kry-
stof from Palacký Uni-
versity, Olomouc, Czech 
Republic 
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Round-bottom tubes 5 ml for flow cytometry  Becton Dickinson 
Sonificator, Sonoplus GM70  Bandelin 
Spectrophotometer, U 2000  Hitachi 
Streptavidin 
X-ray film processor, Typ 1140  Protec Gerätebau 
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 II.  List of used antibodies 
 
 A.  Primary antibodies 
14-3-3-θ/τ (Clone 3B9)  Sigma 
Actin (Clone C4)  MP Biomedicals LLC 
P-Ser112-Bad  Millipore 
Bad (Clone BYC001)  Millipore 
pro-Caspase-3  DAKO Corp. 
P-Ser216-cdc25C  Cell Signaling 
cdc25C  Cell Signaling 
P-Thr161-CDK1  Cell Signaling 
P-Thr14/Tyr15-CDK1  Sigma 
CDK1  Cell Signaling  
P-Thr160-CDK2  Cell Signaling 
CDK2 (Clone 2B6 + 8D4)  Neomarkers 
P-Ser164/Thr170-CDK7  Biolegend 
CDK7 (Clone MO-1.1)  Sigma 
CytoDEATH M30-fluoresceine-coupled antibody  Roche Diag. GmbH 
E6 (Clone BF7)  Abcam 
E7  Abcam 
P-Ser909-LATS-1  Cell Signaling 
LATS-1  Cell Signaling 
P-Thr199-NPM  Cell Signaling 
NPM (Clone Ab-1)  Neomarkers 
P-Ser536-NFκB  Cell Signaling 
NFκB (p65)  Cell Signaling 
PARP-1 (Clone C2-10)  from Dr. Guy Poirier,  
  Laval University of  
  Quebec 
PCNA (Clone PC-10)  Calbiochem 
Ran (Clone 20)  BD Transd. Lab. 
P-Ser780-Rb  Cell Signaling 
P-Ser807/811-Rb  Cell Signaling 
Rb (Clone IF-8)  Santa Cruz Biotech. 
P-Ser2-RNA Polymerase II (Clone H5)  Abcam 
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P-Ser5-RNA Polymerase II (Clone H14)  Abcam 
RNA Polymerase II  Alexis 
p53 (Clone DO-1)  was a kind gift from  
  Dr. Vojtesec 
P-Thr34-Survivin  Biolegend 
Survivin  Santa Cruz Biotech. 
 
 B.  Secondary antibodies 
anti-mouse IgG, peroxidase conjugated  Pierce 
anti-rabbit IgG, peroxidase conjugated  Sigma 
anti-mouse IgM, biotin conjugated Amersham Biosc. 
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 V.  Abbreviations 
 
7-AAD 7-Aminoactinomycin D 
APC Anaphase-promoting complex 
APS Ammonium persulfate 
ATM Ataxia telangiectasia mutated 
ATR AMT- and Rad3-related 
BSA Bovine serum albumin 
CAK CDK-activating kinase 
Caspase Cystein aspartic acid protease 
CCD camera Charge-coupled device camera 
CDK Cyclin-dependent kinase 
cE Endconcentration 
Chk1/2 Checkpoint kinase 1/2 
Cip CDK inhibitor protein 
CP Cisplatin 
DAPI 4’, 6-Diamidino-2-phenylindole 
ddH2O bi-destilled water 
DMF Dimethylforamide 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DOX Doxorubicin (= adriamycin) 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EtOH Ethanol 
FITC Fluorescein 
HCl Hydrochloric acid 
HRP Horseradish peroxidase 
IC50 Inhibitory concentration of a drug, which kills 50  
 % of alls cells 
JC-1 5,5',6,6'-Tetrachloro-1,1',3,3'- 
 tetraethylbenzimidazolylcarbocyanine iodide 
Kip Kinase inhibitor protein 
OLOII Olomoucine II 
  {2-{[2-((1-R)-1-hydroxymethyl-propylamino)-9- 
  isopropyl-9Hpurin-6-ylamino]-methyl}-phenol} 
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MC  Medium change 
MeOH Methanol 
MIMO  L-Mimosine, (S)-α-Amino-β-[1-(3-hydroxy-4  
  oxopyridine)]propionic acid 
Na-Doc Natrium deoxycholic acid 
NaF Natrium fluoride 
NaN3 Natrium acid 
NaOH Natrium hydroxid 
NaVO3 Natrium vanadate 
NLS  Nuclear localization signal 
NP-40 Nonidet P-40  
PBS Phosphate buffered saline 
Pefabloc® SC 4-(2-Aminoethyl)-benzolsulfonylfluorid- 
 hydrochlorid 
PMSF Phenylmethylsulfonylfluoride 
pRb Retinoblastoma protein 
PVDF Polyvinylidendifluoride 
RIPA Radioimmuno precipitation assay buffer 
RNA  Ribonucleic acid 
ROSC Roscovitine 
 [(2-R)-2-(6-benzylamino-9-isopropyl-9Hpurin-2- 
 ylamino)-butan-1-ol)] 
RSB Reticulocytes suspension buffer 
Ser  Serine 
SDS Sodium dodecyl sulfate 
TBS Tris-buffered saline 
TEMED Tetramethylethylendiamine 
Thr  Threonine 
Tris  Tris base, tris(hydroxymethyl)aminomethane 
TSA Trichostatin A 
  R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N- 
  hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide 
Tyr  Tyrosine 
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Exposure of asynchronously growing human HeLa cervical carcinoma cells to roscovitine (ROSC), a selective cyclin-dependent kinases (CDKs)
inhibitor, arrests their progression at the transition between G2/M and/or induces apoptosis. The outcome depends on the ROSC concentration.
At higher dose ROSC represses HPV-encoded E7 oncoprotein and initiates caspase-dependent apoptosis. Inhibition of the site-specific
phosphorylation of survivin and Bad, occurring at high-dose ROSC treatment, precedes the onset of apoptosis and seems to be a prerequisite
for cell death. Considering the fact that in HeLa cells the G1/S restriction checkpoint is abolished by E7, we addressed the question whether
the inhibition of CDKs by pharmacological inhibitors in synchronized cells would be able to block the cell-cycle in G1 phase. For this purpose,
we attempted to synchronize cells by serum withdrawal or by blocking of the mitotic apparatus using nocodazole. Unlike human MCF-7
cells, HeLa cells do not undergo G1 block after serum starvation, but respond with a slight increase of the ratio of G1 population. Exposure
of G1-enriched HeLa cells to ROSC after re-feeding does not block their cell-cycle progression at G1-phase, but increases the ratio of S- and
G2-phase, thereby mimicking the effect on asynchronously growing cells. A quite different impact is observed after treatment of HeLa cells
released from mitotic block. ROSC prevents their cell cycle progression and cells transiently accumulate in G1-phase. These results show that
inhibition of CDKs by ROSC in cells lacking the G1/S restriction checkpoint has different outcomes depending on the cell-cycle status prior to
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genes encoding CDK regulatory partners, including cyclins E and D,
Cip/Kip and INK4 inhibitors, and their substrates (mainly
retinoblastoma protein, pRb) [Malumbres and Barbacid, 2007;
Besson et al., 2008]. This permits escape from senescence during
malignant transformation and allows cancer cells to proliferate with
increased CDK activity and accumulate further mutations.
On the basis of deregulated activity of CDKs detected in cancers,
inhibitors targeting specifically these kinases have been developed
as anticancer therapeutics. A growing number of small molecule
inhibitors are now in preclinical testing or even in clinical trials
[Fischer and Lane, 2000; Dai and Grant, 2003; Malumbres et al.,
2008]. The most success so far has been obtained with ATP-
mimicking competitive inhibitors of CDK. They are usually classified
according to their specificities as pan-specific (do not discriminate
among different CDKs) and oligo-specific (preferentially inhibit
only some CDKs). PD-0332991, which has been developed to
preferentially target CDK4/6, is a typical example of the latter
group [Fry et al., 2004]. However, the majority of developed
drugs, including flavopiridol, roscovitine (ROSC), or SNS-032, hit
simultaneously multiple CDKs. These oligo-specific compounds
potently arrest the cell cycle in transformed cells, due to inhibition
of cell cycle regulating CDK1, CDK2, and/or CDK4, and induce
apoptosis as well, apparently as a result of transcriptional pertur-
bations caused by CDK7 and CDK9 inactivation [Shapiro, 2006].
Interestingly, several pharmacological CDK inhibitors also
potently block transcription and replication of some viruses, such
as HIV, HCMV, VZV, HSVs, and EBV, that rely on the activity of
endogenous CDKs in host animal cells [Schang et al., 2005]. Some
viruses can inactivate pRb through direct binding of viral proteins
and the consequent abrogating of the G1 restriction point, the others
are able to constitutively activate cellular CDKs by virally encoded
cyclin proteins [Helt and Galloway, 2003], or even encode
kinases able to substitute CDKs in their ability to phosphorylate
pRb [Hume et al., 2008]. It is assumed that the antiviral activity of
CDK inhibitors is based on interference with viral transcription.
Importantly, as some human cancers are induced by oncogenic
viruses, like Kaposi’s sarcoma or HPV-induced cervical carcinoma,
therapy based on CDK inhibitors would not only stop the prolife-
ration of transformed cells, but also advantageously limit the life-
cycle of the transforming viruses, both dependent on cellular CDKs.
Human papilloma viruses (HPV) are small double-stranded DNA
viruses infecting squamous epithelia, inducing proliferative lesions
within infected tissues that are prerequisite for the development of
cancer. The high risk HPV-encoded proteins E6 and E7, substantially
contributing to transforming capability, play a major role in the
deregulation of the cell cycle control. Protein E6 binds p53 and
directs it to ubiquitin-mediated degradation, further promoting
genetic instability in infected cells [Scheffner et al., 1990]. E7 not
only induces aberrant S-phase entry through the inactivation of
pRb tumor suppressor and related pocket-proteins, but also
increases expression of E2F-responsive cell cycle regulators such
as the cdc25a tyrosine phosphatase that further contribute to G1/S
deregulation [Nguyen et al., 2002]. Moreover, E7 prevents p21Waf1
both from inhibiting activity of CDK2/cyclin E and DNA replication
and thus disrupts normal cell cycle control by increased CDK2
activity and enhanced expression of E2F-responsive genes [Funk938 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEet al., 1997]. As shown in mouse models, inactivation of pRb by E7
is not sufficient to overcome G1 restriction point; also other E2F
regulators are important targets of E7 that play critical roles in
cervical carcinogenesis [Balsitis et al., 2006]. For example, recent
experiments demonstrated that E7 can associate with and inactivate
the transcriptional repression activity of E2F-6, thereby extending
S-phase competence of HPV infected cells [McLaughlin-Drubin
et al., 2008]. Down-regulation of both viral oncoproteins increases
the efficacy of the therapy [Wesierska-Gadek et al., 2002].
In the light of the facts mentioned above, the question appeared
whether the inhibition of cellular CDKs by pharmacological
inhibitors would be able to reduce the proliferation rate of cancer
cells infected with high risk HPV and to restore the proper cell cycle
control as well as to optionally trigger them to undergo apoptosis.
For this purpose we decided to apply ROSC, a relatively selective
CDK inhibitor targeting not only kinases regulating cell cycle
progression but also CDK7, the dual acting kinase that is also
implicated in the regulation of transcription [Fisher, 2005].
Considering the fact that cellular RNA polymerase II is required
for transcription of HPV-encoded proteins and that CDK7
complexed with cyclin H is a constituent of the basal transcription
factor TFIIF, which phosphorylates the serine residues within the
heptapeptide repeat of the carboxy terminal domain (CTD) of RNA
polymerase II, one might expect that ROSC would not only affect
the functionality of the intrinsic cellular cell cycle regulators but
would also prevent transcription of genes encoded by the infecting
pathogen. We chose human HeLa cervical carcinoma cells, the most
frequently investigated cell line derived from HPV-positive cervical
carcinoma, as an experimental model. The action of ROSC was
previously studied in detail in asynchronously growing [Wojcie-
chowski et al., 2003; Wesierska-Gadek et al., 2005a, 2006, 2007c]
and partially synchronized human MCF-7 breast cancer cells
[[David-Pfeuty, 1999] as well as in normal healthy cells [Alessi et al.,
1998; Wesierska-Gadek et al., 2007a]. The susceptibility of
asynchronously growing MCF-7 cells and cells released from a
partial mitotic block substantially differed. Exposure of MCF-7 cells
released from a partial mitotic block to ROSC slowed their G1 to S
progression [David-Pfeuty, 1999]. In contrast, ROSC arrested
asynchronously growing MCF-7 cells in the G2 phase of the cell
cycle, and after longer exposure induced caspase-3 independent
apoptosis. ROSC-induced cell death was mediated by wt p53.
ROSC strongly enhanced the cellular expression of p53 protein
and markedly extended its half-life [Wojciechowski et al., 2003;
Wesierska-Gadek et al., 2005a]. Interestingly, ROSC-induced
phosphorylation of p53 protein at serine 46 resulted in an up-
regulation of p53AIP1 protein, its specific downstream target that
after de novo synthesis and translocation into the mitochondria
[Wesierska-Gadek et al., 2005a] initiated apoptosis in MCF-7 cells
which lack caspase-3. Unlike in asynchronously growing MCF-7
cells, in those released from a partial mitotic block, ROSC slowed the
transition of cells from G1 to S phases [David-Pfeuty, 1999].
Surprisingly, reconstitution of MCF-7 cells with human caspase-3
did not sensitize them to the action of ROSC [Wesierska-Gadek
et al., 2005a]. ROSC failed to induce P-Ser46 p53 protein and its
downstream target in asynchronously growing, caspase-3 proficient
MCF-7 cells [Wesierska-Gadek et al., 2005a], thereby indicating thatJOURNAL OF CELLULAR BIOCHEMISTRY
the outcomes of the inhibition of cellular CDKs strongly depends on
cell types, their intrinsic features and cell cycle status prior to the
onset of therapy. This observation was additionally substantiated by
the fact that phenol red, a weakly estrogenic component of culture
medium, affects the susceptibility of exponentially growing MCF-7
cells, that are known to express ER-a, to the action of ROSC
[Wesierska-Gadek et al., 2006].
In the light of the above discussed cognitions it is incontrovertible
that the outcomes of action of CDK inhibitors cannot be exactly
predicted in different tumor cell lines, especially in those differing in
the status of cell cycle and apoptosis regulators.
In this work we studied the effect of the CDK inhibitor ROSC
on normal MRC-5 human fibroblasts and two human cervical
carcinoma cell lines (HTB-31 and HeLa cells). HeLa cells are positive
for HPV-18, while in HTB-31 no viral infection was detected.
Both cancer cell lines differ in the p53 status. We determined the
anti-proliferative and pro-apoptotic effect of ROSC on exponen-
tially growing cells. Inhibition of CDKs most strongly affects the
proliferation of HeLa cells. The marked reduction of the number of
viable cells upon exposure of HeLa cells to ROSC is attributable to
induction of cell cycle block at G2/M and/or apoptosis. The outcome
depends on the ROSC concentration. At higher dose ROSC eliminates
HeLa cells by apoptosis. Moreover, ROSC represses the HPV-encoded
oncoproteins. Unlike HeLa, HTB-31 cancer cells are markedly less
susceptible to the tested CDK inhibitors. The ROSC-induced accu-
mulation of the S- and G2/M-phase population is not accompanied
by apoptosis.
We also addressed the question whether the inhibition of CDKs
in synchronized cells would be able to block the cell cycle in
G1 phase. For this purpose, we attempted to synchronize cells by
serum withdrawal or by blocking the mitotic apparatus using
nocodazole. Our results show that inhibition of CDKs in cells lacking
the G1/S checkpoint has different outcomes depending on the cell
cycle status prior to the onset of treatment; ROSC does not inhibit
HeLa cells in G1-phase, but is solely able to maintain the early
G1-phase cell cycle arrest of cells released from the nocodazole-
induced mitotic block. The results clearly show that ROSC effectively
restricts growth of HeLa cells and the outcome is dose-dependent.
It became evident that a higher ROSC concentration is necessary
to promote apoptosis through abrogation of the activity of its
inhibitors.
MATERIALS AND METHODS
CELLS
The human cervical carcinoma cell lines HeLaS3, HTB-31 (C-33A),
and normal MRC-5 human fibroblasts obtained from American
Type Culture Collection (ATCC), were cultured in RPMI medium
supplemented with 10% foetal calf serum (FCS). Cells were grown up
to 60–70% confluence and then treated with indicated drugs.
DRUGS
Roscovitine (ROSC) was prepared according to the published
procedure [Havlicek et al., 1997] and prepared as 50 mM stock
solution in DMSO. Aliquots of the stock solution were stored until
use at208C. Nocodazole (NOC) from Sigma–Aldrich, Inc. (St. Louis,JOURNAL OF CELLULAR BIOCHEMISTRYMO) at a final concentration of 0.05 mg/ml was used to induce
mitotic block.
ANTIBODIES
The following specific antibodies were used to detect the relevant
proteins: monoclonal anti-p53 antibody DO-1 (a kind gift from
Dr. B. Vojtesek, Masaryk Memorial Cancer Institute, Czech Republic),
the polyclonal anti-phospho-Thr161 CDK1, anti-phospho-Thr14/
Tyr15 CDK1, anti-phospho-Thr160 CDK2, anti-phospho-Ser216
CDC25C, anti-phospho-Ser780 pRb, anti-phospho-Ser807/81 pRb,
anti-phospho-Ser139-H2A.X, anti-phospho-Ser112 Bad, and cor-
responding antibodies against the total antigen (all from New
England Biolabs, Beverly, MA), polyclonal anti-phospho-Ser164/
Thr170 CDK7 and anti-phospho-Ser199 NPM (BioLegend, San
Diego, CA), anti-caspase-3 (DAKO AS, Glostrup, Denmark),
monoclonal anti-CDK2 (Ab-4) antibodies (Lab Vision Co., Fremont,
CA), polyclonal-anti-phospho-Thr34 survivin, monoclonal anti-
PCNA (clone PC-10), anti-pRb (IF-8), anti-cyclin A, anti-NPM (all
from Santa Cruz Biotechnology, CA), anti-CDK7 (clone MO-1.1,
Sigma–Aldrich, Inc.), anti-actin (clone C4, ICN Biochemicals,
Aurora, OH), anti-E7 oncoprotein were from Abcam Ltd (Cambridge,
England). Appropriate secondary antibodies linked to horseradish
peroxidase (HRP) were from R&D Systems (Minneapolis, MN).
DETERMINATION OF THE NUMBER OF VIABLE CELLS
Proliferation of human cervical carcinoma cell lines HeLaS3,
HTB-31 (C-33A), and normal MRC-5 human fibroblasts and their
sensitivity to increasing concentrations of ROSC was determined by
the CellTiter-GloTM Luminescent Cell Viability Assay (Promega
Corporation, Madison, WI). As described recently in more detail
[Wesierska-Gadek et al., 2005b], the CellTiter-GloTM Luminescent
Cell Viability Assay, generating luminescent signal, is based on
quantification of the cellular ATP levels. Tests were performed at
least in quadruplicates. Luminescence was measured in the Wallac
1420 Victor, a microplate luminescence reader. Each point
represents the mean SD (bars) of replicates from at least three
experiments.
DETERMINATION OF CASPASE-3/7 ACTIVITY
The activity of both caspases was determined using the APO-ONE
Homogenous Caspase-3/7 Assay (Promega Corporation) which uses
the caspase-3/7 substrate rhodamine 110, bis-(N-CBZ-L-aspartyl-L-
glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-R100) as described
previously [Wesierska-Gadek et al., 2005b]. Briefly, HeLaS3 cells
were plated in 96-well microtiter plates. One day after plating the
cells were exposed for 24 h to increasing drug concentrations.
Thereafter, the culture supernatant was transferred into another
microtiter plate to separately determine the caspase activity in cells
and in culture medium. Then an equal volume of caspase substrate
was added and samples were incubated at 378C for different
periods of time to assess the best signal-to-background ratio.
The fluorescence was measured at 485 nm. Luminescence and
fluorescence were measured in the Wallac 1420 Victor, a microplate
luminescence reader. Each point represents the mean SD (bars) of
replicates from at least three experiments.ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASE 939
MEASUREMENT OF THE DNA CONTENT OF SINGLE CELLS
BY FLOW CYTOMETRY
Measurement of the DNA-content was performed by flow cyto-
metric analysis based on a slightly modified method [Wesierska-
Gadek and Schmid, 2000] described previously by Vindelov et al.
[1983]. The cells were detached from substratum by limited
trypsinization, then all cells were harvested by centrifugation and
washed in PBS. Aliquots of 106 cells were used for further analysis.
Cells were stained with propidium iodide as described previously
and then the fluorescence was measured using the Becton Dickinson
FACScan after at least 2 h incubation at 48C in the dark.Fig. 1. Reduction of the number of viable human HeLa and HTB-31 cervical
cancer cells after treatment with ROSC. A: Exponentially growing HeLa cells
plated in 96-well microtiter plates were treated for 12, 18, and 24 h,IMMUNOBLOTTING
Total cellular proteins dissolved in SDS sample buffer were
separated on SDS slab gels, transferred electrophoretically onto
PVDF membrane (PVDF) (Amersham Biosciences), and immuno-
blotted as previously described [Wojciechowski et al., 2003]. Equal
protein loading was confirmed by Ponceau S staining. To determine
the phosphorylation status of selected proteins, antibodies recog-
nizing site-specifically phosphorylated proteins were diluted to a
final concentration of 1:1,000 in 1% BSA in Tris-saline-Tween-20
buffer. In some cases, blots were used for sequential incubations.respectively, with indicated concentrations of ROSC. The number of viable
cells was determined directly after the treatment, or eventually after medium
change (MC) and post-incubation for 48 h in a drug-free medium. The graph
represents mean values from three independent experiments, each performed
at least in quadruplicates. B: Exponentially growing HTB-31 cells plated in 96-
well microtiter plates were treated for 24 and 48 h with ROSC. The differences
between the number of control and treated cells are statistically highlySTATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism software
and significance levels were evaluated using Bonferroni’s Multiple
Comparison Test.significant (; 0.001< P< 0.01) or very highly significant (P< 0.001)
according to the Bonferroni’s comparison.
TABLE I. Treatment With ROSC for 24 h
Cell line IC50 (mM)
HeLa 28.1
HTB-31 91.5
MRC-5 Not achievedRESULTS
ROSC MORE STRONGLY INHIBITS THE PROLIFERATION OF HUMAN
HeLa CERVICAL CANCER CELLS THAN THAT OF HTB-31 CELLS
To determine the effect of ROSC on the proliferation of expo-
nentially growing human HeLa cells, the cells were continuously
exposed to the drug for 12, 18, or 24 h, respectively. Then the cell
number was determined using CellTiter-Glo viability assay
immediately upon termination of the treatment, or alternatively
the medium was changed, and then cells were post-incubated in a
drug-free medium for a further 2 days and thereafter the assay was
performed (Fig. 1A). According to the statistical analysis, 40 mM
ROSC very significantly reduced the number of living cells already
after 12 h treatment. The effect was even stronger after longer
incubation periods (18 and 24 h) and persisted upon medium
change. Reduction of living cells following treatment with lower
doses of ROSC (i.e., 10 and 20 mM) was not statistically significant
over the 24 h period. However, when cells incubated with 20 mM
ROSC for 24 h were transferred to the drug-free medium, the number
of living cells was significantly reduced after the further 48 h
cultivation.
In contrast, human HTB-31 cancer cells are less susceptible to the
action of CDK inhibitors. Approximately a fourfold higher dose of
ROSC is required to reduce the number of viable cells by 50% within
24 h (Fig. 1B).940 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEAs expected, normal human fibroblasts (MRC-5) were only
negligibly affected by the selective CDK inhibitor. The IC50 values
are shown in Table I.
ROSC INHIBITS THE CELL CYCLE OF ASYNCHRONOUSLY GROWING
HeLa CELLS AT THE G2/M TRANSITION
The next experimental series were performed to find out how ROSC
modulates the cell cycle progression and whether it is also able to
induce apoptosis in HeLa cells. The DNA concentration in single cells
was measured by flow cytometry. The population of hypoploid cells
representing cells undergoing apoptotic changes was classified as a
sub-G1 population. HeLa cells were exposed to two concentrations
of ROSC. As shown in Figure 2, ROSC at a final concentration of 20mM
increased the frequency of G2/M population and concomitantlyJOURNAL OF CELLULAR BIOCHEMISTRY
diminished that of G1-phase, with transient accumulation of S-phase
after 18 h treatment. Two times higher concentration of ROSC
increased the frequency of G2/M population even more strongly at the
same time point, but simultaneously, the population of hypoploid cells
(30%) appeared after incubation for 18 and 24 h.
Concurrently, whole cell lysates obtained from HeLa cells treated
with ROSC were analyzed by immunoblotting to monitor changes inFig. 2. Effect of ROSC on the cell cycle progression of asynchronously growing HeLa cel
indicated periods of time. Control and drug-treated cells were harvested by trypsinizati
single cells was measured using the Becton Dickinson FACScan flow cytometer. DNA his
using the CellQuest evaluation program (A) and diagrams showing the changed distributi
constructed (B). The distribution was determined using ModFIT cell cycle analysis soft
JOURNAL OF CELLULAR BIOCHEMISTRYmain cell cycle protein regulators (Fig. 3A,B). According to the
predictions, phosphorylation of CDK2 at Thr160 was diminished in
ROSC-treated cells indicating decreased activity of this kinase
already after 12 h. The kinase responsible for activation of CDK2
by phosphorylating its Thr160 is CDK7, whose reduced phosphory-
lation at Ser164/Thr170 suggests one possible mechanism by
which ROSC leads to inactivation of CDKs in cells. As expected,ls. Exponentially growing HeLa cells were treated with either 20 or 40mM ROSC for the
on and single cell suspension was used for propidium iodide staining. DNA content in
tograms depicting a representative experiment performed in duplicate were prepared
on of cells in distinct cell cycle phases and the frequency of sub-G1 cell population were
ware. The values represent a mean of two replicates.
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Fig. 2. (Continued )ROSC prevented phosphorylation of pRb at Ser780 and Ser807/811,
which correlates with decreased proliferation and observed
reduction of G1-phase in treated cells. However, pRb is phosphory-
lated by several CDKs, and one cannot discriminate which kinase
is responsible for this effect. Therefore, we also analyzed phos-
phorylation of another CDK2-specific substrate—nucleophosmin
(NPM) (Fig. 3B). A reduced signal from its phosphorylation at
Thr199 is another evidence for inactivated CDK2. Surprisingly,
after exposure of cells to 40 mM ROSC for 24 h the site-specific
phosphorylation of NPM increased. It remains to prove
whether this event might be linked in any way to the ongoing
apoptosis.
REPRESSION OF THE CELLULAR LEVELS OF HPV-ENCODED
ONCOPROTEINS UPON ROSC TREATMENT
One might expect that inactivation of CDK7 and of cellular RNA
polymerase II would shut down the expression of HPV-encoded
proteins. Indeed, ROSC at high dosage reduced the levels of E6 (not
shown) and E7 oncoproteins (Fig. 3C). The decrease of E7 protein
was observed after treatment with ROSC for 18 h.
HIGHER DOSES OF ROSC INDUCE CASPASE-DEPENDENT
APOPTOSIS IN HeLa CELLS
The exposure of HeLa cells to 40 mM ROSC for 24 h resulted in a
marked reduction of the number of viable cells. This effect seems to
be attributable not only to the cell cycle arrest but additionally to the
increased accumulation of a sub-G1 cell population as detected by
flow cytometry (Fig. 2), which is an indication of apoptosis. To
substantiate this assumption, activity of caspase-3/7 in control and
ROSC-treated cells was determined. The activity of cellular caspase-
3/7 increased fourfold in HeLa cells treated with 40 mM ROSC after
12 h or even more than eightfold after 24 h (Fig. 4A). Importantly, 20
mM ROSC did not enhance activity of caspase-3/7 in HeLa cells even
after 24 h. However, the long term effect of ROSC became evident942 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEafter medium change and post-incubation of ROSC-treated cells in a
drug-free medium for a further 48 h. Activated effector caspases
were released into the culture medium. An approximately
hundredfold increase of caspase-3/7 activity in culture medium
was detected with both doses of ROSC (Fig. 4B).
ROSC-MEDIATED ABROGATION OF PHOSPHORYLATION OF
SURVIVIN AND OF BAD PRECEDES THE ONSET OF APOPTOSIS
To identify the mechanism by which inhibition of CDKs may
contribute to the initiation of apoptosis, we examined the
phosphorylation status of some factors regulating apoptosis.
Interestingly, ROSC at the higher dose abolished site-specific
phosphorylation of two proteins involved in the regulation of
apoptosis: namely of survivin and of Bad (Fig. 5). The decrease of
survivin phosphorylation starting after 18 h of exposure to 40 mM
but not to 20 mM ROSC became even more evident after further 6 h.
Beginning at 12 h treatment ROSC also clearly reduced and
thereafter abolished phosphorylation of Bad at Ser112 rendering it
disposed to heterodimerize with Bcl-2 proteins. ROSC-mediated
decrease of site-specific phosphorylation of Bad did not affect its
total level. Interestingly, this was accompanied by down-regulation
of the tau form of 14-3-3 protein (Fig. 5). Considering the fact that
after treatment with ROSC for 24 h CDK1 is inhibited by
modification at Thr14/Tyr15 and (Fig. 3A) and CDC25C phosphatase
is inactivated by phosphorylation at Ser216 (Fig. 5), one might
speculate that coinciding abrogation of phosphorylation of
surviving and Bad trigger apoptosis in G2/M arrested cells.
The ROSC-mediated abrogation of the phosphorylation of both
proteins seems to be a prerequisite for initiation of apoptosis in HeLa
cells. Interestingly, exposure of more confluent HeLa cells to high
ROSC dose failed to enhance the apoptosis and resulted in solely an
accumulation of G2/M arrested cells (results not shown). Remark-
ably, in this experimental series the phosphorylation of survivin and
Bad was not abolished upon ROSC treatment even at the higher doseJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 3. Cell cycle regulators in asynchronously growing HeLa cells. Untreated and ROSC-treated HeLa cells were harvested and lysed. Whole cell lysates (WCLs) were loaded on
10% or 12% SDS slab gels. After electrophoretic transfer onto PVDF membrane, protein loading and transfer was checked by Ponceau S staining. The proteins as well as their
phosphorylation statuses were examined by incubation with specific antibodies. The equal protein loading was checked by immunoblotting with anti-actin antibodies.(results not shown), thereby indicating that their dephosphorylation
is essential for initiation of cell death.
HTB-31 CELLS ACCUMULATE IN G2/M BUT DO NOT DIE AFTER
EXPOSURE TO ROSC
The exposure of HTB-31 cells to ROSC inhibits their cell cycle
progression. As depicted in Figure 6A,B, HTB-31 cells accumulate inJOURNAL OF CELLULAR BIOCHEMISTRYthe S- and G2/M-phase. The frequency of the S-phase population of
HTB-31 cells was differentially affected by both ROSC doses
(Fig. 6B). At higher dosage percentage of S-phase cells was clearly
diminished. After treatment with ROSC at a final concentration of
20 mM frequency of G1 cell population was clearly reduced.
However, no substantial increase of the frequency of hypoploid cells
was recorded (Fig. 6A,B).ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASE 943
Fig. 3. (Continued )
Fig. 4. Activation of caspase-3/7 in ROSC-treated HeLa cells. Exponentially
growing HeLa cells were treated in a multiwell plate for either 12 or 24 h with
ROSC at indicated concentrations. The activity of cellular caspase-3/7 (A) or
caspase-3/7 released to the culture medium (B) was determined in quad-
ruplicates using the APO-One Assay. The caspase-3/7 activity [relative fluor-
escence units (RFU)] SD was normalized to the number of viable cells
that were determined by CellTiterGlo Assay. The differences between the
caspase-3/7 activity in control and treated cells are statistically very highly
significant (P< 0.001) according to the Bonferroni’s comparison.
944 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEROSC DOES NOT ACTIVATE EFFECTOR CASPASES IN HTB-31 CELLS
Analysis of WCLs by immunoblotting revealed that levels of pro-
caspase-3 in HTB-31 cells remain unchanged after ROSC treatment
for 12 and 24 h (Fig. 6C) indicating that ROSC fails to activate
caspase-3. This observation was additionally confirmed by deter-
mination of caspase-3/7 activity using the APO-One assay (not
shown). Moreover, unlike in HeLa cells, in HTB-31 cells ROSC did
not abolish the phosphorylation of survivin and of Bad. However, it
is apparent that HTB-31 express lower levels of Bad protein (Fig. 6C)
as compared to HeLa cells and other cancer cell lines. The lack
of the activation of pro-apoptotic protein and effector caspases
correlate with the results of measurement of DNA concentration in
single HTB-31 cells performed by flow cytometry (Fig. 6A,B).
EFFECT OF SERUM WITHDRAWAL ON THE CELL CYCLE
PROGRESSION OF HeLa CELLS
In the next experiment, the effect of serum withdrawal on the cell
cycle progression in HeLa cells was examined. Unlike other cancer
cell lines (e.g., MCF-7, used as a positive control), HeLa cells did not
undergo G1 block after serum deprivation when kept in a serum-free
medium for 24 or 48 h (Fig. 7A,B). Surprisingly, serum starvation did
not induce apoptosis in HeLa cells thereby confirming that the cells
are able to survive and proliferate in the absence of growth factors.
Analysis of whole cell lysates obtained from serum-starved HeLa
cells by immunoblotting revealed changes in major cell cycle
regulators (Fig. 8). During starvation, a slow decrease of the
activating phosphorylation of CDK2 and of the total protein level
was observed (after 24 h) that was, however, recovered after serum
supplementation. Interestingly, simultaneous increase in activating
phosphorylation of CDK7 at Ser164/Thr170 was observed in starved
cells, followed by its decrease in ROSC-treated cells. The level of site-
specific phosphorylation of NPM, which was very low shortly after
plating of HeLa cells, strongly increased after their cultivation for
further 14 h (Fig. 8). Remarkably, it decreased after withdrawal of
serum from the culture medium but not until 20 h and disappeared
after serum supplementation (Fig. 8). The total level of nucleo-
phosmin was less affected by these conditions
EFFECT OF ROSC ON HeLa CELLS RELEASED FROM
SERUM STARVATION
Serum-starved HeLa cells were not able to arrest in G1-phase even
when sequentially treated with ROSC. A short ROSC treatment
(for 12 h) of HeLa cells after re-feeding with serum for 4 h had no
effect on the distribution of cells in the cell cycle phases. However,
exposure of HeLa cells, serum starved for 24 h and then serum re-
fed, to 40 mM ROSC for 24 h markedly reduced the population of
G1 cells and concomitantly led to accumulation of S- and G2/M-
phase cells (Fig. 7C). The distribution of HeLa cells in distinct cell
cycle phases upon ROSC is reflected by the status of the main cell
cycle regulators (Fig. 9). After a short treatment with ROSC (6 h),
the drug reduced the site-specific phosphorylation and total level
of CDK2 and CDK1, as compared to the cells after re-feeding for
10 h. This was accompanied by a slight decrease of the PCNA level.
However, the increase of the ratio of S- and later of G2/M-phase cells
upon longer medication with ROSC coincides with the enhancement
of activating phosphorylation of CDK2 and CDK1. Total levels ofJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 5. ROSC-mediated abrogation of phosphorylation of survivin and of Bad in HeLa cells. Untreated control and ROSC-treated HeLa cells were harvested and lysed. Whole
cell lysates (WCLs) were loaded on 10% or 12% SDS slab gels. Conditions of immunoblotting as described in detail in Figure 3.
Fig. 6. Effect of ROSC on the cell cycle progression and cell cycle regulators in asynchronously growing HTB-31 cells. A,B: Cell cycle progression. Exponentially growing HTB-
31 cells were treated with either 20 or 40 mM ROSC for the indicated periods of time. Control and drug-treated cells were harvested by trypsinization and single cell suspension
was used for propidium iodide staining. DNA histograms (A) and diagrams showing the changed distribution of cells in distinct cell cycle phases and the frequency of sub-G1 cell
population (B). Conditions of staining and measurement as described in detail in the Figure 2. C: ROSC does not activate effector caspase-3 in HTB-31 cells. Untreated and
ROSC-treated HTB-31 cells were harvested and lysed. Whole cell lysates (WCLs) were loaded on 12% or 15% SDS slab gels. After electrophoretic transfer onto PVDF membrane,
protein loading and transfer was checked by Ponceau S staining. The proteins as well as their phosphorylation statuses were examined by incubation with specific antibodies. The
equal protein loading was checked by immunoblotting with anti-actin antibodies.
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Fig. 6. (Continued )CDK1 and CDK2 also increased (Fig. 9). Although the protein loading
was not absolutely equal as evidenced by sequential incubation of
the blots with anti-actin antibodies, the fluctuations of the intensity
of the CDK1 and CDK2 bands are much stronger than those of actin
and thereby support the results gained by flow cytometry.ROSC MAINTAINS CELL CYCLE BLOCK IN CELLS ARRESTED IN
EARLY G1 PHASE
To verify the inability of ROSC to arrest serum-starved HeLa cells
in G1, we performed the cell cycle analysis of cells synchronized
at G2/M transition followed by a short release from the block and
treatment with ROSC. Exposure of HeLa cells for 18 h to NOC at a
final concentration of 0.05 mg/ml resulted in a reversible mitotic
block. Interestingly, when the cells were released from the block and
progressed to early G1 phase, they became much more susceptible to
treatment with ROSC, preventing the cell cycle progression and
resulting in a marked G1 arrest (Fig. 10). The maintenance of G1
arrest became clearly evident after treatment with ROSC for 12 h;
HeLa cells accumulated in the G1 phase even at lower concentration946 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEof ROSC. However, the G1 arrest was not permanent, the cell cycle
progression was rather delayed and after 20 h treatment G1
population decreased as cells passed through S phase to G2/M.
Progression through S to G2/M monitored by flow cytometry was
also supported by immunoblotting analysis of CDK1, showing not
only accumulation of the total CDK1 protein level, but also its
phosphorylation at Thr161 (Fig. 11). Similar changes were also
observed with the CDK2 level and phosphorylation at Thr160. The
DNA profile revealed that after release of HeLa cells from
nocodazole-induced mitotic block the ratio of hypoploid cells
markedly increased. To check whether after removal of the mitotic
blocker DNA is damaged in cells entering the cell cycle,
phosphorylation of histone H2A.X at Ser139 was determined.
Indeed, after release of HeLa cells from the mitotic block for 4 h the
site-specific phosphorylation of H2A.X increased and remained
elevated during at least next 20 h in controls as well as ROSC treated
cells (Fig. 11). ROSC also increased the cellular levels of p53 protein.
However, the p53 increase in cells released from mitotic block
was much weaker than that in asynchronously growing cells
[Wesierska-Gadek et al., 2008a,b].JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 7. Lack of G1 synchronization of HeLa cells after serum deprivation. HeLa
cells were plated under normal medium conditions. Twenty four hours after
plating, medium was changed and cells were cultivated for indicated periods of
time without FCS. At indicated time points cells were refed with serum and
cultivated further for indicated periods in the absence or presence of ROSC.
Then, cells were collected and prepared for measurement of DNA concentra-
tions as described in more detail in Figure 2. MCF-7 cells were used as a positive
control for serum starvation experiment. DNA histograms depicting a repre-
sentative experiment were prepared using the CellQuest evaluation program
(A) and diagrams showing the changed distribution of cells in distinct cell cycle
phases and the frequency of sub-G1 cell population were constructed for cells
kept without ROSC (B) or in the presence of ROSC (C).DISCUSSION
It is well documented that ROSC, a highly selective CDK inhibitor,
influences cell cycle progression as a consequence of interference
with multiple CDKs, but different outcomes are observed in different
cell lines. Most often, cells arrest at G2/M transition following ROSC
application, as shown for example with asynchronously growing
MCF-7 breast carcinoma, HCT-116 colon carcinoma, or K-562
chronic myelogeneous leukaemia cell lines [Penuelas et al., 2003;
Wojciechowski et al., 2003; Raynaud et al., 2005], despite weaker
inhibition of the mitotic CDK1/cyclin B activity determined in vitro
[McClue et al., 2002]. At the same time, however, an increased
G1 population and diminution of the number of S-phase cells
was observed in MCF-7 cells or HT-29 colon carcinoma cells
[Wojciechowski et al., 2003; Wesierska-Gadek et al., 2005a, 2006;
Krystof et al., 2006], probably as a result of inhibition of CDK2
activity. Other CDK inhibitors were reported to have similar effects
on the cell division cycle of animal cells; aminopurvalanol or
indirubin-30-monoxime strongly block G2/M transition in the
Chinese hamster CCL39 lung fibroblast cell line or in SV-40
transformed human HBL-100 breast epithelial cells, respectively
[Damiens et al., 2001; Knockaert et al., 2002]. In synchronized cell
populations, ROSC, as well as other CDK inhibitors, arrest the cell
cycle progression depending on the cell cycle status prior to the
onset of the treatment. MCF-7 cells partially synchronized by
nocodazole in metaphase were primarily arrested in G1 phase of the
cell cycle after a release from the block and exposure to ROSC
[David-Pfeuty, 1999] and the related compound aminopurvalanol
induces a G1 block in the serum-starved CCL39 cell line [Knockaert
et al., 2002].
In this work, we studied the anti-proliferative and pro-apoptotic
action of ROSC in two human HeLa cervical carcinoma cell lines:
HeLa and HTB-31 cells. In HeLa cells the cell cycle is deregulated by
infection with HPV-18 virus. Protein products of viral genes E6 and
E7 deregulate the host cell growth cycle through binding and
inactivating tumor suppressor proteins p53 and pRb, respectively.
Considering this fact one might entertain suspicion that inhibition of
CDK2 by ROSC would not affect cell cycle progression through G1/S
transition due to inactivation of pRb by E7 oncoprotein, our results
were not so straightforward. ROSC indeed reduced the number of
viable HeLa cells in the asynchronously growing culture by multiple
mechanisms. At a lower dose, it rather directly blocked proliferation,
as evidenced by accumulation of cells in G2/M phases and
concomitant decrease of G1 population. However, at the double
ROSC dosage, the frequency of G1 population increased beginning
from 12 h after onset of treatment. This outcome closely coincides
with repression of virally encoded E6 [Wesierska-Gadek et al.,
2008a] and E7 oncoproteins. The down-regulation of E6 viral
product is essential for up-regulation and reactivation of p53 tumor
suppressor protein [Wesierska-Gadek et al., 2008a,b], while the
repression of E7 protein is crucial for abrogation of HPV-mediated
disruption of the cell cycle control. Thus, it is a sign of the
reconstitution of the G1/S checkpoint in HeLa cells. The con-
sequences of the ROSC-mediated effect became clearly evident
during the monitoring of the phosphorylation status of pRb proteinJOURNAL OF CELLULAR BIOCHEMISTRY ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASE 947
Fig. 7. (Continued )
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Fig. 8. Cell cycle regulators in HeLa cells after release from serum starvation. Control and serum-starved HeLa cells were harvested at the indicated time points and lysed.
Whole cell lysates (WCLs) were loaded on 12% SDS slab gels. After electrophoretic transfer onto PVDF membrane, protein loading and transfer was checked by Ponceau S
staining. The proteins as well as their phosphorylation statuses were examined by incubation with specific antibodies. The equal protein loading was checked by immunoblotting
with anti-actin antibodies.that showed decreased signal on immunoblots, as published earlier
[Whittaker et al., 2004]. However, pRb is phosphorylated not only by
CDK2, but also by CDK4, and therefore we analyzed phosphorylation
of nucleophosmin (NPM) at Thr199 as another CDK2-specific
substrate. Decreased phosphorylation of NPM following ROSC
treatment confirmed inhibition of CDK2 in cells. By phosphorylating
this particular residue at NPM, CDK2 allows the centrosome to be
duplicated [Matsumoto et al., 1999; Okuda et al., 2000]. Thus, ROSC-
mediated dephosphorylation of NPM is another mechanism by
which this compound may exert its anti-proliferative action and
directly contribute to the G2/M arrest.
ROSC not only limits cell cycle progression of HeLa cells, but after
longer period of incubation, also eliminates the cells by induction of
apoptosis, like in other cancer cell lines [Wojciechowski et al., 2003;JOURNAL OF CELLULAR BIOCHEMISTRYWesierska-Gadek et al., 2005a, 2008b]. The ability of ROSC to induce
caspase-dependent apoptosis is, however, manifested much more
strongly after longer incubation periods and with higher doses of the
inhibitor (Fig. 4). It has been shown that inactivation of single cell-
cycle regulating CDK leads to cell cycle delay or arrest, while
combined genetic or pharmacologic inactivation of CDK1, CDK2,
CDK7, and CDK9 induces apoptosis through both E2F- and RNA
polymerase II-mediated effects [Cai et al., 2006]. The action of ROSC
in HeLa cells probably depends on its relative selectivity towards
respective cellular targets, for example, CDK1, CDK2, CDK7, and
CDK9 [McClue et al., 2002; Raynaud et al., 2005]. The effect of ROSC
on the phosphorylation of CDK7 at Ser164/Thr170 has not been
shown yet; it has been only known that ROSC directly inhibits the
activity of CDK7 [Hajduch et al., 1999; McClue et al., 2002].ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASE 949
Fig. 9. Effect of ROSC on cell cycle regulators in HeLa cells after release from serum starvation. Untreated control and serum-starved HeLa cells were subsequentially treated
with ROSC for indicated periods of time, harvested and lysed. Whole cell lysates (WCLs) were loaded on 12% SDS slab gels. After electrophoretic transfer onto PVDF membrane,
the proteins as well as their phosphorylation statuses were examined by incubation with specific antibodies. The equal protein loading was checked by Ponceau S staining and by
immunoblotting with anti-actin antibodies.Similarly to other CDKs, where phosphorylated T-loop uncovers the
catalytic site, its dephosphorylation leads to decreased CAK activity
[Lolli et al., 2004], which was evidenced here by decreased
phosphorylation of CDK1 and CDK2 on their T-loops
(Figs. 3A and 8). Although it is not clear yet which kinase is
responsible for activation of CDK7 by phosphorylating its T-loop,
CDK7 can be activated by its targets CDK1 and CDK2 in vitro [Garrett
et al., 2001; Lolli et al., 2004], which are ROSC-sensitive. Hence,
activities of all CDK1, CDK2, and CDK7 may decrease in a feedback
loop. The situation complicates functional redundancy of multiple
CDKs; absence of one CDK is readily compensated with formation of
unusual CDK/cyclin complexes as demonstrated by RNAi depletions
of CDK1 and CDK2 [Cai et al., 2006]. Moreover, activity of CDK2 is
apparently not absolutely dependent on CDK7, as it is able to
activate itself by autophosphorylation at Thr160 [Abbas et al.,
2007]. By inhibiting CDK1 and CDK2, ROSC in lower doses blocks
cell cycle only, while its higher doses, that sufficiently inhibit more950 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEkinases in cells (including CDK7), are able to initiate apoptosis, an
outcome resembling depletion of multiple CDKs [Cai et al., 2006].
Our results clearly evidence the causal link between activity status of
kinases and apoptosis in HeLa cells. We checked the site-specific
phosphorylation of some inducers as well as inhibitors of apoptosis.
The abrogation of the phosphorylation of two distinct regulators of
apoptosis upon treatment with ROSC was achieved solely at higher
ROSC dosage and preceded the onset of apoptosis. It is well
established that the apoptosis promoting function of Bad protein
strongly depends on its phosphorylation status [Harada et al., 1999].
Bad, a cytosolic protein is phosphorylated at serine residues 112 and
136 in response to growth factors resulting in its sequestration by
the tau form of 14-3-3 protein. The complex formation with the tau
form of 14-3-3 protein abrogates its heterodimerization with Bcl-xL,
thereby promoting Bcl-xL-mediated cell survival. ROSC at higher
concentration reduced and thereafter abolished Bad phosphoryla-
tion already after 12 h. It coincided with the decrease of the totalJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 10. Effect of ROSC on the cell cycle progression of HeLa cells synchronized by nocodazole. Exponentially growing HeLa cells were synchronized by treatment with
nocodazole for 18 h. Then, cells were released from the G2/M block by medium change and treated for indicated periods of time with either 20 or 40 mM ROSC. Then, cells were
collected and prepared for measurement of DNA concentrations as described in more detail in Figure 2. DNA histograms depicting a representative experiment were prepared
using the CellQuest evaluation program (A) and diagrams showing the changed distribution of cells in distinct cell cycle phases and the frequency of sub-G1 cell population were
constructed (B).
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Fig. 10. (Continued )level of 14-3-3 tau protein. ROSC also abrogated the phosphoryla-
tion of survivin, the smallest member of the family of inhibitors of
apoptois (IAPs). Survivin, a structurally unique IAP lacking a
carboxy-terminal RING finger, is a bifunctional protein that acts not
only as a suppressor of apoptosis, but is also an essential regulator of
cell division [Altieri, 2003]. The highly increased expression of
survivin in the majority of human malignancies, resulting in evasion
of apoptosis and aberrant regulation of cell division was reported.
Remarkably, survivin can be negatively regulated by functional p53
protein [Wesierska-Gadek and Schmid, 2007b] implicating that its
expression and activity in response to ROSC treatment may be
modulated by two independent mechanisms. The functional status
and activity of survivin is regulated by phosphorylation [O’Connor
et al., 2000]. Although survivin harbors a few phosphorylation sites
that are known to be covalently modified by different cellular
kinases, the phosphorylation of Thr34 catalyzed by CDK1 seems to
be crucial for its anti-apoptotic activity [Wall et al., 2003].
Threonine 34 is ideally positioned in the acidic knuckle of the
survivin molecule [Verdecia et al., 2000] to modulate its interaction
with constituents of the apoptotic pathway such as caspase-9 or
SMAC/DIABLO and to regulate the binding of client proteins
controlling survivin stability. Phosphorylation of survivin at Thr34
increasing protein stability simultaneously enhances its interaction
with caspase-9 and SMAC/DIABLO [Song et al., 2003]. Recently,
multiple evidences were collected demonstrating that inhibition of
survivin phosphorylation on Thr34 [Wall et al., 2003] or expression
of non-phosphorylatable survivin mutant Thr34!Ala reduce its
stability [Blanc-Brude et al., 2003]. It has been also reported that a
single amino acid change within amino-terminus converts survivin
activity from antiapoptotic to proapoptotic [Song et al., 2004]. These
observations encouraged some oncologists to develop new
therapeutic approaches based on the prevention of the survivin
phosphorylation on Thr34 or its repression [Altieri, 2003; Lu et al.,
2004; Zaffaroni et al. 2005].
The observed anti-proliferative and especially pro-apoptotic
effect of ROSC is probably enhanced in a p53-dependent manner,952 ROSC ARRESTS HeLa CELLS IN EARLY G1-PHASEbecause this tumor suppressor accumulated upon longer incubation
periods in HeLa cells [Wesierska-Gadek et al., 2008b]. The positive
effect of ROSC on activation of p53 and induction of p53-dependent
apoptosis has been described several times in the MCF-7 breast
carcinoma cell line [David-Pfeuty, 1999; Wojciechowski et al.,
2003; Wesierska-Gadek et al., 2005a]. Protein p53, as a transcrip-
tional regulator, operates according to its post-translational
modifications, especially phosphorylation and acetylation. For
example when phosphorylated at Ser46, that is, at the residue
important for its pro-apoptotic activity, p53 can transactivate a set
of genes inducing apoptosis (e.g., Bad, Puma, Noxa, p53AIP1, Bax)
and simultaneously suppress expression of anti-apoptotic genes
(e.g., survivin, bcl-2) [Oda et al., 2000]. Moreover, p53 obviously
induces apoptosis also independently of transcription; upon a stress
signal, cytoplasmic p53 translocates to mitochondria, where it
directly activates Bax, leading to the membrane depolarization and
caspase activation [Chipuk et al., 2004]. Only recently we have
found that ROSC is able to accumulate p53 phosphorylated at Ser46
also in HeLa cells, despite HPV infection [Wesierska-Gadek et al.,
2008b]. Interestingly, accumulation of p53 in ROSC-treated HeLa
cells is attributable to its stabilization by site-specific phosphory-
lation [Wesierska-Gadek et al., 2008b]. Moreover, the repression of
cellular E6 oncoprotein levels following ROSC treatment allows p53
to restore its physiological activity [Wesierska-Gadek et al., 2008a].
As expected, serum starvation had no influence on progression of
HeLa cells through G1, and even ROSC, applied to the cells shortly
after the release from starvation, was not able to maintain cells in G1
phase, probably due to inactivation of the key G1-regulator pRb by
E7 oncoprotein. Although ROSC at high dosage down-regulates
E7 oncoprotein, this effect takes place with some delay. Reduction
of E7 in asynchronously growing HeLa cells was observed after
18 h. Conversely, populations in S-phase and G2/M phases were
significantly delayed following ROSC treatment for 24 h, probably
as a consequence of unphosphorylated NPM that further block onset
of mitosis [Matsumoto et al., 1999; Okuda et al., 2000]. In fact, the
outcome is very similar to that in asynchronously growing cells,JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 11. Effect of ROSC on cell cycle regulators in NOC-synchronized HeLa cells. Unsynchronized control and NOC-synchronized HeLa cells were treated with ROSC for
indicated periods of time, harvested and lysed. Whole cell lysates (WCLs) were loaded on 12 or 10% SDS slab gels. After electrophoretic transfer onto PVDF membrane, protein
loading and transfer was checked by Ponceau S staining. The proteins as well as their phosphorylation statuses were examined by incubation with specific antibodies. The equal
protein loading was checked by immunoblotting with anti-actin antibodies.reflecting the heterogeneity of HeLa cells cultivated without the
serum.
Although ROSC alone was not able to arrest HeLa cells in G1 phase
in either asynchronous or serum-starved culture, when released
from nocodazole arrest, HeLa cells markedly delayed progression
through G1 phase when subsequently treated with ROSC (Fig. 10B).
As the cells further proliferated and passed slowly through S phase
to G2, they also accumulated Thr-phosphorylated forms of CDK1
and CDK2 (Fig. 11).
In summary, ROSC has been shown to have different effects on
HeLa cells depending on the concentration used and on the cell cycle
status prior to the onset of treatment. Generally, lower doses reduce
the proliferation rate by inhibition of cyclin-dependent kinases,
while higher doses induce caspase-dependent apoptosis in HeLa
cells. Moreover, the results also show that inhibition of CDKs by
ROSC in cells lacking the G1/S restriction checkpoint has different
outcomes depending on the cell cycle status of the treated cells.JOURNAL OF CELLULAR BIOCHEMISTRYConsidering the fact that after radiotherapy cancer cells are blocked
at G2/M, the ability of ROSC to induce apoptosis in G2/M arrested
cells may be of therapeutic importance.ACKNOWLEDGMENTS
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Increased expression and activity of proteins driving cell cycle progression as well as inactivation 
of endogenous inhibitors of cyclin-dependent kinases (CDKs) enhance the proliferative poten-
tial of cells. Escape of cells during malignant transformation from the proper cell cycle control 
rendering them independent from growth factors provides rationale for therapeutic targeting of 
CDKs. Exposure of rapidly growing human MCF-7 breast cancer and HeLa cervix cancer cells to 
roscovitine (ROSC), a selective inhibitor of CDKs, inhibits their proliferation by induction of 
cell cycle arrest and/or apoptosis. The outcome strongly depends on the intrinsic traits of the tu-
mor cells, on their cell cycle status prior to the onset of treatment and also on ROSC concentra-
tion. At lower dose ROSC primarily inhibits the cell cycle-related CDKs resulting in a strong 
cell cycle arrest. Interestingly, ROSC arrests asynchronously growing cells at the G2/M transition 
irrespective of the status of their restriction checkpoint. However, the exposure of cancer cells 
synchronized after serum starvation in the late G1 phase results in a transient G1 arrest only in 
cells displaying the intact G1/S checkpoint. At higher dosage ROSC triggers apoptosis. In HeLa 
cells inhibition of the activity of CDK7 and, in consequence, that of RNA polymerase II is a 
major event that facilitates the initiation of caspase-dependent apoptosis. In contrast, in the cas-
pase-3-deficient MCF-7 breast cancer cells ROSC induces apoptosis by a p53-dependent pathway. 
HIPK2-mediated activation of the p53 transcription factor by phosphorylation at Ser46 results in 
upregulation of p53AIP1 protein. This protein after de novo synthesis and translocation into the 
mitochondria promotes depolarization of the mitochondrial membrane.
Keywords: apoptosis, cell cycle arrest, cyclin-dependent kinases, inhibitors of cyclin-dependent kinases, roscovitine
INTRODuCTION
Proper progression of the cell division cycle 
is controlled in normal cells by activating and in-
hibiting cellular factors (for reviews, see Malumbres 
& Barbacid, 2005; Besson et al., 2008). Each phase of 
the cell cycle is regulated by the complexes consist-
ing of cyclin-dependent kinases (CDKs) and their 
regulatory subunits called cyclins. Periodic activa-
tion of the catalytic constituent is, at least partially, 
attributable to the presence of their appropriate 
regulatory component. Unlike the kinases, cyclins 
fluctuate during the cell cycle. Their transient cell 
cycle-dependent expression is regulated by both de 
novo synthesis and by proteasome mediated degra-
dation. Apart from the activating factors, the cell 
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cycle is additionally regulated by inhibitory factors 
like inhibitors of CDKs (CKI) or tumor suppressor 
proteins (e.g., p53, pRb or Pten). The fine-tuned 
balance between these positive- and negative-act-
ing regulators guarantees proper cell cycle progres-
sion in normal cells and facilitates adequate cellu-
lar responses to different physiological conditions 
like exhaustion of nutrients and a variety of stress 
stimuli. A constitutive activation or increased ex-
pression of the positive regulators of the cell cycle 
in cancer cells is frequently accompanied by a loss 
or inactivation of inhibitors of CDKs (Malumbres 
& Barbacid, 2007). The deregulation of the inhibi-
tors of CDKs commonly observed in many types of 
human malignancies is attributable to the deletion 
or silencing of genes (e.g., products of the INK4A 
gene) or to impaired protein synthesis, mislocaliza-
tion or enhanced protein destruction (e.g., p27Kip1 
protein). Degradation of such cell cycle regulators 
is carried out by the ubiquitin system in which 
covalent attachment of polyubiquitin targets pro-
teins for proteolysis by the proteasome. Although 
the specificity of the polyubiquitylation system is 
mainly determined by the ubiquitin ligase complex, 
the recognition of substrates seems to be mediated 
by another mechanism. It has been demonstrated 
that the stability of p27Kip1 is regulated by threo-
nine phosphorylation in position 187. Only phos-
phorylated p27Kip1 molecules are targeted by Skp2, 
a component of the SCF ubiquitin ligase complex. 
The critical modification of p27Kip1 protein is prob-
ably mediated by the CDK2-cyclin E complex (Bes-
son et al., 2008). Thus, CDKs seem to control dis-
tinct events in the cell cycle progression at multiple 
levels. The fact that cancer cells escape from the cell 
control cycle and acquire unlimited proliferation 
potential as a consequence of a loss or inactivation 
of endogenous CKIs provides rationale to counter-
act this deficit by administration of pharmacologi-
cal inhibitors of CDKS for cancer therapy (Fischer 
& Lane, 2005; Malumbres et al., 2008).
In this paper the action of roscovitine (ROSC), 
a CDK inhibitors belonging to trisubstituted purines, 
on human cancer cells differing in the status of the 
restriction checkpoint was examined. Asynchronous-
ly growing human MCF-7 breast cancer, and HeLa 
cervical cancer cells were exposed to ROSC. Inhibi-
tion of CDKs arrested the cancer cells in G2/M and 
induced apoptosis. The kinetics of cell cycle arrest 
and concentration dependency differed between the 
two cell lines. Moreover, the CDK inhibitor trig-
gered apoptosis by activation of caspase-dependent 
or independent pathways. ROSC simultaneously 
inhibited cell cycle progression and transcriptional 
elongation. The latter had a strong impact on virally 
encoded oncoproteins. Interestingly, ROSC showed 
a weak inhibitory effect on proliferation and cell cy-
cle progression of normal human MRC-5 and F2000 
fibroblasts (Wesierska-Gadek et al., 2008a).
Our results clearly evidence that the bi-func-
tionality of some pharmacological inhibitors of CDKs 
like ROSC markedly enhances their therapeutic effi-
cacy via targeting several cellular pathways.
MATERIALS AND METHODS
Cells. The human MCF-7 breast cancer and 
HeLaS3 cervical carcinoma cell lines obtained from 
American Type Culture Collection (ATCC), were 
cultured in RPMI medium supplemented with 10% 
foetal calf serum (FCS). Cells were grown up to 60% 
confluence and then treated with indicated drugs. 
Drugs. Roscovitine (ROSC) was prepared ac-
cording to the published procedure (Havlicek et al., 
1997) and prepared as a 50 mM stock solution in 
DMSO (dimethylosulfoxide). Aliquots of the stock 
solution were stored until use at –20°C. 
Cell treatment. Cells were treated with ROSC 
at a final concentration ranging from 1 to 60 µM for 
indicated periods of time. The highest concentra-
tion of solvent (DMSO) did not exceed 1‰. DMSO 
at this concentration had no detectable effect on cell 
cycle progression and on the number of living cells.
Antibodies. The following specific antibod-
ies were used to detect the relevant proteins: mono-
clonal anti-p53 antibody DO-1 (a kind gift from Dr. 
B. Vojtesek, Masaryk Memorial Cancer Institute, 
Czech Republic), polyclonal anti-phospho-Ser46 p53, 
anti-phospho-Thr160 CDK2 and anti-phospho-Ser780 
pRb (all from New England Biolabs, Beverly, MA, 
USA), polyclonal anti-phospho-Ser164/Thr170 CDK7 
and monoclonal anti- MCM-7 antibodies (clone DCS-
141) (BioLegend, San Diego, CA, USA), monoclonal 
anti-CDK2 (Clone 2B6 +8D4) antibodies (Lab Vision 
Co., Fremont, CA), monoclonal anti-PCNA (clone 
PC-10), anti-pRb (IF-8), (all from Santa Cruz Biotech-
nology, CA, USA), anti-CDK7 (clone MO-1.1, Sigma-
Aldrich, St. Louis, MO, USA), mouse monoclonal 
(BF7) antibodies to HPV18 E6, mouse monoclonal 
antibodies (H5) to phospho-Ser2 RNA polymerase 
II, mouse monoclonal antibodies (H14) to phospho-
Ser5 RNA polymerase II (Abcam Cambridge, UK), 
monoclonal antibodies to RNA polymerase II (clone 
ARNA-3), (Acris Antibodies GmbH, Herford, Ger-
many), and anti-actin (clone C4, ICN Biochemicals, 
Aurora, OH, USA). Appropriate secondary antibod-
ies linked to horseradish peroxidase (HRP) were 
from R&D Systems (Minneapolis, MN, USA).
Determination of the number of viable cells. 
Proliferation of human MCF-7 breast cancer  and 
HeLaS3 cervical carcinoma cells and their sensitiv-
ity to increasing concentrations of ROSC was de-
termined by the CellTiter-GloTM Luminescent Cell 
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Viability Assay (Promega Corporation, Madison, WI, 
USA). As described recently in more detail (Wesier-
ska-Gadek et al., 2007), the assay, generating a lumi-
nescent signal, is based on quantification of cellular 
ATP. Tests were performed at least in quadrupli-
cates. Luminescence was measured in a Wallac 1420 
Victor microplate luminescence reader. Each point 
represents the mean ± S.D. (bars) for at least four ex-
periments.
Measurement of DNA content of single 
cells by flow cytometry. Measurement of the DNA 
content was performed by flow cytometric analy-
sis based on a slightly modified method (Wesier-
ska-Gadek & Schmid, 2000) described previously by 
Vindelov et al. (1983). The cells were detached from 
substratum by limited trypsinization, harvested by 
centrifugation and washed in PBS (phosphate-buff-
ered saline). Aliquots of 106 cells were used for further 
analysis. Cells were stained with propidium iodide as 
described previously and then the fluorescence was 
measured using a Becton Dickinson FACScan after at 
least 2 h incubation at 4°C in the dark.
Immunoblotting. Total cellular proteins dis-
solved in SDS sample buffer were separated on SDS/
polyacrylamide slab gels, transferred electrophoreti-
cally onto polyvinylidene difluoride (PVDF) mem-
brane (Amersham Biosciences), and immunoblotted 
as previously described (Wojciechowski et al., 2003). 
Equal protein loading was confirmed by Ponceau 
S staining. To avoid non-specific protein binding 
sites, the membranes were saturated with 5% non-fat 
dry milk in TBS (10 mM Tris/HCl, pH 7.5, 150 mM 
NaCl) for at least 1 h at room temperature. After ex-
tensive washing in TBS containing 0.05% Tween 20 
(TBST), blots were incubated with specific primary 
antibodies at an appropriate final dilution and the 
immune complexes were detected using appropri-
ate HRP-conjugated secondary antibodies and the 
enhanced chemiluminescent detection reagent ECL+ 
(Amersham International, Little Chalfont, Bucking-
hamshire, England) (Wesierska-Gadek et al., 2005). 
To determine the phosphorylation status of select-
ed proteins, antibodies recognizing site-specifically 
phosphorylated proteins were diluted to a final con-
centration of 1 : 1 000 in 1% BSA (bovine serum albu-
min) in Tris/saline/Tween-20 buffer. In some cases, 
blots were used for sequential incubations. Chemi-
luminescence was analysed and documented using 
ChemiSmart 5100 equipped with a high resolution 
camera and image master software. Acquisition of 
chemiluminescence images using ChemiSmart 5100 
offers unrivalled sensitivity and maximum dynamic 
range. Incubation with anti-actin antibodies con-
firmed equal protein loading.
Statistical analysis. Statistical analyses were 
performed using GraphPad Prism software and sig-
nificance levels were evaluated using Bonferroni’s 
Multiple Comparison Test.
RESuLTS
ROSC more strongly inhibits proliferation of hu-
man MCF-7 breast cancer cells than that of HeLa 
cervical cancer cells
To determine the anti-proliferative effect of 
ROSC on exponentially growing human cancer cells 
differing in the G1/S checkpoint status (HeLa and 
MCF-7 cells), the cells were continuously exposed 
to the drug for 24 h. Then the cell number was de-
termined using the CellTiterLumiGlo viability assay 
immediately upon termination of the treatment, or 
alternatively the medium was changed and the cells 
Figure 1. Reduction of the number of viable human MCF-7 breast cancer and HeLa cervical cancer cells after treat-
ment with ROSC.
Exponentially growing cells plated in 96-well microtiter plates were treated for 24 h with indicated concentrations of 
ROSC. The number of viable cells was determined directly after the treatment, or additionally after medium change 
(MC) and post-incubation for 48 h (MCF-7 cells, left panel) or for 24 h (HeLa cells, right panel) in a drug-free medium. 
The graph represents mean values from three independent experiments, each performed at least in quadruplicates. The 
differences between the number of control and treated cells are statistically highly significant (**0.001 < P < 0.01) or very 
highly significant (***P < 0.001) according to the Bonferroni’s comparison. 
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were post-incubated in a drug-free medium for a 
further 1 or 2 days and the assay was performed 
then (Fig. 1). ROSC affected the proliferation of 
MCF-7 cells more strongly than that of HeLa cells. 
An approximately three-fold higher drug concentra-
tion was necessary to reduce the number of living 
HeLa cells by 50%. Remarkably, when cells incubat-
ed with ROSC for 24 h were transferred to drug-free 
medium, the number of living cells was significantly 
reduced further after cultivation for 24 h (HeLa cells) 
or 48 h (MCF-7 cells). The IC50 values decreased ap-
proximately three-fold as shown in Fig. 1. These 
results evidence that the effect of ROSC on cancer 
cells is prolonged and even during post-incubation 
in a drug-free medium a delayed outcome becomes 
apparent.
ROSC inhibits the cell cycle of asynchronously 
growing MCF-7 and HeLa cells at the G2/M transi-
tion with different kinetics
The next experimental series was performed 
to find out how ROSC modulates the cell cycle pro-
gression of the cancer cells tested and whether it is 
also able to induce apoptosis in HeLa cells. The DNA 
concentration in single cells was measured by flow 
cytometry. The population of hypoploid cells repre-
senting cells undergoing apoptotic changes was clas-
sified as a sub-G1 population. Interestingly, MCF-7 
cells rapidly responded to 20 µM ROSC, whereas in 
HeLa cells the changes in the distribution of cell cy-
cle phases became evident after 24 h (Figs. 2 and 3). 
In MCF-7 cells ROSC at a final concentration of 20 
µM increased the frequency of the G2/M population 
already after 8 h and concomitantly diminished that 
of G1- and S-phase. At this dosage ROSC exerted 
a much weaker and delayed effect on HeLa cells 
(Figs. 2 and 3). These results are in concordance 
with the data provided by cell viability tests (Fig. 1). 
Further experiments revealed that a two-fold higher 
concentration of ROSC increased the frequency of 
G2/M population of HeLa cells more strongly at the 
same time point, and simultaneously, the population 
of hypoploid cells (30%) appeared after incubation 
for 18 h and 24 h (not shown). In contrast, after ex-
posure of MCF-7 cells to ROSC no hypoploid cells 
were detected (Figs. 2 and 3). This observation is not 
surprising because these cells are apoptosis-resistant 
due to disruption of the gene encoding caspase-3.
ROSC inhibits global transcription resulting in re-
pression of virally-encoded oncoproteins
The lower susceptibility of human HeLa cer-
vical cancer cells to the inhibition of cellular CDKs 
is not surprising since they are HPV-18-positive. 
The virally encoded E6 und E7 oncoproteins inacti-
vate wt p53 tumor suppressor protein and the G1/S 
checkpoint, respectively (Scheffner et al., 1990; Helt & 
Galoway 2003). Therefore, we decided to assess the 
effect of ROSC on the expression of HPV-encoded 
proteins. Whole cell lysates (WCLs) were prepared 
from ROSC-treated HeLa cells concurrently to the 
flow cytometric measurement, and were subsequent-
ly analysed by immunoblotting to monitor changes 
in major cell cycle protein regulators (Fig. 4). ROSC 
inhibited in a time- and concentration-dependent 
Figure 2. Effect of ROSC on cell cycle progression of 
asynchronously growing human MCF-7 and HeLa cells.
Exponentially growing MCF-7 and HeLa cells were treat-
ed with 20 µM ROSC for the indicated periods of time. 
Control and drug-treated cells were harvested by trypsini-
zation and single-cell suspension was used for propidium 
iodide staining. DNA content in single cells was measured 
using Becton Dickinson FACScan flow cytometer. DNA 
histograms depicting a representative experiment per-
formed in duplicate were prepared using the CellQuest 
evaluation program.
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manner the activating phosphorylation of CDK7 and, 
in consequence, that of RNA polymerase II (Fig. 4A). 
After treatment with ROSC for 12 h the phosphor-
ylation of CDK7 was markedly reduced and almost 
completely abolished after treatment with a lower 
dose (20 µM) for a further 6 h (Fig. 4A). The loss of 
the site-specific phosphorylation of CDK7 was associ-
ated with its inactivation. The CDK7-mediated phos-
Figure 3. Rapid G2/M arrest of human MCF-7 breast cancer cells after exposure to ROSC.
Diagrams show changed distribution of HeLa and MCF-7 cells in distinct cell cycle phases and the frequency of sub-G1 
cell population. The distribution was determined using ModFIT cell cycle analysis software. Values for HeLa cells repre-
sent a mean of two replicates.
Figure 4. Repression of virally encoded E6 
oncoprotein in asynchronously growing 
HeLa cells upon ROSC treatment.
Untreated and ROSC-treated HeLa cells were 
harvested and lysed in RIPA extraction buffer 
yielding whole cell lysates (WCLs). In some 
experiments cells were fractionated yielding 
nuclei and post-nuclear supernatant represent-
ing crude cytosolic fraction. Protein samples 
(WCLs and subcellular fractions) were loaded 
on 10% (B, C), 12% (A) or 15% (D) SDS/poly-
acrylamide slab gels. After protein separa-
tion and electrophoretic transfer onto PVDF 
membrane, protein loading and transfer was 
checked by Ponceau S staining. Proteins and 
their phosphorylation status were examined 
by incubation with specific antibodies. Mem-
branes were incubated with specific primary 
antibodies at appropriate final dilution and 
immune complexes were detected using ap-
propriate HRP-conjugated secondary antibod-
ies and enhanced chemiluminescent detection 
reagent ECL+ (Amersham International, Little 
Chalfont, Buckinghamshire, England). Equal 
protein loading was checked by immunoblot-
ting with anti-actin antibodies. Chemilumi-
nescence was analysed and documented us-
ing ChemiSmart 5100 equipped with a high 
resolution camera and image master software.
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phorylation of RNA polymerase II was markedly re-
duced after exposure of HeLa cells to ROSC for 12 h 
(Fig. 4B). ROSC also inactivated CDK2 (not shown) 
resulting in the concentration-dependent diminu-
tion or even loss of phosphorylation of pRb protein 
(Fig. 4C). Surprisingly, ROSC increased the cellular 
level of p53 protein that was undetectable in un-
treated controls. The up-regulation of p53 was time- 
and concentration-dependent (Fig. 4C). Considering 
the fact that in HeLa cells wt p53 protein is antago-
nized by a virally-encoded E6 protein, its re-activa-
tion upon ROSC treatment would indicate that p53 
escapes from the destructive action of its negative 
regulator or that the latter is repressed. The immu-
noblotting analysis confirmed that ROSC represses 
the expression of virally encoded proteins (Fig. 4D). 
The cellular level of E6 obviously decreased after 12 
h of ROSC action (Fig. 4D) and after further 12 h E6 
became undetectable (not shown). Exposure of HeLa 
cells to ROSC also induced apoptosis as evidenced 
by accumulation of hypoploid cells (Fig. 3) (see also 
Wesierska-Gadek et al., 2008a; 2008b). The apoptosis 
rate was concentration-dependent. The inhibition of 
cellular CDKs and RNA Pol II strongly affected the 
cellular levels of distinct pro-survival factors such as 
survivin, Bad, and Mcl-1 (not shown). Moreover, the 
ROSC-mediated reactivation of p53 protein also pro-
moted initiation and execution of apoptosis.
Activation of p53 protein in ROSC-treated MCF-7 
cells by phosphorylation at Ser46
Exposure of human MCF-7 cells to ROSC re-
sulted in an inactivation of CDK2 as evidenced by 
loss of its phosphorylation at Thr160 (Fig. 5A). Inter-
estingly, ROSC induced phosphorylation of p53 pro-
tein at Ser46 (Fig. 5B). The modification coincided 
with a strong up-regulation of the tumor suppres-
sor protein thereby indicating that the post-transla-
tional modification considerably contributed to its 
stabilization. Determination of p53 protein stability 
in control and ROSC-treated MCF-7 cells confirmed 
this assumption. The p53 half-life increased approxi-
mately 15-fold after ROSC treatment (Wesierska-
Gadek et al., 2008a; 2008b) (not shown). ROSC did 
not affect PCNA level and only slightly diminished 
cellular concentration of MCM-7 protein after longer 
treatment (Fig. 5A). The latter observation coincides 
with a marked decrease of the proportion of S-phase 
cells (Fig. 3).
DISCuSSION
ROSC, a pharmacological CDK inhibitor, af-
fects not only cell cycle kinases like CDK2 and CDK1 
but additionally inhibits CDK7 (Havlicek et al., 1997). 
CDK7, an intriguing enzyme complexed with cyc-
lin H, cannot be simply classified (Fisher, 2005). It 
provides a direct link between regulation of the cell 
cycle and transcription, because it is both a CDK-ac-
tivating kinase (CAK) and a constituent of the ba-
sal transcription factor TFIIF which phosphorylates 
serine residues within the heptapeptide repeat of the 
carboxy terminal domain (CTD) of RNA polymerase 
II (Palancade & Bensaude, 2003). The direct connec-
tion between the regulation of the activity status of 
CDKs and the transcription machinery maintained 
by CDK7 raises a number of questions. It is not 
clear how CDK7 is able to discriminate between two 
distinct substrates. CAK itself is in mammalian cells 
a trimeric complex consisting of the catalytic com-
ponent p40MO15 designated as CDK7, a regulatory 
subunit cyclin H, and a RING finger assembly factor 
called ménage a trois, MAT1 (Fisher, 2005).
It has been shown that CDK7 forms a sta-
ble complex with cyclin H and MAT1 in vivo only 
when phosphorylated on either one of two residues 
(Ser164 or Thr170) in its T-loop. The phosphoryla-
tion status of the T-loop seems to modulate the sub-
Figure 5. ROSC induces rapid phosphorylation of p53 
protein at Ser46 in MCF-7 cells.
Exponentially growing MCF-7 cells were treated with 20 
µM ROSC for indicated periods of time. WCLs prepared 
from untreated controls and ROSC-treated cells were ana-
lysed by immunoblotting using antibodies recognizing 
P-Thr160 CDK2 and sequentially antibodies against total 
CDK2. The blot was sequentially incubated with mono-
clonal anti-MCM-7 and anti-PCNA antibodies (A). Second 
membrane was probed with antibodies reacting exclusive-
ly with p53 protein phosphorylated at Ser46 and sequen-
tially with monoclonal DO-1 antibody recognizing total 
p53 protein (B). Immune complexes were detected as de-
scribed in Fig. 4.
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strate specificity of CDK7 to favour CTD over CDKs. 
We monitored the impact of ROSC on the site-spe-
cific phosphorylation of CDK7 in HeLa cells. After 
treatment for 12 h the phosphorylation of CDK7 at 
critical amino acids decreased and after further 6 it 
was abolished. The unphosphorylated CDK7 became 
unable to modify serine residues within the CTD. 
This coincided with a stepwise increase of p53 pro-
tein concentration and reduction of E6 level. These 
results indicate that ROSC efficiently represses the 
transcription of HPV-encoded proteins. These results 
also confirm previous observation that CDK inhibi-
tory nucleoside analogs repress transcription from 
viral genomes (Schang et al., 2005). Apart of the in-
terference with the transcriptional machinery, ROSC 
also inhibited CDK2 (Wesierska-Gadek et al., 2008b). 
The repression of E6 protein contributed to re-acti-
vation of p53 tumor suppressor protein. Considering 
the strong involvement of p53 protein in the induc-
tion of apoptosis and of cell cycle arrest, one might 
assume that reactivated p53 protein additionally en-
hanced the therapeutic effect of ROSC. Unlike HeLa 
cells, MCF-7 cells are more resistant to pro-apoptotic 
stimuli due to inactivation of caspase-3. ROSC arrest-
ed very rapidly MCF-7 cells at the G2/M transition. 
These results are in concordance with our previous 
data (Wesierska-Gadek et al., 2005; Wojciechowski et 
al., 2003). Interestingly, ROSC strongly activated wt 
p53 via phosphorylation of Ser46. The p53 protein 
modified at Ser46 is a potent transcriptional activa-
tor of the p53AIP1 gene (Oda et al., 2000). The up-
regulation of the p53AIP1 protein, a pro-apoptotic 
mitochondrial factor, resulted in induction of apop-
tosis in MCF-7 cells (Wesierska-Gadek et al., 2005). 
We conclude that the dual action of ROSC enhanced 
its therapeutic potential on MCF-7 cells.
Our results evidence that CDK inhibitors tar-
geting simultaneously CDKs involved in the regula-
tion of cell cycle and transcription, such as ROSC, 
display high therapeutic potential. Their bi-func-
tionality allows them to affect several pathways in 
malignant cells and even to overcome resistance to 
apoptosis.
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